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ABSTRACT
The work in this thesis was initiated by the development of an extensive serum, plasma, 
cerebrospinal fluid (CSF) and deoxyribonucleic acid (DNA) multiple sclerosis (MS) 
disease and control biobank, with samples linked to extensive longitudinal clinical 
information. The biobank was designed to be utilised with the aim of identifying serum, 
plasma, CSF and genetic biomarkers for MS. Further, to examine the relevance of 
potential biomarkers to disease ignition, disease course and progression, response to 
treatment and ability to predict prognosis in patients with MS, comparing markers to 
clinical phenotype and non-neurological controls. I elected to investigate various 
components, fragments and regulators of the complement (C) system based on work 
showing C to be an important player in MS and in other neuroinflammatory diseases.
An initial pilot study examined serum C regulator factor H (fH) in MS disease 
subgroups and showed differential expression of fH in patients with progressive disease 
compared to patients with relapsing remitting disease and controls. These initial results 
were expanded demonstrating fH as a potentially sensitive and specific biomarker of 
disease course subgroups. Further, this thesis examines other complement proteins, 
fragments and regulators in plasma so as to build patient complement profiles specific 
to, and therefore biomarkers of, disease states.
In an attempt to further knowledge in relation to the expression and extent of C 
activation in MS, the thesis examines C in CSF and then immunohistochemically in
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brain and spinal cord tissue showing up-regulation of C in relation to MS plaques 
throughout disease course.
This work has identified a novel serum biomarker of MS disease course and patterns of 
C markers which provide biomarkers of MS and disease state. Up-regulation of C in 
MS and deposition within white matter plaques, implies a pathogenic role for C in MS.
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ABBREVIATIONS
AD Alzheimer ’s disease
ADEAE Antibody-mediated demyelinating experimental autoimmune
encephalomyelitis
AMD Age-related macular degeneration
APC Antigen presenting cells
APP Amyloid precursor protein
A-RRMS Acute-relapsing remitting multiple sclerosis
BBB Blood-brain barrier
Blocking buffer 1% bovine serum albumin in phosphate buffer solution
BCB Blood-CSF barrier
BSA Bovine serum albumin
C Complement
CDMS Clinically definite multiple sclerosis
Cl Confidence interval
CIS Clinically isolated syndrome
CNS Central nervous system
CPMS Clinically probable multiple sclerosis
CRP C-reactive protein
CR1 Complement receptor 1
CSF Cerebrospinal fluid
cv% Coefficient of variation
CVF Cobra venom factor
Cl-inh Cl inhibitor
C4bp C4 binding protein
C9neo C9 neoantigen
DAB Diaminobenzidine
DAF Decay accelerating factor
DNA Deoxyribonucleic acid
EAE Experimental autoimmune encephalomyelitis
EBV Epstein-Barr virus
EBNA Epstein-Barr Virus nuclear antigen
EDSS Expanded disability status scale
ELISA Enzyme-linked immunosorbant assay
GFAP Glial fibrillary acidic protein
FB Factor B
FH Factor H
FHL-1 Factor H-like protein-1
FI Factor I
GM Grey matter
GWAS Genome wide association studies
ICC Intraclass correlation coefficient
IFN Interferon
ig Immunoglobulin
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IL Interleukin
LFB Luxol fast blue
LSDMS Laboratory supported definite multiple sclerosis
LSPMS Laboratory supported probable multiple sclerosis
IQR Interquartile range
mAb Monoclonal antibody
MAC Membrane attack complex
MAG Myelin associated glycoprotein
MBP Myelin basic protein
MCP Membrane cofactor protein
MHC Major histocompatibility complex
MMP Matrix metalloproteinases
MOG Myelin oligodendrocyte glycoprotein
MRI Magnetic resonance imaging
MS Multiple sclerosis
MSSS Multiple sclerosis severity score
M0 Macrophages
NAMW Normal appearing white matter
NF Neurofilament
NMO Neuromyelitis optica
NO Nitric oxide
OCB Oligoclonal bands
OGD Oligodendrocyte
OPD Orthophenylenediamine
OR Odds Ratio
0 3 Oxygen free radicals
PBS Phosphate buffer solution
PLP Proteolipoprotein
PPMS Primary progressive multiple sclerosis
PQ Postal questionnaire
ROC Receiver operating characteristic
RRMS Relapsing remitting multiple sclerosis
sCRl Soluble complement receptor 1
SD Standard deviation
SNP Single nucleotide polymorphism
SPMS Secondary progressive multiple sclerosis
SPSS Statistical package for Social Sciences
S-RRMS Stable-relapsing remitting multiple sclerosis
TCC Terminal complement complex
Th T helper
TI Telephone interview
TNF Tumor necrosis factor
VEP Visual evoked potential
VLA-4 Very Late Antigen-4
Washing Buffer Phosphate buffer solution/0.1 % Tween 20
CHAPTER SUMMARIES
Chapter 1: Introduction
MS is a complex and heterogeneous disease of the central nervous system (CNS) in 
which clinical features, including presentation, disease course, and rates of 
accumulation of disability, demonstrate high degrees of individual variation. This 
makes the prediction of disease course and outcome by clinical measures difficult. 
Currently, available markers of disease necessary for accurate diagnosis, prediction of 
disease course and monitoring of treatments are limited, and for patient management, 
reliable and practical biomarkers are essential. Chapter 1 reviews the clinical features, 
aetiology, pathogenesis, and current diagnostic and prognostic markers of MS and 
examines potential candidates for disease biomarkers.
Chapter 2: Complement in multiple sclerosis: its role in disease and 
potential as a biomarker
MS has a poorly defined and complex immunopathogenesis; although initiated by 
reactive T cells, persistent inflammation is evident throughout the disease course. A 
contribution from C has long been suspected, based on the results of pathological and 
functional studies which have demonstrated C activation products in MS brain and 
biological fluids. However, the extent and nature of C activation, and its contribution to 
disease phenotype and long term outcome, remain unclear. Furthermore, functional 
polymorphisms in components and regulators of the C system which cause
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dysregulation and are known to contribute to other autoimmune inflammatory 
disorders, have not to date been investigated in MS in any detail. In this chapter I 
review evidence from pathological, animal model and human functional and genetic 
studies, implicating activation of C in MS. I also evaluate the potential of C 
components, fragments and regulators as biomarkers of disease, and suggest 
appropriate directions for research.
Chapter 3: Methods
For analysis of potential biomarkers, it is essential to have a comprehensive, well- 
maintained biobank with appropriately processed plasma, serum, CSF and DNA 
samples linked to clinical data. Here I describe the development of the biobank used for 
my research and outline the standards for sample collection and processing which 
ensure reliability of samples for analysis.
Chapter 4: Validity of patient derived disability and clinical data in 
multiple sclerosis
The South Wales MS clinical database provides detailed information on over 2200 
patients; however, given a disease course of over 30 years, longitudinal data, essential 
for accurate biomarker studies, is often incomplete. The objectives of this study were to 
determine validity of patient derived historical data and describe the utility of a locally 
relevant, patient administered questionnaire designed to ascertain current disability and 
other important disease milestones, allowing retrieval of retrospective missing patient
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data. A well-described cohort of 99 patients was identified for whom comparable 
detailed prospective longitudinal clinician derived data was available. Patient derived 
data was collected by completion of a standardised questionnaire or telephone interview 
for comparison.
Reliability analysis for current expanded disability status scale (EDSS) demonstrated an 
intraclass correlation coefficient (ICC) of 0.79 between questionnaire and clinician 
derived data in 79 patients with complete agreement in 75.9%. ICC for year of disease 
onset, diagnosis and onset of secondary progression was 0.86, 0.91 and 0.78 
respectively. Time to EDSS >4.0, 6.0 and 8.0 all had ICC of >0.9. Less robust 
agreement was observed for current disease course (Kappa coefficient 0.71), initial 
relapse rate (ICC 0.37) and clinical features at disease onset (Kappa 0.25).
In conclusion, self-reported questionnaires can provide reliable current and 
retrospective data on time to disability milestones with high levels of correlation 
observed for some additional elements, supporting the use of selected components of 
patient derived data in clinical practice and for epidemiological, genetic and biomarker 
studies.
Chapter 5: Complement regulator factor H as a serum biomarker of 
multiple sclerosis disease state
C regulator fH and its Tyr402His polymorphism have recently been implicated as 
potential biomarkers of disease in chronic inflammatory CNS conditions such as
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Alzheimer’s disease (AD) and age-related macular degeneration (AMD). Given the 
known association of MS and C, regulator fH was examined to determine if it might 
identify or predict specific pathological processes and outcomes in MS.
Employing novel assays, fH and its His402 variant was measured in serum from 350 
MS patients classified according to disease course and relapse status. Serum fH levels 
were significantly higher in progressive disease (p<0.001) compared to controls and 
relapsing patients, after controlling for variables including disease duration, age, 
gender, disability and treatment. Serum fH levels were capable of distinguishing 
secondary progressive from relapsing remitting disease (excluding patients in clinical 
relapse) with a sensitivity of 89.41%, specificity of 69.47% and a positive predictive 
value of 72.38%. Acute relapse was also associated with transiently increased fH levels 
(p=0.009) compared to stable relapsing disease. In clinically stable patients, fH levels 
remained constant over one year (coefficient of variation% (CV%, standard deviation 
(SD)/mean) = 6.8%), however, in patients in transition from relapsing to progressive 
disease, fH levels significantly increased over a period of 2 years (p=0.007). 
Concentration of the His402 variant in heterozygotes was significantly higher in 
secondary progressive (p<0.01) and primary progressive (p<0.05) disease, suggesting 
altered expression or consumption of variants when fH is up-regulated.
Serum fH may be an effective indicator of progression and a practical and accessible 
biomarker and stratifying tool in determining disease course, providing objective 
evidence to help guide therapeutic decisions.
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Chapter 6: Elevated plasma C4a levels in multiple sclerosis correlate 
with disease activity
C plays a pivotal role in the pathogenesis of MS and C4a, an activated fragment of C 
component C4, has recently been linked to disease activity. Plasma C4 and plasma and 
CSF C4a were correlated with clinical disease in a well-characterised cohort of patients 
and controls.
Plasma C4 levels weakly correlated with plasma C4a (r=0.27, p=0.001). Plasma C4 was 
non-significantly (p=0.056) elevated overall in patients compared to controls. Plasma 
C4a levels were significantly elevated in patients sampled during acute relapse 
compared to both controls (p<0.001) and patients with stable relapsing remitting 
disease (p=0.004); decreasing in convalescent post-relapse samples over 2 months 
(p=0.04). CSF C4a was significantly (p=0.003) elevated in MS patients compared to 
controls and furthermore showed correlation with a raised immunoglobulin (Ig) G 
CSF:plasma ratio, indicating intrathecal production.
Dynamic changes in C4a levels were demonstrated in patients in acute relapse, 
implying a systemic humoral inflammatory component at relapse ignition; however, 
because of low sensitivity and specificity between patient groups it is unlikely that C4 
or C4a could be employed as reliable clinical diagnostic or disease state biomarkers. In 
addition, results demonstrate intrathecal and systemic activation of C, reflected in
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changes in CSF and plasma C4a. These data support a role for C activation in MS 
pathogenesis and suggests a systemic component to disease.
Chapter 7: Systemic complement profiles in multiple sclerosis are 
useful as biomarkers of disease state
Chapters 5 and 6 demonstrate a significant and dynamic systemic and local activation 
and up-regulation of C evident from C components fH, C4 and C4a, detectable in 
serum/plasma and CSF samples. The source of C proteins involved in these processes 
remains unclear and although the majority of C synthesis is hepatic, local production 
may also contribute to tissue injury. In this chapter analysis of local and systemic C 
proteins, activation products and regulators is extended in a well phenotyped cohort of 
MS patients to more completely characterise C activation in MS and to examine 
complotype profiles as potential biomarkers of disease state.
Using in-house and commercially available assays, C proteins C3, fB, C4 and Cls, 
activation products Bb, C4a and TCC, and regulators Cl inhibitor (Cl-inh), fH and 
clusterin were measured in plasma from 194 carefully phenotyped patients with MS, 
together with 35 healthy controls. Additional analysis of CSF for a similar array of C 
components was performed in a further 37 patients with MS, 5 with CIS and 24 
neurological controls. Results were inserted into a logistic regression analysis to 
develop predictive models for disease state.
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Increased plasma levels of C3 (p=0.004), C4 (p=0.001), C4a (p<0.001), Cl-inh 
(p<0.001), and fH (p<0.001) and reduced levels of C9 (p<0.001) were observed in MS 
patients compared to controls. A combined profile of these C proteins and regulators 
resulted in a model which differentiated cases from controls with a predictive value of 
97%. In addition, independent increases in levels of C9, C4a and fH were observed in 
acute relapse which in combination with objective clinical markers differentiated 
patients in acute relapse from those in stable remission with a predictive value of 75%. 
It was possible to measure Cls, fB, C9, fH, clusterin and TCC concentrations in the 
CSF; however, there were no significant differences seen between subgroups. CSF 
plasma correlations suggest the principal source of synthesis for fH, Cls and clusterin 
is systemic whilst fB and C9 is both systemic and local.
In this chapter, further evidence is provided of alterations in both local and systemic 
expression of C in MS. C activation occurred via both classical and alternative 
pathways in acute and chronic disease, suggesting that C targeted therapies may be of 
use in addition to therapies targeting adaptive immune responses. Furthermore, 
combined models of systemic C levels with objective phenotypic characteristics seem 
to be useful biomarkers of disease state and may inform response to treatment.
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Chapter 8: An immunohistochemical analysis of complement in 
multiple sclerosis post-mortem tissue.
There remains some controversy as to the contribution of inflammation to axonal 
degeneration in MS and the extent and nature of C activation and regulation in relation 
to pathological processes. The aim of this study was to evaluate a broad range of C 
proteins, activation products and regulators in MS brain and spinal cord tissue to 
determine the relationship of C to inflammation and axonal degeneration.
Thirteen plaques from 9 cases of late-stage progressive MS and 3 control patients were 
examined immunohistochemically with quantification of antibodies in different tissue 
areas. Extensive deposition and synthesis of C was found predominantly in plaque and 
periplaque areas specific to astrocytes, with staining of neurons in periplaque grey 
matter, indicating C synthesis. The data also demonstrate variable myelin staining, 
predominantly of C regulators, in periplaque and normal appearing white matter 
(NAWM) areas, co-localizing with APP positive damaged axons. Activation of C was 
evident even in the centers’ of inactive plaques from patients with long disease 
duration; whereas control patients were consistently negative for cellular C staining.
C immunostaining of MS plaques in this study was specific and was interpreted as 
direct evidence of C contributing to pathogenic processes even in late-stage disease.
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The data suggest that anti-C therapies should be considered in addition to traditional T- 
cell mediated treatments for preventing disease progression.
Chapter 9: Inflammatory disease associated complement
polymorphisms do not contribute to disease phenotype in multiple 
sclerosis.
Dysregulation of the C system caused by polymorphisms in C components and 
regulators has been shown to contribute to disease process in a number of neuro- 
inflammatory disorders including AMD, AD, schizophrenia and vascular disorders. 
Chapter 9 assesses 8 SNPs in C genes, known to be associated with other neuro- 
inflammatory diseases, and examines genotype-phenotype correlations in 887 
comprehensively characterised MS patients.
After correcting for multiple tests, significant associations were demonstrated between 
a SNP in C receptor 1 (CR1) and age at onset, and a SNP in fH and typical magnetic 
resonance imaging (MRI) at disease onset. In addition, association was seen for 3 SNPs 
in C5 and C3 for reduced time to disability milestones; however, after correcting for 
multiple tests only one of these remained significant. No association was seen for other 
phenotypic variables including time to secondary progression. Previous studies 
examining phenotype-genotype correlations in MS have been limited and none have 
been convincingly replicated. It is therefore difficult to determine the appropriate 
number of patients needed to power such a study and it maybe that replication of this
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work in larger, similarly phenotyped populations, will provide a clearer picture of 
relevant associations.
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CHAPTER 1: MULTIPLE SCLEROSIS
1.1 Definition and history
MS was first described in 1838 by the pathologist Robert Carswell, then later, in 1841, 
by Jean Cruveilhier, a Parisian anatomist. However, the first complete description of 
the disease was presented to the Societe Medicale des Hospitaux in March 1865 and in 
May 1866 by a French Neurologist, Jean Martin Charcot. Charcot’s description of “la 
sclerose en plaque disseminees” included the clinical and pathological features taken 
from 3 cases and included insights into the duel nature of myelin loss and axonal 
damage seen in MS (Sherwin 1957). Since that time MS has become one if the 
commonest causes of neurological disability in young adults in northern European, 
Caucasian populations with an approximate life-time risk of 1 in 400 (Compston et al. 
2002). MS is a chronic inflammatory demyelinating disease in which lesions are 
disseminated in time and space. It is characterised by recurrent episodes of focal 
neurological disability within the CNS, which occur at an unpredictable frequency and 
remit to varying extents over many years (Confavreux et al. 2006b).
1.2 Epidemiology and aetiology
The prevalence of MS world wide varies, with most studies showing prevalence 
between 84 (Ford et al. 1998) and 203 (Rothwell et al. 1998) per 100,000 population. 
The UK lies in a region of high prevalence and has recorded one of the highest disease 
frequencies in the world at 258 per 100,000 population (Poskanzer et al. 1976); 
however a recent study in South Wales showed a prevalence of 146 per 100,000
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population which had risen over 20 years from 101 per 100,000 population (Swingler et 
al. 1988; Hirst et al. 2009). This study suggests that the increase in prevalence is 
predominantly a result of a rising incidence in females, with an increasing sex ratio of 
incident patients from 1.8:1 to 4.3:1 female:male in the 20 year period; the majority of 
previous studies have shown female:male ratios of 2:1 (Kurtzke et al. 1979). MS 
typically effects young adults, the mean age at onset ranges from 28.8-32.6 years 
(Panelius 1969; Confavreux et al. 1980) for females and 28.7 -31.6 years for males 
(Panelius 1969; Poser et al. 1979); however, approximately 7-13% of patients present 
before age 20 years (Panelius 1969; Phadke 1990) and 10% after the age of 50 years 
(Noseworthy et al. 1983).
The aetiology of MS is likely to be a combination of unidentified environmental 
challenges and genetic factors. Epidemiological studies have long recognised the 
important role of genetic factors in the susceptibility to MS with classical twin studies 
demonstrating a monozygotic concordance rate of 25-38% compared to 3-5% in 
dizygotic twins (Mumford et al. 1994), a background population risk for non-biological 
relatives of adoptees compared to biological relatives (Ebers et al. 1995) and increased 
offspring recurrence in conjugal pairs (Robertson et al. 1997). In addition, a decreasing 
recurrence risk with genetic distance from the proband in both population-based and 
clinic cohort studies has been modelled to suggest involvement of multiple genetic loci, 
each exerting a modest individual effect (Kalman et al. 2002).
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Early studies of gene candidates recognised the importance of the major 
histocompatibility complex (MHC), located on chromosome 6p21 (Bertrams et al. 
1972; Jersild et al. 1972; Winchester et al. 1975; Compston et al. 1976). Since that 
time, nearly all populations studied have shown association with allele DRB1*1501, 
(Compston et al. 2006) the few exceptions to this being studies in which the frequency 
of DRB1*1501 is too low or high in the local population making the studies 
underpowered (Poskanzer et al. 1980). Other DR alleles have also been shown to 
influence susceptibility - DR08 adds extra risk, whereas DR 14 essentially nullifies the 
risk from DR1501 (Dyment et al. 2005; Barcellos et al. 2006). Other work has 
confirmed a residual association beyond that attributable to the DRB1 gene, in the 
HLA-C gene; specifically, the HLA-C*05 allele (or a variant within the area of high 
linkage disequilibrium (LD)) showed a protective effect (p = 3.3 x 10'5) (Yeo et al.
2007). MHC genes have been suggested by a number of studies to influence disease 
type and severity as well as susceptibility (Hensiek et al. 2002; Barcellos et al. 2003; 
DeLuca et al. 2007; Smestad et al. 2007); however, none has been conclusively 
replicated.
Identification of risk alleles outside of the MHC region has proven more difficult with 
an increasing realisation of the sample sizes required for definitive genetic studies 
(Sawcer et al. 2005). More recently, advances in molecular genetic technologies 
together with increased power from collaborative clinical resources have led to 
identification and confirmation of single nucleotide polymorphisms (SNPs) within the 
interleukin-7 receptor (IL7R) (rs6897932; p=5.45xlO'20) and interleukin-2 receptor
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(IL2R) (rs2104286; p=9.59xl0‘29) genes, in which the major allele of each 
polymorphism confers susceptibility to MS (Gregory et al. 2007; Hafler et al. 2007; 
Lundmark et al. 2007; IMSGC 2008). The degree of risk for developing MS conferred 
by these polymorphisms is small (odds ratios: 1.17 IL7R, 1.22 IL2R); however, the 
SNP variation in these genes causes subtle changes in regulation of these inflammatory 
mediators including reduction of IL7Ro: expression and dysfunction of CD25 regulatory 
T cells (Puel et al. 1998; Roifman et al. 2000; Shevach et al. 2001; Gregory et al. 2007). 
Further to this, SNPs rs34536443 from the tyrosine kinase 2 gene (p=2.7xl0'6), 
rsl2708716 from the CLEC16A gene (p=1.6xl0‘16) and rs763361from the CD226 gene 
(p=5.4xl0'8) (the later two both also associated with type 1 diabetes) have also shown 
association with MS. Further SNPs are likely to be identified with more genome wide 
association studies (GWAS). Understanding the pathological implications of this 
expanding set of disease related polymorphisms will give vital disease information for 
MS and for other autoimmune disorder in which these genes have also been implicated 
(Vella et al. 2005; Brand et al. 2007).
1.3 Pathogenesis 
Overview
The fundamental concept underlying the perceived pathogenesis of MS is of wide 
arrays of inflammatory mediators interacting to cause both demyelination and axonal 
damage which in turn results in a variety of neurological deficits (Compston 2004) (fig 
1. 1).
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T-cell activation
T cells are initially activated in the systemic circulation via foreign antigens presented 
by antigen presenting cells (APCs) with interaction of CD40 on APCs and CD40L on T 
cells. They are then reactivated within the CNS at times of inflammation or relapse. 
Unfortunately, the story in MS is not this simple; myelin auto-reactive T cells are 
present in both MS patients and healthy individuals and normally are suppressed in the 
immune system by regulatory T cells (Costantino et al. 2008). However, in the MS 
patient this immune regulation is broken down possibly by impaired functioning of T 
regulatory cells, which has recently been linked to expression of IL-7Ra (Michel et al.
2008). The failure of regulation leads to proliferation and activation in the systemic 
circulation of auto-reactive T cells.
Another widely accepted hypothesis in autoimmune disease is the concept of molecular 
mimicry -  if an invading microbe has a component immunologically indistinguishable 
from a part of the human body (in the case of MS, a component of the oligodendrocyte 
(OGD) -myelin unit), the immune system can attack “self’ by mistake; hence some 
individuals with auto-reactive T cells develop disease whilst other individuals have 
high levels of auto-reactive T cells and no autoimmune dysfunction (Libbey et al. 
2007). Relapses of MS are often thought to be triggered by a viral infection or 
immunization. Many common viruses such as Influenza, Measles and Epstein-Barr 
virus (EBV), have genetic sequences that mimic those found in the myelin sheath 
(Olson et al. 2001; Olson et al. 2005). The concept of molecular mimicry would explain
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how T cell activation by common viruses can precipitate a demyelinating event (Libbey 
et al. 2007).
Blood-brain barrier breakdown
The CNS is separated from the systemic circulation by a blood-brain barrier (BBB) 
which consists of a layer of endothelial cells interspersed with tight junctions abutting a 
basement membrane; a continuous covering to this is provided by the extended foot 
processes of astrocytes (Persidsky et al. 2006; Correale et al. 2007). In inflammatory 
episodes of MS, activated T cells express integrins such as Very Late Antigen-4 (VLA- 
4), which bind to up-regulated cell adhesion molecules on the BBB endothelial surface 
and allow T cells to adhere to and “walk through” the tight junctions. They then pass 
through the extracellular matrix which is broken down by various inflammatory 
molecules including matrix metalloproteinases (MMPs), thereby allowing diapedesis of 
T cells into the CNS (Rosenberg 2009). Once in the CNS, T cells reencounter antigen 
and activate microglia, which in turn re-present antigen to T cells setting up a pro- 
inflammatory loop.
Conduction block
The pathology most clearly responsible for conduction block in MS is segmental 
demyelination of varying lengths along an intemode. However, inflammatory mediators 
have been recognized to independently cause conduction block; for example, nitric 
oxide has been shown in animal studies to cause reversible conduction block in central 
and peripheral demyelinated axons (Redford et al. 1997) and is thought to be 
responsible for reversible symptoms in MS such as Uhthoffs phenomenon
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(symptomatic deterioration with increases in body temperature) and transient worsening 
of old symptoms at times of infection. Other mechanisms of conduction blockage are 
unproven but are thought to be due to either impaired function of ion channels (seen in 
experimental autoimmune neuritis) (Novakovic et al. 1996) or disturbance of metabolic 
functions of glial cell (Wolswijk et al. 2003).
Demyelination
Demyelination in MS is dependent on multiple factors and the extent of involvement of 
various mediators is thought to differ in individuals. Activated T cells bind directly to 
myelin epitopes leading to activation of macrophages which can directly phagocytose 
myelin or, along with T cells and glial cells, can release toxic products such as 
proteases (Cuzner et al. 1999) or cytotoxic mediators. These include pro-inflammatory 
cytokines e.g. tumour necrosis factor (TNF) -a, Interferon (IFN) -y (Selmaj et al. 1988; 
Navikas et al. 1996), soluble reactive oxygen and nitrogen intermediate mediators 
(Smith et al. 1999; Smith et al. 2002), free radicals causing oxidative stress, and 
glutamic acid causing excitotoxicity (Bruck 2005b). The presence of extensive 
inflammatory infiltrates such as TNF-a can result in oligodendrocyte death through 
activation of an apoptotic cascade ultimately involving release by damaged 
oligodendrocytes, of death ligands or receptors such as Fas, FasL or Trail (Cannella et 
al. 2007). Further attack to myelin comes from antibodies and C components, mainly 
the terminal C complex C5b-9 released from infiltrating B cells (Morgan et al. 1984).
Initial studies in MS supported the concept of a T-helper (Th) 1 driven autoimmune 
condition with the predominant secretion of IFN-y (Sospedra et al. 2005). However,
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more recent work suggests a more complex model including different T-cell 
populations including Th-17 cells which predominantly secrete IL-17 (Harrington et al.
2005). Evidence from animal models has demonstrated that IL-17 deficient mice are 
protected from experimental autoimmune encephalomyelitis (EAE) (Komiyama et al.
2006); also Th-1, Th-9 and Th-17 cells have been shown to induce EAE, although each 
population of T cells induced a different phenotype suggesting that the predominant T- 
cell population may contribute to disease heterogeneity (Jager et al. 2009). Two papers 
have now translated this work into humans and established the importance of Th-17 in 
MS, showing increased numbers of Th-17 cells in blood (Durelli et al. 2009) and CSF 
(Brucklacher-Waldert et al. 2009) of patients with active disease. Despite this work, the 
precise contribution of the T-cell subsets and their associated cytokines to disease 
remains unclear.
Remyelination
At the end of a functional relapse, resolution of inflammation and loss of conduction 
block leads to variable clinical recovery. Axonal remyelination has been shown to 
contribute to clinical recovery, evidenced by MRI studies showing up to 40% of 
sclerotic plaques with signs of remyelination (Barkhof et al. 2003) and pathological 
studies showing remyelination in some, but not all, areas (Lucchinetti et al. 1996). 
Remyelinated areas are also known as shadow plaques, inflecting that the remyelination 
is incomplete with thinner myelin and shorter intemodal lengths more susceptible to 
conduction block at times of recurrent inflammation. The extent to which axons 
remyelinate is dependent on a number of factors including: the extent of axonal injury,
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the survival of OGDs and recruitment of OGD precursor cells, as well as the presence 
of a conducive environment (Chari et al. 2002).
Axonal damage
Axonal loss, initially attributed to acute episodes of demyelination, has traditionally 
been felt to play a larger role in the later progressive stages of disease (Bitsch et al.
2000). However, axonal damage has been demonstrated in active and inactive 
demyelinated plaques (Ferguson et al. 1997; Bitsch et al. 2000; Komek et al. 2000), as 
well as in normal appearing white matter outside inflammatory foci (Bjartmar et al.
2001). Axonal damage has also been shown to be present in very early disease, possibly 
representing an independent primary physiological anomaly (Ferguson et al. 1997; De 
Stefano et al. 2001; De Stefano et al. 2010). This persistent slow axonal loss is thought 
to be caused by chronic inflammation but also loss of trophic support from growth 
factors for neurons and axons (Weiner 2008). The degree to which inflammation and 
degenerative processes contribute to axonal loss is not clear; however, axonal and 
neuronal losses are now recognized to be central features of MS occurring throughout 
all parts of the CNS without the need for prior demyelination (Bruck 2005a).
Relapsing to progressive disease
At initiation, disease is driven by the adaptive immune response, with antigen primed T 
cells migrating into the CSF where Thl and Thl7 cells release pro-inflammatory 
cytokines to mount an inflammatory attack (Gocke et al. 2007; Kebir et al. 2007; 
McFarland et al. 2007). However, it has been suggested that as patients move through 
their disease course into the progressive phase, the innate immune system (consisting of
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macrophages, dendritic cells, mast cells and C) plays a larger role. Progressive disease 
has been characterised by chronic inflammation associated with activation of peripheral 
dendritic cells evidenced by higher concentrations of interleukin-12 and 18 released 
from dendritic cells in progressive patients compared to relapsing patients, with some 
correlation seen with disease duration (Weiner 2008). Adding to this, a recent 
pathological study of 67 post-mortem cases has demonstrated inflammatory cells in 
both early RRMS and progressive patients with high correlation between the amount of 
inflammation and degree of axonal injury. Interestingly, the authors noted the nature of 
inflammation changed, with T cells and B cells dominating in RRMS and plasma cells 
in progressive disease (Frischer et al. 2009).
1.4 Immunopathology
The first detailed histological descriptions of MS describing the pathogenesis of the
tfidemyelinating process were documented in the middle of the 19 century. In 1868 
Charcot observed: ‘...the long persistence of the axis cylinders deprived of medullary 
sheathing, in the midst of the foci of sclerosis, probably play an important part here. 
Transmission of voluntary impulses would still proceed by means of the denuded axis 
cylinders, but it would be carried on irregularly, in a broken or jerky manner’.
Central to the pathology of MS is the demyelinating plaque in which, macroscopically, 
lesions are round, greyish areas with finger-like extensions, centred on medium-sized 
vessels and accumulating either periventricularly or near the outer surfaces of brain or 
spinal cord (Bruck 2005b). Microscopically, plaques show axons devoid of myelin
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sheaths, embedded in astroglial scar tissue and surrounded by a heterogeneous array of 
inflammatory infiltrates mainly consisting of lymphocytes and macrophages; but also 
adhesion molecules, cytokines, chemokines, antibodies, C and other toxic substances. 
The inflammatory response, located around vessels, is not restricted to areas of 
demyelination but can affect areas of normal looking white and grey matter (Lovas et 
al. 2000; Bjartmar et al. 2001) where axonal injury correlates with the degree of 
residual inflammation (Komek et al. 2000).
Lesions can be further classified into active demyelinating, inactive demyelinated 
(distinguished by the extent of destruction of myelin sheaths and myelin debris within 
macrophages) or remyelinated (so-called shadow plaques in which areas have a reduced 
density of myelinated fibres associated with thin myelin sheaths) (Lassmann 1983). The 
active demyelinating plaque typically shows myelin sheaths in the process of 
dissolution and can be classified further into “acute” or “chronic active”. An acute 
plaque will show heterogeneous demyelination whereas the chronic active plaque has a 
demyelinated centre surrounded by a zone of active demyelination. Active plaques 
typically show dense macrophage and T cell infiltration with C and immunoglobulin 
deposition (Prineas et al. 2001). One study has also suggested that in early MS there is 
heterogeneity of lesions with some patients showing a pattern with predominant 
oligodendrocyte apoptosis (Lucchinetti et al. 1996). This is discussed in further detail in 
Chapters 2 and 8.
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1.5 Clinical features and disease course
MS is a highly variable condition in which clinical features are determined by the 
anatomical location of demyelination. Classical clinical presentations and features 
include optic neuritis, weakness or sensory loss in arms or legs, ataxia or vertigo. In the 
presence of classical features in relapsing disease, a firm diagnosis can often be easily 
confirmed; however, patients can present atypically with progressive disease, or 
prominent cortical signs such as early dementia, seizures, apraxia or fatigue; in these 
situations diagnosis can be more complicated.
Natural history studies suggest that about 80% of patients present with a relapsing 
remitting course (RRMS) (Confavreux et al. 2006a) in which relapses are defined as the 
first occurrence, recurrence or worsening of symptoms representing neurological 
dysfunction, marked by a sub-acute onset followed by variable recovery. The whole 
relapse must last at least 24 hours and there must be at least a month period between 2 
relapses (Schumacker et al. 1965; Lublin et al. 1996). The frequency with which 
relapses occur is highly variable, but clinic based cohorts suggest relapse rates to be 
around 0.6-1.1 per year (Fog et al. 1970; Patzold et al. 1982), decreasing over time 
(Panelius 1969; Patzold et al. 1982).
Of the patients presenting with RRMS, less than 20% have a benign disease course with 
little accumulation of disability EDSS (typically less than 4 over a 20 year period) 
(Amato et al. 2007; Hirst et al. 2008). However, even within this benign group the 
majority go on to disability in the long term (Hirst et al. 2008). The term malignant
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disease, or aggressive MS, has been historically somewhat poorly defined. A recent 
well accepted definition states malignant or aggressive disease to be “disease with a 
rapid progressive course, leading to significant disability in multiple neurological 
systems or death in a relatively short time after disease onset” (Lublin et al. 1996). 
Identifying individuals within these specific disease subgroups is becoming more 
important with the advent of newer therapies with higher side effect profiles which are 
currently being reserved for patients with more aggressive disease.
At around 10 years from onset approximately 80% of patients with RRMS go on to 
develop secondary progressive MS (SPMS) in which relapses abate and there is a slow 
accumulation of disability over a number of years (Lublin et al. 1996). Studies suggest 
between 5 and 20% of patients present with a primary progressive course (PPMS) 
which often develops as an upper motor neurone myelopathy affecting the legs, which 
slowly deteriorates (Cottrell et al. 1999).
At disease onset clinical information offers limited evidence when predicting disease 
course. It has been suggested that patients with benign disease have a younger age of 
onset and are more likely to present with sensory symptoms, whilst patients with ataxia 
and high pyramidal scores on the EDSS, will have a more aggressive disease (Poser et 
al. 1986; Weinshenker et al. 1991; Hirst et al. 2008). However, at best this information 
gives us clues as to which patients will benefit from early aggressive treatment, and no 
firm clinical prognostic markers are available.
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1.6 Diagnosis
Classification
Classification of MS has traditionally focussed on a level of probability with the use of 
paraclinical markers to enhance the likelihood of disease. There have been a number of 
different classification systems which have been refined over the years including the 
Allison and Millar classification system in 1954 (Allison et al. 1954), the diagnostic 
criteria of Schumacher in 1965 (Schumacker et al. 1965) and the Me Alpine system in 
1972 (McAlpine et al. 1972). One of the most commonly used systems has been the 
Poser criteria, first established in 1983 (Poser et al. 1983). This has 4 categories -  
clinically definite (CDMS) or probable (CPMS), and laboratory supported definite 
(LSDMS) or probable (LSPMS) MS. Using the most recent diagnostic system, the 
McDonald criteria (McDonald et al. 2001), a definite diagnosis, after excluding 
differentials, is based on history, examination and, if necessary, the use of additional 
investigations, to establish dissemination of inflammatory lesions in time and space.
The differential diagnosis of MS is broad and on presentation, investigations such as 
MRI, CSF examination and blood tests are used to exclude mimicking conditions such 
as structural lesions, central nervous system vasculitis or vascular malformations. These 
tests however, are limited in their diagnostic capacities and must be interpreted 
correctly. The use of visual evoked potentials (VEPs) is helpful in some cases when 
diagnosis is uncertain or to clarify risk of progression from clinically isolated syndrome 
(CIS) to CDMS (Gronseth et al. 2000).
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Magnetic resonance imaging
T2 weighted MRI studies of the brain and spinal cord are now used routinely to verify 
diagnosis according to dissemination in time and space, especially useful in the patient 
with a CIS in whom MRI can be repeated at intervals to assess accumulation of lesions 
(Miller et al. 1998). The use of serial MRI scans to monitor disease progression and 
response to treatment is less reliable. Gadolinium enhancement in Ti weighted MR 
images reflects active inflammation, and these enhanced lesions can be present for 4-6 
weeks. This can be useful in assessment of a patient’s disease activity and is often used 
as a surrogate marker when considering disease modifying treatments (NICE 2007). 
There is only weak to moderate correlation between disability and MRI parameters, in 
particular T2 lesion load (Li et al. 2006); however, more recent studies are showing 
MRI to be more predictive of outcome, especially when looking at quantitative 
techniques such as volume measurement (Rashid et al. 2008) and combined lesion and 
atrophy measures (Bakshi et al. 2008). When considering MR scans, it is important to 
remember that significant CNS pathology may be present in the absence of signs and 
symptoms, and changes in MRI are not always consistent with clinical deterioration in 
the patient (Isaac et al. 1988).
Cerebrospinal fluid
The examination of lumbar puncture fluid has been used for over 70 years in the 
diagnosis of MS. In the 1960’s CSF protein electrophoresis to detect oligocolonal bands 
(OCB), bands in the gammaglobulin region representing IgG, not paired in serum 
samples; was first used to increase the sensitivity, if not specificity, of diagnosis in MS 
(Link 1967). Their role remains important in some more complex cases in which
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verification of an immunological mechanism of disease is necessary (Link et al. 2006). 
Despite their use in diagnosis, OCBs have not reliably demonstrated correlation with 
clinical phenotype (Koch et al. 2007), although more recently a better prognosis has 
been reported in OCB negative patients (Joseph et al. 2009).
1.7 Biomarkers in MS
A biomarker may be defined as a “characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to therapeutic intervention” (Bielekova et al. 2004). In order 
to be clinically useful, a biomarker must be easy to acquire with minimally invasive 
techniques, and measurement should be simple, reproducible to a standardized level 
and cost effective.
In MS the main biomarkers currently used are clinical details and MRI; however, these 
have limitations as described above. The main biological specimen types deemed to be 
useful are CSF, serum, plasma, urine, sputum and DNA. Although CSF is likely to 
provide higher concentrations of relevant biomarkers and reflect alterations in the brain 
more accurately, it can only be acquired through invasive techniques and hence sample 
numbers and subgroups are limited for testing and recurrent sampling is impractical. 
Serum, plasma, sputum and urine are easy to collect in significant quantities and large 
numbers; however, the levels of markers may be lower and can be altered by sample 
processing factors such as time to separation, separation techniques and storage 
(Bielekova et al. 2004). The use of serum markers in MS is not novel; indeed, the well-
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known serum marker, oligoclonal IgG, reflects systemic immune disturbance and is 
associated with elevated intrathecal IgG synthesis in MS (Zeman et al. 1996). Serum 
markers may exist in MS if there is a systemic component to the disease, or if 
peripheral changes mimic central disease.
When considering MS, a clinically useful biomarker would provide information on 
disease ignition, progression and response to treatment, as well as on clinical subtype of 
disease. In this way it would be easier to predict prognosis and allow rational 
therapeutic decisions. In view of the two distinct pathological processes of 
demyelination and axonal loss seen in MS, a single surrogate marker is unlikely to be 
universally informative and multiple markers reflecting the balance between different 
pathological processes may be more useful.
Candidate disease markers
Potential biomarkers for investigation in MS may be discovered from either a screening 
approach using proteomics, or data gained from GWAS or a candidate approach. 
Candidate biomarkers may be generated from epidemiological, pathological, 
physiological or animal model studies. For example, sero-epidemiological studies have 
demonstrated association between MS and prior EBV infection and it has been 
hypothesised that intermittent peripheral EBV reactivation may drive continuing central 
inflammation. Recent small scale investigation has shown significant differences in 
median serum levels of EBV nuclear antigen-1 (EBNA-1) IgG between disease 
subgroups and positive correlation with disease activity reflected by number of Gd-
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enhancing lesions and T2 lesion volume (Farrell et al. 2009). These data have led to 
hopes that EBNA-1 may be useful as an easily accessible and effective biomarker of 
disease activity; however, results are yet to be replicated or shown to be clinically 
applicable (Ingram et al. 2010).
Bielekova et al (Bielekova et al. 2004) have suggested a classification of biomarkers in 
MS, split into seven categories according to their pathological relevance and / or 
function:
i. Alteration in the immune system.
ii. Blood-brain barrier disruption.
iii. Demyelination.
iv. Oxidative stress and excitotoxicity.
v. Axonal / neuronal damage.
vi. Gliosis.
vii. Remyelination and repair.
Markers of inflammation
To date, most research has focused on biomarkers involved in the immune process 
including cytokines, chemokines, antibodies, C, adhesion molecules and other 
activation markers (table 1.1). Most current research is limited to small studies of CSF 
and therefore necessarily reflects changes in early phase disease; research has also been 
restricted by lack of phenotypic analysis of disease in comparison to the potential 
biomarker.
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Markers of axonal damage
The major constituents of the axon cytoskeleton are light, intermediate and heavy chain 
neurofilaments (NF). NF-light forms the backbone to which NF-intermediate and NF- 
heavy co-polymerise to form the NF. The NFs are phosphorylated and the extent of 
phosphorylation determines the diameter of the axon and the velocity of axonal 
transport (Teunissen et al. 2005). In active MS lesions there is increased 
immunoreactivity of non-phosphorylated NFs (Mancardi et al. 2001), therefore, NFs 
with different levels of phosphorylation are potential biomarkers for axonal 
degeneration. Several studies have shown increased concentrations of NF-light in the 
CSF of MS patients in comparison to healthy controls (Lycke et al. 1998; Semra et al. 
2002; Malmestrom et al. 2003; Haghighi et al. 2004; Norgren et al. 2004). 
Concentrations of NF-light are also higher in relapse than remission with 
concentrations peaking at 3 weeks (Malmestrom et al. 2003); however, correlation with 
disability has been variable (Lycke et al. 1998; Semra et al. 2002; Eikelenboom et al. 
2003; Malmestrom et al. 2003). More recently however, NF-light in CSF of 99 patients 
with MS has shown correlation not only with disability but also prognosis; NF-light 
levels >386ng/L increased the risk for severe MS fivefold, and conversion to SPMS 
was more likely in cases with NF-light levels >386 ng/L (Salzer et al. 2010). There is a 
pressing need for this work now to be replicated to confirm this potentially exciting 
biomarker.
Other possible markers of axonal damage are tau protein; a phosphorylated 
microtubule-associated protein mainly found in neuronal axons (Binder et al. 1985;
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Kapaki et al. 2000; Sussmuth et al. 2001; Jimenez-Jimenez et al. 2002; Bartosik-Psujek 
et al. 2004; Martinez-Yelamos et al. 2004; Brettschneider et al. 2005); amyloid 
precursor protein (APP) - induced in glial cells in response to injury such as 
inflammation (Gehrmann et al. 1995; Ferguson et al. 1997; Komek et al. 2000) and 
24S-hydroxycholesterol - an oxysterol exclusively derived from the brain and reported 
to be acutely raised at times of demyelination (Leoni et al. 2002; Teunissen et al. 2003). 
Although having potential for surrogacy, none have yet been established as biomarkers 
of disease.
1.8 Conclusion
MS is a disease of immense complexity, with heterogeneity shown in clinical, 
pathological and immunological features leading to recent debate into whether it is a 
single disease or a syndrome with different aetiologies (Confavreux et al. 2006a). 
Pathological separation of neuromyelitis optica (NMO) by clinical features and 
biomarkers of MRI and NMO IgG has enhanced this discussion (Wingerchuk et al. 
2006).
The heterogeneity of disease course and the lack of objective clinical markers of 
prognosis make treatment decisions difficult for both clinician and patient. The advent 
of newer therapies, with higher side effect profiles, makes distinguishing aggressive, 
benign and progressive patients more important. Simple, easily repeatable, sensitive 
biomarkers would help with disease diagnosis, predicting prognosis as well as in 
monitoring of treatments. This thesis focuses on the C system and its components, 
fragments and regulators, as potential biomarkers in MS. There is a large body of
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evidence (detailed in Chapter 2) demonstrating a contribution from C to the 
pathogenesis of MS; however, there is little previous work specifically examining 
individual or combined elements of the C system as potential biomarkers. Together 
with the departmental expertise available, the C system was viewed as a good potential 
target for investigation.
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Figure 1.1: The pathogenic cascade in MS
The initiation of inflammation central to the pathogenesis of MS depends on the 
peripheral activation of T cells via foreign antigens. Activated T cells pass through the 
BBB into the CNS where they re-encounter specific antigen, are reactivated and bind 
directly to myelin epitopes leading to activation of macrophages (M0). These can 
directly phagocytose myelin or, along with T cells and glial cells, can release cytotoxic 
products and mediators. Further myelin attack comes from antibodies and C 
components. MBP =  myelin basic protein. MOG =  myelin oligodendrocyte glycoprotein. 
NO =  nitric oxide. O3 =  oxygen free radicals. Th = T helper cells.
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Table 1.1: Candidate inflammatory biomarkers in MS
Examples Type of Level in MS Correlation Recent evidence
Potential specimen compared to to activity or
Biomarker used controls progression
Immune markers
Cytokines IL6 CSF & plasma Raised No (Frei et al. 1991; Hautecoeur et al.
IL10 Reduced ? 1997; Filion et al. 2003)
IL12 Raised ?
TNF alpha Raised Possible
Chemokines and CCL2 CSF and blood Varying data N/A (Trebst et al. 2001; Sorensen et al.
their receptors CCL5
CXCL10
2004)
Adhesion sE-selectin Serum Raised No (Giovannoni et al. 2001; Kuenz et al.
molecules sP-selectin, 
sPECAM-1 
sVCAM-1 
sIC AM-1
Raised
Raised
Raised
Raised
No
No
No
No
2005)
Complement C3/C4 CSF & serum Varying data No See Chapter 2
TCC / C9 CSF & serum Varying data Possible
Antibodies Anti-MOG Serum Raised No (Berger et al. 2003; Lim et al. 2005;
Anti-MBP Serum Raised No Schwarz et al. 2006)
Anti-Glc Serum Raised N/A
Uric acid Serum Lowered No (Rentzos et al. 2006)
Nitric oxide Serum Raised Possible (Giovannoni et al. 2001)
Activation marker Neopterin Serum Altered No (Giovannoni et al. 2001)
CRP Serum No difference None (Soilu-Hanninen et al. 2005)
Markers of gliosis
GFAP CSF Raised Possible (Rosengren et al. 1995; Malmestrom et 
al. 2003)
S-100 CSF Varying data No (Malmestrom, Haghighi et al. 2003; 
Lim, Petzold et al. 2004)
Markers of BBB disruption
MMP 9 CSF & Serum Raised Possible (Cossins et al. 1997; Leppert et al.
3 CSF & Serum Raised Possible 1998; Waubant et al. 1999; Williams et
2 CSF Not detected N/A al. 2002; Kanesaka et al. 2006)
7 CSF Not detected N/A
Markers of membrane homeostasis
24s-hydroxycholesterol CSF & serum Altered Possible (Leoni et al. 2002; Teunissen et al.
2003)
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CHAPTER 2: COMPLEMENT IN MULTIPLE 
SCLEROSIS: ITS ROLE IN DISEASE AND POTENTIAL
AS A BIOMARKER
2.1 Introduction
Understanding of the role of C in the CNS and in systemic inflammatory disorders is 
now evolving at a considerable pace. Although first suggested to play a role in the 
pathogenesis of MS in the early 1970’s (Lumsden 1971), the extent of C activation in 
subgroups of MS patients, the mechanisms of activation and the role of C in 
inflammation, axonal damage and neuroprotection all remain unclear. In particular the 
involvement of inflammatory mediators, including C, to the progressive phase of 
disease caused by axonal injury remains a point for debate and, without good animal 
models of axonal injury, remains difficult to investigate.
In part because of limited access to pathological human tissue, the animal model of MS, 
EAE, has proved useful in developing insights into the role of C in MS. Indeed, in a 
recent review it has been suggested that animal models of MS may provide the best and 
broadest understanding of underlying disease processes and should be the primary 
focus of research (Bamum et al. 2005). However, there are many well-rehearsed 
problems in extrapolating models of animal disease to the human context, and 
pathological, functional and genetic studies in man will continue to provide a valuable 
contribution that should not be overlooked.
48
Although C activation is not specific to MS, patterns of activation, assessed in 
combination with other inflammatory and immune markers, may be of value as 
biomarkers in MS subgroups. This chapter reviews the evidence from pathological 
work, animal model studies and human functional and genetic studies, implicating C in 
the pathogenesis of MS, and discusses the potential use of C components, fragments, 
activation products, regulators and their polymorphic variants as biomarkers of disease.
2.2 Complement activation and regulation
C plays a central role in the innate immune system, providing an important defence 
against infection and immune complex disease. The system consists of approximately 
30 circulating and membrane expressed proteins which collaborate to provide 
protection from infection (Walport 2001b; Walport 2001a). The physiological actions 
of C are mediated through production of opsonins (molecules that enhance the ability of 
macrophages and neutrophils with C receptors to phagocytose material - C3b, iC3b, 
C4b etc.), anaphylatoxins (peptides that induce local and systemic inflammatory 
responses, increasing the permeability of blood vessels and attracting neutrophils 
through their chemotactic properties - C3a, C4a and C5a), and through direct killing of 
organisms by the terminal C complex (TCC) (C5b-9) which disrupts and forms pores in 
the phospholipid bilayer of a target cell. Although the C components in plasma are 
synthesised mainly by hepatocytes in the liver, within the CNS it is clear that glial cells 
and neurons can produce the majority of C proteins and expression is increased in
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response to inflammation (Levi-Strauss et al. 1987; Morgan et al. 1996; Gasque et al.
2000).
The C system is activated via three initiating pathways (classical, alternative and 
lectin), all of which converge on a common effector pathway with formation of the 
TCC (fig 2.1). Inappropriate activation of C leading to depletion of the C components is 
normally prevented by C inhibitors present either in the fluid-phase or membrane 
bound (Morgan et al. 1994; Morgan et al. 1999) (fig 2.1). Regulation in the alternative 
pathway is particularly important because the pathway is characterised by a constant 
‘tick over’ activation of C3 which can be amplified in pathology. Regulation in plasma 
is provided by fH and deficiency of fH allows unregulated amplification with 
breakdown of C3 leading to C3 deficiency.
2.3 Humoral immunity in neuromyelitis optica and MS
NMO is an inflammatory demyelinating disease predominantly affecting the optic 
nerves and spinal cord. Traditionally seen as a variant of MS, it has recently been 
redefined according to new criteria using a combination of phenotypic sub-typing along 
with a newly developed biomarker of disease, NMO-IgG (reported sensitivity of 58- 
76% and a specificity of 85-99% for NMO) (Giovannoni 2006; Wingerchuk et al.
2006). The clinical differences between NMO and MS are mirrored by pathological 
differences. NMO is typified by abundant Ig and C deposits surrounding blood vessels 
in a distinctive rim or rosette fashion (corresponding with aquaporin-4 expression) 
(Jarius et al. 2008) and thought to be driven by humoral processes (Wingerchuk 2006).
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Therapeutic plasma exchange, known to non-selectively deplete plasma proteins, has 
been reported as having a beneficial role in NMO (Keegan et al. 2002; Watanabe et al.
2007) and thought to exert its therapeutic effect by reducing circulating levels of 
relevant auto-antibodies.
Until recently, studies of MS pathogenesis and treatment have focussed on the role of T 
cells, however, it is now clear that humoral immune mechanisms also play an important 
role which has recently been reassessed (Franciotta et al. 2008; Racke 2008). 
Circumstantial evidence for a B cell contribution to disease initially came from the 
demonstration of central clonal expansion of B cells and production of oligoclonal 
cerebrospinal fluid IgG (used routinely as a diagnostic biomarker in MS) (Link et al.
2006). More recently, several studies have demonstrated antibodies to myelin and other 
CNS autoantigens in MS patients, but without convincing disease specificity, and the 
specific antigens responsible for initiating the immune response in MS remain 
unidentified (Berger et al. 2007). Although Ig and C deposits are described in MS 
lesions, the localization of infiltrate is different from that in NMO (Breij et al. 2008) 
and has been suggested to only be present in a histological subgroup of patients (pattern 
II lesions) (Lucchinetti et al. 1996).
Therapies targeting humoral mechanisms, such as plasma exchange (Weinshenker et al. 
1999; Weinshenker 2001; Keegan et al. 2002) and rituximab (a B cell depleting mAb) 
(Hauser et al. 2008), have been tested with variable success in acute demyelinating 
events and it has been suggested that patients with pattern II histological lesions,
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showing prominent Ig and C deposition, are more likely to have a favourable response 
to this intervention (Keegan et al. 2005). The recognition of specific biomarkers for MS 
patients with extensive C activation may therefore be important in identifying patients 
who may benefit most from therapies targeting humoral immunity (Oh et al. 2008).
2.4 Complement in MS -  evidence from pathology
A role for C in MS was initially proposed following the demonstration of C component 
C3 deposited in the brains of MS patients (Lumsden 1971). Immunocytochemical 
localization of the TCC in the brains of 5 of 7 MS patients was reported in 1989; TCC 
was demonstrated in association with capillary endothelial cells, predominantly within 
plaques and adjacent white matter (Compston et al. 1989). Localization of C activation 
to areas of active myelin destruction was demonstrated in a case report showing TCC 
deposited exclusively in such areas (Storch et al. 1998). In a study of 23 cases of 
SPMS, the opsonin C3d was shown deposited in association with short segments of 
disrupted myelin in plaques with low grade active demyelination and provided evidence 
for C contribution to disease progression as well as acute inflammation (Prineas et al.
2001).
More recently, a complex and heterogeneous pathological model for MS has been 
proposed by Luchinetti et al, who have described four distinct patterns of demyelination 
in a group of 83 patients, with specimens collected either at autopsy (n = 32) or biopsy 
(n = 51) (Lucchinetti et al. 1996; Lucchinetti et al. 2000). The pathological 
classification was based mainly on the presence of Ig and activated C (pattern II only),
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remyelination (patterns I and II); and primary OGD damage (pattern III and IV). The 
authors suggested that the four different patterns of disease provided evidence for 
different mechanisms of immune-mediated demyelination, with C playing a role in a 
distinct but large subgroup of patients.
When considering the pathological subgroups and their relation to disease phenotype it 
must be noted that the frequencies of the different patterns seen may be heavily skewed 
by patient selection for biopsy (possibly more aggressive disease). Further, the 
specimens collected in the study by Luchinetti et al were from a cohort of patients with 
very early disease (the mean disease duration before autopsy or biopsy was 39 and 9 
months respectively) and therefore may not accurately represent a global picture of MS. 
In addition the study showed C and Ig depositions only in pattern II lesions, represented 
exclusively in over 50% of the patients and in all subgroups of disease (relapsing 
remitting, secondary and primary progressive). A more recent study has failed to 
demonstrate this heterogeneity, showing C and Ig deposition consistently present in 
areas of demyelination (Breij et al. 2008). These authors have suggested that the 
heterogeneity described by Luchinetti et al may have been a phenomenon of early 
disease and was therefore not seen in their samples in which the mean disease duration 
was 22 years. Serum or CSF biomarkers that accurately identify any pathological 
subgroups would help considerably with clarifying these issues and would provide 
direction for future research.
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2.5 Complement in MS -  animal models
EAE, most commonly in rodents, has long been used as an animal model for MS 
(Mackay et al. 1973; Lassmann 2008), but was initially constructed to examine the 
monophasic illness; acute disseminated encephalomyelitis (Kabat et al. 1949). 
However, since its introduction numerous variations to the initial concept have evolved. 
Disease induction with a known CNS antigen (such as MBP (Zamvil et al. 1985), 
proteolipid protein (PLP) (Yamamura et al. 1986), MOG, myelin associated 
glycoprotein (MAG) and S-100 protein (Kojima et al. 1997)) causes a paralysis in 
animals with varying degrees of demyelination depending on the method of EAE 
induction and species used (Lassmann 2007). The two main models employed are the 
MBP model (resulting in a monophasic, non-demyelinating disease) and the antibody- 
mediated demyelinating EAE model (ADEAE) (where MBP immunisation is followed 
by administration of anti-MOG antibodies). Although the MBP induced model of EAE 
is thought by some to bear the closest resemblance to MS, it is likely that different 
models will have relevance in the understanding of different immunopathological 
subtypes or phases of disease. Information gained from these studies must be tempered 
by the knowledge that EAE, like most animal models of disease, is an incomplete and 
not entirely accurate reflection of the human situation. Models reflecting the axonal 
damage seen in MS have yet to be used to analyse disruption of the CNS but may yet 
give a clearer understanding of progressive disease (Bjartmar et al. 2003). Despite all 
these problems, much information on C pathology, potential C biomarkers and 
therapeutics has been obtained from EAE studies in normal animals and transgenic
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mouse models (Steinman et al. 2006), and these model have provided a test bed for 
studies of treatment with C suppressors (Oh et al. 2008).
Anti-complement Agents in EAE
The first studies to examine the role of C in EAE used the C activator cobra-venom 
factor (CVF) as a treatment to reduce serum C; markedly reducing the severity of EAE 
(Abrahamson 1971; Pabst et al. 1971; Linington et al. 1989; Hinman et al. 1999). 
Despite initial success, it was soon realised that response to this treatment was transient 
and repeated injections were highly immunogenic; further, CVF-induced C activation 
led to production of vast quantities of the pro-inflammatory anaphylatoxins C3a and 
C5a, sufficient to cause a shock syndrome in recipients. It was also reported that, 
although CVF treatment in MBP induced EAE caused suppression of disease, in the 
ADEAE model CVF had no effect on disease severity despite C9 deposition being 
abolished (Piddlesden et al. 1991).
To combat the problems of CVF, sCRl (which blocks the action of C3 and C5 
convertases) was trialled as a treatment to decrease C activity and reduce the severity of 
EAE (Piddlesden et al. 1994). Treatment with sCRl worked to some extent but showed 
much less reduction in clinical severity scores when compared to treatment with CVF, 
perhaps reflecting an incomplete blockade of C activation (Vriesendorp et al. 1997).
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Gene Deletion Models in EAE
Gene deleted (knock-out) animal models have been used to enhance our understanding 
of the roles of the pathways of C activation in EAE. A study of C3 and factor B (fB) 
knock-out mice (the former unable to activate C, the latter alternative pathway 
deficient) demonstrated normal incidence of MOG-induced EAE but attenuated 
severity of chronic disease in both mouse strains, with decreased numbers of infiltrating 
macrophages and T cells (Nataf et al. 2000). This work showed unequivocally that C 
contributed to the development of EAE, and also that the alternative pathway was vital 
in the development of disease. The role of C3 has since been questioned, with C3 
knock-out mice showing similar disease to wild type mice in one study (Calida et al. 
2001), but attenuated disease in others (Bamum et al. 2006; Szalai et al. 2007). The 
differences here may be explained by the use of different mouse models. Evidence that 
the alternative pathway is the main player is supported by studies in C4-deficient 
(classical pathway absent) animals, which showed EAE onset and progression virtually 
identical to wild-type animals (Morariu et al. 1978; Boos et al. 2005).
Once activated, C has multiple roles in the EAE inflammatory lesion, causing 
demyelination (Piddlesden et al. 1993a), axonal damage and OGD injury (Linington et 
al. 1989). The mechanisms by which this damage is mediated have been examined in 
detail. The membrane attack complex (MAC), the cytolytic end-product of the C 
cascade, is thought to play a significant role in demyelination, with evidence from 
pathological studies (as discussed), in vitro studies (deficiency of the MAC inhibitor 
CD59 was shown to be the cause of rat OGD susceptibility to lysis in culture
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(Piddlesden et al. 1993b)), and in vivo studies. C9/MAC deposition was shown to 
correlate closely with demyelination in the spinal cord of rats in which EAE was 
induced with anti-MOG antibodies (Piddlesden et al. 1993a), while C6-deficient rats 
(unable to produce MAC), when immunised with MBP and given anti-MOG antibodies 
to induce ADEAE, failed to develop demyelination, axonal damage or paralysis, but 
when reconstituted with C6 went on to develop pathology and clinical disease similar to 
wild type rats (Mead et al. 2002). Despite these findings, the role of MAC has been 
questioned (Bamum et al. 2006); C5 knock-out mice were not protected from MBP- 
induced EAE, suggesting that the terminal pathway was not essential for disease 
(Weerth et al. 2003; Niculescu et al. 2004). The extent of the role of MAC in 
demyelination and remyelination in models and MS thus remains uncertain.
Anaphylatoxins C3a and C5a are important inflammatory mediators and were initially 
considered to play an important role in CNS inflammation, based predominantly on 
evidence showing the expression of their receptors (C3aR and C5aR) on neuronal cells 
(Gasque et al. 2002). C3aR expression on microglia and infiltrating macrophages was 
increased during EAE but neuronal expression was largely unchanged (Davoust et al.
1999). The expression of C5aR on microglia and hypertrophic astrocytes within the 
spinal cords of Lewis rats was highly up-regulated in EAE (Nataf et al. 1998), leading 
to the hypothesis that C5a is an important inflammatory mediator in EAE. Since these 
initial studies, it has been demonstrated that C5a plays no role in demyelination in 
EAE; C5aR deficient animals are fully susceptible to EAE (Reiman et al. 2005), and 
treatment with a C5aR antagonist failed to protect against development of EAE
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(Morgan et al. 2004). In contrast to this, C3aR-deficient mice in which EAE was 
induced, exhibited an attenuated clinical course, and immunohistochemical analysis 
revealed reduced demyelination and infiltration of macrophages and T cells compared 
to control mice, indicating that anaphylatoxin C3a plays a role in inflammatory cell 
recruitment and demyelination (Boos et al. 2004). Interestingly, these effects were more 
apparent in the chronic phase of disease, corresponding with results from C3-deficient 
mice (Nataf et al. 2000). More recent work with C3aR and C5aR double knock out 
mice failed to demonstrate any protection against EAE severity although disease onset 
was delayed; the authors claim the data indicated a level of cross-modulation between 
the C3aR and C5aR during EAE (Ramos et al. 2009).
Summary
Animal models have been useful in clarifying the role of C in EAE. It is clear that the 
alternative pathway contributes to disease, while the roles of the classical and terminal 
pathways are less clear, with the latter reported to be vital for demyelination in some 
but not all EAE models. The anaphylatoxin C5a likely contributes little to disease, 
while C3a plays a larger part -  predominantly through recruitment of inflammatory 
cells. The alternative pathway plays a dominant role in EAE, as has been shown in 
many other disease models (Abarrategui-Garrido et al. 2008; Fang et al. 2008), 
impacting particularly in chronic disease. While direct translation of these findings into 
human disease is not possible, they may suggest that the alternative pathway is 
important in disease perpetuation after initiation by a primary source. The roles of C in
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mediating axonal damage need to be further investigated and require animal models 
that represent axonal damage and chronic disease more clearly.
2.6 Complement as a serological or CSF biomarker of MS
In light of the evidence implicating C in MS, various C proteins have been considered 
as biomarkers of disease activity. These are summarised in table 2.1 and discussed 
below.
C3 and C4
C3 and C4 are the most abundant of the C proteins and are routinely measured in many 
laboratories. Like most of the C components, both C3 and C4 are acute-phase reactants 
and increased synthesis in response to inflammation can mask even quite marked 
consumption. Perhaps, as a consequence, studies of C3 and C4 levels in MS serum and 
CSF have shown inconsistent and conflicting results (Jans et al. 1984; Jongen et al.
2000). Levels in serum and CSF from patients with neuroinflammatory diseases are 
likely to be influenced both by the presence of active inflammation and the integrity of 
the BBB, both highly fluctuant in MS. Indeed, positive correlation of C3 and C4 
CSF:serum ratios with albumin CSF: serum ratios has been identified in controls but not 
in MS patients (Jongen et al. 2000).
Terminal Pathway Components and the Terminal Complement Complex
Measurements of the terminal component, C9, and of the TCC have been performed in 
MS, although results have again been inconsistent. Low levels of C9 in MS CSF have 
been demonstrated in two studies including one in which patients were sub-classified
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into acute relapsing, remission and progressive with lowered C9 levels in all groups, 
implicating prior activation of the terminal C pathway (Morgan et al. 1984; Compston 
et al. 1989). Other studies have shown no difference in C9 levels compared to controls 
(Halawa et al. 1989; Rodriguez et al. 1990). Measurement of TCC in CSF in three 
studies has consistently shown raised levels in MS patients (Sanders et al. 1986; 
Mollnes et al. 1987; Sellebjerg et al. 1998), one study showing good correlation of CSF 
TCC concentration with disability (Sellebjerg et al. 1998). There were no changes in C9 
or C5b-9 levels in plasma in any of these studies, suggesting that CSF changes were a 
much better indicator of CNS disease.
Complement Regulators
To date, little work has been conducted looking specifically at C regulators in MS. A 
recent study using proteomic analyses to examine C proteins in MS CSF found 
significant reduction in one unspecified isoform of fB, and of the alternative splice 
product of the fH gene, fH-like protein-1 (fHL-1), in MS CSF (Finehout et al. 2005). 
The authors suggested that measurement of specific C component and regulator protein 
isoforms would be most informative as biomarkers. Although there have been no 
follow-up studies, this work highlights the potential of C measurements as biomarkers 
in MS.
In one study, antibodies to two membrane C regulators (CD46 and CD59) were 
identified in MS serum, present in the acute phase of RRMS but not in chronic MS or 
control groups (Pinter et al. 2000). The antibodies were directed against the active site 
of the C regulator, inactivating their regulatory function and leading to excess
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activation of C. The authors suggest this as a mechanism for damage caused during 
acute relapse but so far no one has either replicated this very small study performed 
with less than 20 patients in each subgroup or investigated these antibodies as possible 
biomarkers of disease. Nevertheless, the study does highlight the need for the sub­
classification of MS on clinical grounds at the point of study design.
Summary
Although showing some variation in MS, C components and activation products have 
not been established as biomarkers of disease, in part because results obtained from 
different studies measuring the same C component have often been conflicting. These 
differences could be due to lack of standard techniques of measurement or to low 
patient numbers leading to underpowered studies; however, universally there has been 
poor stratification of study groups according to phenotype. In a relapsing 
immunologically heterogeneous inflammatory disease, clinical phenotype (such as 
aggressive or benign disease or inter-current relapse) is likely to have a large effect on 
levels of C components. It is the view of the author that much information can be 
gained from further analysis of C components and regulators in serum, plasma and CSF 
employing correlation of levels with clinical phenotype and other modalities of disease 
activity and severity such as MRI.
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2.7 Role of complement in neuroprotection in MS
Neuroprotection from Sublytic MAC
The neurotoxic effects of MAC are concentration dependent and it has been suggested 
that partial deficiency of terminal components has evolutionary benefits (Ross et al. 
1984; Wurzner et al. 1992; Tanhehco et al. 2000). Several groups have shown that a 
sublytic dose of MAC can be cytoprotective, with prior exposure leading to 
accumulated resistance to a subsequent lytic attack (Wurzner 2003; Rus et al. 2005).
In one study in EAE, C5 deficient mice showed greater inflammatory demyelination 
and axonal loss (Weerth et al. 2003), with more OGD apoptosis compared to controls 
(Niculescu et al. 2004). Studies in vitro strongly suggested that this was a consequence 
of sublytic levels of MAC conferring protection from OGD apoptosis (Soane et al. 
1999; Soane et al. 2001; Cudrici et al. 2006a; Cudrici et al. 2006b).
It is known that OGD apoptosis is associated with activation of caspases 3, 8, 9 and 11 
(Soane et al. 1999; Shibata et al. 2000; Hisahara et al. 2001; Cudrici et al. 2006b) and 
inhibition with caspase-3 and -8 inhibitor can prevent OGD apoptosis in vitro (Soane et 
al. 1999). Sublytic MAC has been shown in vitro to inhibit cytochrome c activation of 
caspase-3 and 9 and induce phosphorylation of BCL2-antagonist of cell death (Bad) 
which, when phosphorylated, can bind to cytoplasmic 14-3-3 protein and increase cell 
survival (Soane et al. 2001). Sublytic MAC has also be shown to inhibit Fas ligand 
(FasL) and TNF-a induced OGD apoptosis by inhibition of caspase-8 processing 
(Soane et al. 1999; Cudrici et al. 2006a). This provides in vitro and in vivo evidence of
62
neuroprotection mediated by low levels of MAC, acting primarily via regulation of 
caspases (Rus et al. 2006a; Rus et al. 2006b).
Neuroprotection by Anaphylatoxins
In vitro studies of anaphylatoxins C3a and C5a have shown potential neuroprotective 
effects. Pre-treatment of primary murine corticohippocampal neurons with human or 
mouse recombinant C5a reduced glutamate neurotoxicity and prevented glutamate 
induced neuronal apoptosis (Osaka et al. 1999); these events were signalled through 
mitogen-activated protein kinase (MAPK)-mediated regulation of caspase cascades 
(Mukheijee et al. 2001). C3a was neuroprotective against N-methyl-d-aspartate 
(NMDA) toxicity in the presence of astrocytes, but did not protect against serum 
deprivation-induced apoptotic neuronal death, or a-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionate (AMPA)/kainate-mediated excitotoxicity (van Beek et al. 2001). In 
animal models, C5a-receptor deficient mice were more susceptible to apoptotic injury 
in vivo due to increased excitotoxicity (Mukheijee et al. 2008).
2.8 Genetic findings implicating complement in MS
Epidemiological studies have long recognised the important role of genetic factors in 
susceptibility to MS, with a number of largely unidentified genes contributing to 
disease risk (Ebers et al. 1986; Robertson et al. 1996; Sadovnick et al. 1996). More 
recently genome-wide association studies have confirmed that SNPs in inflammatory
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cytokine receptors IL2Ra and IL7R are associated with susceptibility to MS (Gregory 
et al. 2007; Hafler et al. 2007; IMSGC 2008).
A more significant role for genetic variability influencing C in MS may be signaled by 
recent findings in other CNS disorders with a significant inflammatory component. 
Studies in AMD have recently identified a SNP in the locus encoding the C regulator 
fH (Tyr402His); homozygosity for the minor allele conferred a six-fold increased risk 
of disease (Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005). This 
common polymorphism is located in short consensus repeat 7, a region implicated in 
binding multiple ligands, and has been suggested to alter affinity of fH for surfaces, 
thereby influencing capacity to inhibit C (Skerka et al. 2007). Other identified 
polymorphisms in the alternative pathway component fB and the classical pathway 
component C2 may further contribute to disease risk (Gold et al. 2006). These minor 
changes in the C proteins causing subtle dysregulation in C have been shown to be 
strongly associated with the disease and are suggested to be global markers for AMD 
(Kaur et al. 2006). The Tyr402His polymorphism in fH described in AMD has also 
been identified as a risk allele for AD in some but not all studies (Hamilton et al. 2007; 
Zetterberg et al. 2008).
Given the role of C in neuro-inflammation and the reports of C polymorphisms 
contributing to other inflammatory conditions, a candidate gene approach in MS to 
identify association with C components and regulators would seem logical. Although, 
no studies have yet identified susceptibility genes within C components or receptors
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(table 2.2), evidence for linkage in MS in the region around the centromere of 
chromosome 5 (containing genes for C components C6, C7, and C9), has been 
identified in four independent linkage studies (Ebers et al. 1996; Haines et al. 1996; 
Sawcer et al. 1996; Kuokkanen et al. 1997).
All of the studies so far looking at candidate genes have been underpowered to detect 
significant differences where the risk proportioned to each identified allele is very small 
(odds ratios <1.3) (Sawcer et al. 2005), therefore negative studies can not be deemed 
reliable. Also, work to date has focused on disease susceptibility risk and has not 
examined phenotype, which may be more likely to be altered by C dysregulation. 
Further studies with large groups of patients are needed in order to uncover genetic 
biomarkers for MS within the C system, and to direct functional studies.
2.9 Complement activation and dysregulation in neurological 
disorders
C has been firmly implicated in the pathology of a number of diseases of the CNS and 
its role in NMO and AMD has been discussed. In addition, there have been reports of 
the alternative pathway regulator fH being a marker in AD, significantly elevated in 
AD patients compared to controls (Hye et al. 2006). Further evidence of a role for fH 
in AD pathology has been provided by Honda and co-workers who developed a mAb 
that specifically stained senile plaques and subsequently demonstrated that the mAb 
bound fH, present both in the senile plaques and in CSF in AD (Honda et al. 2000). The 
Tyr402His polymorphism in fH described in AMD has also been identified as a risk
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allele for AD in some but not all studies (Hamilton et al. 2007; Zetterberg et al. 2008). 
More recently the GWAS in AD has revealed further SNPs in C regulator clusterin 
(rsl 1136000) and CR1 (rs6656401) with odds ratios for disease 0.81 and 1.21 
respectively (Lambert et al. 2009). Further genetic and functional work is being done to 
establish these C regulators as clinically useful biomarkers in AD.
C activation is also described in several other CNS conditions including Guillain-Barre 
syndromes in which antibody and C-mediated mechanisms have been shown to be 
important in pathogenesis (Willison et al. 2008), and ischemia-reperfusion injuries such 
as trauma and stroke in which C inhibition has been shown to be neuroprotective 
(Arumugam et al. 2004; Arumugam et al. 2009) (reviewed in (Gasque et al. 2000)). 
These disorders demonstrate how, although not being the primary pathogenic factor, C 
dysregulation can significantly contribute to disease in the presence of other disease 
initiating mechanisms.
2.10 Conclusion
Chapter 2 summarises compelling evidence from pathological, animal model and 
functional studies, that C plays an important role in the immunopathogenesis of MS. 
Prior understanding of the immunology of MS and knowledge gained from animal 
studies leads us to conclude that C does not initiate disease, but propagates ongoing 
disease with increased contribution over the course of the illness. Severity may vary 
between individuals according to the extent of C dysregulation, contributed to possibly 
by functional polymorphisms in C components and regulators. Despite detailed
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information from animal model studies regarding the activation and regulation of C in 
demyelination, questions still remain as to the role of the terminal pathway, the extent 
of the neuroprotective function of C in disease, the role of C in axonal damage and the 
translation of these studies into the more complex human disease of MS.
This chapter has highlighted the importance of clinical classification of disease 
subgroups at the point of study design for functional and genetic work. In particular, 
studies looking at concentrations of C in serum and CSF have often been complicated 
by the disease heterogeneity in which acute relapse, stable and chronic disease are all 
highly likely to have distinctly varying C contributions. In recent years advances in 
technology, in particular the use of proteomic and genetic analytical techniques, have 
led to better opportunities for finding sensitive and specific biomarkers of disease, as 
proven in other complex disorders such as AD, AMD and NMO. Use of these 
techniques, along with better clinical stratification, will bring us closer to finding useful 
biomarkers for MS; however, given the genetic, pathological, immunological and 
clinical heterogeneity of MS, it is highly unlikely there will be a single effective 
surrogate biomarker for disease and a combination of markers, possibly including C 
components and polymorphisms, are more likely to be informative.
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Figure 2.1: Activation and regulation of the complement system
Activation through both classical and alternative pathways results in the formation of 
C5 convertases, cleaving C5 and eventually forming the MAC (C5b-9). They also 
result in the formation of anaphylatoxins which cause inflammation and chemotaxis. 
The C system is under tight regulation by soluble (in italics) and membrane bound (in 
bold) proteins. (Cl-inh = Cl inhibitor, C4bp = C4 binding protein, fl = factor I, MCP = 
membrane cofactor protein (CD46), CR1 = C receptor 1, DAF = decay accelerating 
factor (CD55), fH = factor H, fB = factor B).
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Table 2.1: Complement components in CSF and serum of MS patients
Reference C component 
measured
Sample
type
Significant alteration in concentration 
compared to controls
(Kuwert et al. 1965) C 3/C 4 CSF Reduced
(Link 1972) C 3/C 4 CSF No difference
(Dube et al. 1973) C 3/C 4 CSF Increased
(Yam et al. 1980) C 3/C 4 CSF C3 -  increased 
C4 - no difference
(Price et al. 1980) C 3/C 4 CSF In relapse -  no difference 
In remission -  decreased
(Jans et al. 1984) C 3/C 4 CSF/
serum
Serum and CSF C3 -  no difference 
Serum C4 -  increased (p=0.05) 
CSF C 4 -  reduced (p<0.01)
(Jongen et al. 2000) C 3/C 4 CSF/
serum
Serum C3 -  reduced in RRMS and SPMS 
CSF C3 - reduced in RRMS 
Serum and CSF C4 -  no difference
(Sellebjerg et al. 1998) C3 and TCC CSF/
plasma
C3 -  no difference
CSF TCC -  increased and levels
correlated with disability (p=0.003)
(Morgan et al. 1984) C9 CSF/
plasma
Reduced in CSF 
No difference in plasma
(Compston et al. 1986) C9 CSF/
plasma
Reduced in CSF 
No difference in plasma
(Sanders et al. 1986) TCC CSF Increased
(Mollnes et al. 1987) TCC CSF/
serum
Increased in CSF 
No difference in serum
(Rodriguez et al. 1990) C9 CSF No difference
(Halawaetal. 1989) C9 CSF No difference
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Table 2.2: Genetic studies of complement in MS
Study Gene No. SNPs tested Cohort of patients 
tested from gene
Result
(Chataway et al. 1999) C6 1
C l 3
(Simon et al. 2007) CR2 9
(Bulman et al. 1991) C3 1 allele
227 multiplex families No association
466 affected siblings No distortion of
112 unaffected siblings transmission
Not disclosed 
129 patients 
69 controls
No association 
No association
70
CHAPTER 3: METHODS
3.1 Patient ascertainment and sample collection
The University Hospital of Wales (UHW) is the major tertiary referral centre for 
neurology in South-East Wales, serving a local population of 1.2 million. The 
Department of Neurology has provided a network of MS clinics across South East 
Wales since 1999, with additional clinical data available on a subset of patients 
recruited in 1985. Approximately 1000 patient contacts are documented annually within 
this clinic network with detailed demographic and clinical data collected at presentation 
and following visits. Initial and subsequent complete datasets are available on 2388 
patients with MS (including 2240 probands), comprising more than 90% of the local 
prevalent patients and may therefore be considered to be a representative sample of the 
prevalent population. All information collected is recorded on a secure NHS database 
so that longitudinal information and disability scores on individual patients can be 
tracked over the disease course. Ethical approval for the study was obtained from the 
South Wales ethics committee ref 05/WSE03/111.
Patients are classified according to diagnostic criteria. Some of the older patients on the 
data base are classified by the Poser criteria (Poser et al. 1983) where patients are 
defined according to clinically or laboratory supported definite or probable disease 
(table 3.1). However, more recently recruited patients are defined by the McDonald 
criteria (McDonald et al. 2001) which combines clinical and paraclinical evidence so as 
to demonstrate dissemination in time and space of lesions (table 3.2). Standardised
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minimum current status data sets are collected at each clinic visit, including information 
on current disease course, relapse status, disability measured by the EDSS and 
therapeutic interventions, together with anatomical site and timing of relapses since last 
review. Patients with suspected relapses are seen within 5 days from initial contact and 
confirmed relapses are offered follow up at 2, 6 and 12 months. The EDSS (Kurtzke 
1983) is a non-linear clinical scale from 0-10 with each point representing a different 
level of disability ranging from neurologically intact to death (table 3.3). EDSS 4 and 
less are compiled of a combination of functional scores based on different parts of the 
neurological examination. EDSS greater than 4 are based on various walking 
milestones, such as EDSS 6 is the ability to walk 100 metres with a single aid.
The MS biobank consists of serum, plasma and DNA samples collected at routine clinic 
visits so that longitudinal samples are matched with routine clinical data. A small 
number of samples were collected outside of these clinics, via home visits or through 
links with MS society groups with similar clinical information collected. Control 
plasma, serum and DNA (Ethics ref no. 09/MRE09/35) was sourced from patients’ 
spouses and friends coming to routine clinics along with hospital and university 
employees. Control patients were excluded if they had a history or family history of any 
neurological disorder, or a history of other inflammatory conditions.
CSF samples were obtained from patients admitted to the neurology ward in the 
University Hospital of Wales, for investigation of either known MS or CIS. Control 
CSF samples were obtained from the investigated patients who subsequently turned out
72
to have an alternative diagnosis. All CSF samples were paired with serum, plasma and 
DNA samples.
3.2 Specimen processing and storage 
CSF
CSF is a dynamic metabolicaily active substance which already has important functions 
in the diagnosis of neurological disorders. It is in direct continuum with the 
extracellular space of the CNS and thus is felt to hold advantages over serum as it is 
more likely to reflect the relevant central biological process. Unfortunately the 
specificity of available tests is often low as constituents can be similar in different 
pathological processes. CSF is obtained relatively easily by lumber puncture, but repeat 
sampling is difficult because of the invasiveness of the procedure.
To create a CSF biobank, storing CSF for use in different projects over many years, it is 
important that all samples are handled in a consistent fashion ensuring continuity. It is 
also important to aliquot samples into small volumes to avoid freeze-thaw cycles, 
which can degrade proteins. Proteomic studies have suggested that many proteins that 
are potential biomarkers for neuroinflammatory conditions degrade if not handled 
correctly, i.e. are not processed in sufficient time or stored at low enough temperatures 
(Bruegel et al. 2009). Our handling techniques are based on recommendations from 
such studies and from guidelines in a recent document by Teunissen et al (Teunissen et 
al. 2009).
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CSF was taken atraumatically from between vertebral bodies L3/4 or L4/5. Bloody 
samples were discarded and samples were centrifuged (2000g/10mins) within 30 
minutes of collection before being aliquoted and frozen at -80°c until use. CSF and 
paired serum samples were analysed in the routine laboratory for IgG, albumin and 
OCBs. IgG and albumin were measured on the BN 11 nephlometer and OCBs on the 
Sebia Hydrasys using Hydrogel 9 CSF Iso-electric focussing. Reference ranges for 
normal values were: serum IgG 5.2-15.5 g/L, CSF IgG <58 mg/L, serum albumin 35-50 
g/L, CSF albumin 160-360 mg/L, albumin/IgG index 0.3-0.8.
Serum and plasma
When considering the storage of blood samples and establishing a biobank, one should 
allow for analysis of the most unstable product in all samples and treat samples 
uniformly. Handling time for serum and plasma has been shown in proteomic studies to 
be extremely important for some proteins and peptides (West-Nielsen et al. 2005). 
Various experiments have suggested optimal standards for sample processing 
(Baumann et al. 2005; Jimenez et al. 2007; Pieragostino et al. 2009). Based on these, 
and for practical reasons, serum and plasma samples were processed within 3 hours of 
retrieval and after centrifuge at 2000g for 10 minutes; supemants were frozen at -80°C 
in multiple aliquots until use; freeze-thaw cycles were avoided. Protocols for serum, 
plasma and CSF handling did not allow for the collection of cells which were not used 
in this thesis but may be useful in other work.
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DNA
Venous blood was collected for DNA and extracted in the University Hospital of Wales 
medical genetics laboratory using the Autopure DNA Purification robot. Samples were 
suspended in DNA Hydration Solution from Qiagen (Product code 158916) and stored 
at -80°c. Saliva samples were collected using the Oragene DNA self-collection kit 
(DNA Genotek Inc, Ottawa, Ontario,Canada) and DNA extracted using the Oragene 
manual purification protocol (www.dnagenotek.com). Concentrations of DNA were 
measured using a NanoDrop Spectrophotometer ND1000.
All samples were labelled anonymously according to a unique patient identifier, date of 
sampling and sample type. The location within the freezer was documented on the 
described database.
3.3 Conclusion
Establishing a comprehensive biobank offers an important resource that can be valuable 
to many research studies for a number of years. However, for a useful biobank, one 
must consider many factors. Our biobank included samples from a range of sources 
(CSF, serum, plasma and DNA) and all samples were collected and stored in a rigorous 
fashion to allow their use for any potential project over the following years (patient 
consent included allowance for the use of samples in future projects not outlined in the 
patient information leaflet). Practical limitations restricted the quality of the handling 
techniques to some extent, and to optimize the biobank, accurate records should be held 
on the exact time to processing and time of day sample was collected (possibly 
important for fluctuations in circadian rhythms). Importantly for any biomarker
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experiment, each sample collected was linked on a convenient and comprehensive 
clinical database with extensive accurate clinical information. These rigorous methods 
allowed accurate analysis of biomarkers in larger numbers of patients with extensive 
correlation to clinical phenotypic data.
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Table 3.1: Poser criteria for multiple sclerosis
Category Attacks Clinical
evidence
Paraclinical
evidence
CSF OCB
CDMS 2 2
2 1 and 1
LSDMS 2 1 or 1 +
1 2 +
1 1 and 1 +
CPMS 2 1
1 2
1 1 and 1
LSPMS 2 +
CDMS: clinically definite multiple sclerosis. LSDMS: laboratory supported definite
multiple sclerosis. CPMS: clinically probably multiple sclerosis. LSPMS: laboratory 
supported probable multiple sclerosis. Attack: the occurrence of neurological 
symptoms lasting at least 24 hours. Clinical evidence: neurological signs evident on 
examination. Paraclinical evidence: neurological dysfunction demonstrable by tests 
such as evoked potentials and tissue imaging studies. CSF OCB: cerebrospinal fluid 
oligoclonal bands. From (Poser et al. 1983).
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Table 3.2: McDonald criteria for multiple sclerosis
Clinical presentation___________________ Additional data needed for diagnosis
Two or more attacks with objective None
clinical evidence of at least 2 lesions
Two or more attacks with objective Dissemination in space on MRI
clinical evidence of 1 lesion or
Up to 2 MRI lesions plus +ve CSF OCBs
One attack with objective clinical Dissemination in time on MRI
evidence of 2 or more lesions
One attack with objective clinical Dissemination in space on MRI
evidence of 1 lesion (i.e. CIS) or
Up to two MRI lesions plus +ve CSF OCBs 
AND
Dissemination in time on MRI
Insidious neurological progression +ve CSF OCBs 
AND
Dissemination in space on MRI 
or
Abnormal VEPs associated with 4-8 brain 
lesions, or less than 4 brain lesions and 1 spinal 
cord lesion on MRI 
AND
Dissemination in time on MRI 
or
Continued progression for 1 year
CIS: clinically isolated syndrome. Dissemination in time and space on MRI scans are
defined in detail in (McDonald et al. 2001). 
From (McDonald et al. 2001).
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Table 3.3: Expanded disability status score
0.0 Normal examination
1.0 No disability, minimal signs 1 FS
1.5 No disability, minimal signs in more than 1 FS
2.0 Minimal disability in 1 FS
2.5 Minimal disability in 2 FS
3.0 Moderate disability in 1 FS
Fully ambulatory with moderate disability in 1 FS 
or
3.5 mild disability in 3 or 4 FS
Fully ambulatory without aid for up 12hrs / day 
AND
able to walk 500m without rest 
AND
4.0 1 FS grade 4 or combinations more than EDSS 3.5 
Up and about much of day
AND
4.5 able to walk without aid or rest for more than 300m
5.0 Ambulatory without aid or rest for 200m
5.5 Ambulatory without aid or rest for 100m
6.0 Intermittent or constant unilateral assistance required to walk 100m
6.5 Constant bilateral assistance required to walk about 20m
7.0 Unable to walk beyond 5m even with aid
7.5 Unable to take more than a few steps
8.0 Restricted to bed or chair with effective use of arms
8.5 Restricted to bed some use of arms
9.0 Restricted to bed can communicate and talk
9.5 Totally helpless bed patient
10.0 Death____________________________________________________________
FS: functional score (these incorporate various elements of neurological examination).
From (Kurtzke 1983)
CHAPTER 4: VALIDITY OF PATIENT DERIVED 
DISABILITY AND CLINICAL DATA IN MULTIPLE 
SCLEROSIS
4.1 Introduction
MS is a complex and heterogeneous disease of the CNS in which clinical features 
including presentation, disease course and rates of accumulation of disability, 
demonstrate high degrees of individual variation (Compston et al. 2002; Hirst et al. 
2008). Since the considerable investment required for long term surveillance commonly 
exceeds the attention of individual clinicians, descriptive accounts of the disease are 
commonly derived from cross-sectional studies of population-based or clinic cohorts 
(Runmarker et al. 1993; Bronnum-Hansen et al. 1994). These data are effective in 
demonstrating the phenotypic range of disease; however, single assessments of 
disability are of limited value since the rate of accumulation of disability is variable, 
long periods of disease stability common and the initial pattern of disease is not 
necessarily predictive of final outcome (Weinshenker et al. 1989). Where reliable, 
extensive longitudinal natural history data has been available in large, robust 
populations, it is considered a rare and valuable resource, contributing to a wide range 
of epidemiological, genetic and interventional studies. (Weinshenker et al. 1991; 
Confavreux et al. 2000; Confavreux et al. 2006a). For a detailed examination of 
biomarkers in MS, it was perceived that an accurate and extensive clinical database was 
necessary. Although the database outlined in Chapter 3 had been established for 10
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years prior to the development of the biobank, it was apparent that a proportion of data 
was missing, especially from patients not seen frequently in a clinic setting and with a 
disease course of more than 10 years. This Chapter outlines the development of a 
simple and cost-effective method to collect accurate historical data from MS patients, 
thereby increasing the extent and reliability of our prior established clinical resource.
In an effort to produce cost-effective methods to derive reliable disability data in large 
epidemiological studies and in order to gain information from patients who have 
difficulty accessing formal clinical settings, attention has turned to the feasibility of 
patient administered measures. In particular, the use of telephone or paper 
questionnaires to assess current disability using the EDSS has become a more widely 
accepted method of data collection, showing good levels of correlation with more 
formal clinician-led assessments (Bowen et al. 2001; Cheng et al. 2001; Lechner-Scott 
et al. 2003). However, even with the use of these self-administered questionnaires, 
collection of sufficient data to develop a detailed, longitudinal profile of disease related 
disability remains a time-consuming process extending over many years and remains 
beyond the scope of many studies.
Historical analysis of disability milestones derived from individual patient testimony is 
commonly presumed to be unreliable, prone to recall bias, and complicated by 
cognitive deficits in affected patients. Despite this, and in the absence of objective 
records, patient testimonies detailing current and historical events, including 
information on disease onset, temporal evolution of disability and relapse frequency,
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are widely employed to develop clinical decisions on management and therapeutic 
interventions. The validity of data collected in this manner has rarely been the subject 
of detailed analysis since it requires access to an established cohort of patients with 
reliable disability and clinical milestone data collected over extended time periods
In this study a patient questionnaire was designed (appendix 1) based on the EDDS 
with incorporated algorithms to determine current EDSS and the year in which patients 
reached well-recognized disability and clinical milestones. Validity of these patient 
derived data, collected either by postal questionnaire or structured telephone interview, 
was examined by employing a well described population-based cohort of patients for 
which comparable and detailed clinician derived clinical and disability data had been 
amassed regularly over a period of more than twenty years. Similar comparisons were 
also made for a range of MS related clinical phenomenology, including year of onset 
and diagnosis, initial and current disease course, time to secondary progression and 
relapse frequency.
4.2 Methods 
Subjects
Inclusion criteria were definite or probable MS according to Poser criteria or MS or 
possible MS according to the McDonald criteria (Poser et al. 1983; McDonald et al.
2001), an EDSS of between 6.0 and 9.0, full clinical data sets including multiple 
assessments in clinics throughout their disease course (allowing accurate assessment of
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time of disease onset and time to EDSS > 4, 6 and 8) and previous consent to be 
contacted by telephone or letter for research purposes. Given that primary endpoint 
evaluated in this study was time in years to EDSS >4, 6 and 8, patients were selected 
who had already reached 2 of the 3 specified milestones and patients with EDSS < 6.0 
were excluded. Of 661 living MS patients with EDSS 6.0-9.0, 160 were considered to 
have complete data sets and of these 99 patients were consented to take part in research. 
To assess the possibility of selection bias, the demographic characteristics of the 562 
patients not included in the study (mean age 54.2, 67.2% female, mean disease duration
20.4 years, mean EDSS 6.8 (range 6-9.0), disease course including 16.9% with PPMS, 
16.4% with RRMS and 66.7% with SPMS) were examined and found to have a 
significantly higher age (p=0.001), disease duration (p=0.008) and EDSS (p=0.001) 
than the assessed population. The characteristics of the 20 non-responders (median age
42.5 years, 75% female, median disease duration 10.5 years, median EDSS 6 (range 6- 
8.5), disease course included 10% with PPMS, 25% with RRMS and 65% with SPMS) 
were assessed and were found to be similar to the examined population. To increase the 
proportion of participants, non-responders to the postal questionnaire were contacted 
via telephone after 3 weeks; in addition contact via telephone was attempted 5 times 
before patients were classified as non-responders.
Patients were stratified according to gender and age (^ 9 ,  >49) and then randomly 
allocated one of two groups -  postal questionnaire (PQ) or telephone interview (TI). 
Patients in the TI group also used a supplemental ‘life course grid’, which identified 
the timing of important life (i.e. marriage, house move, birth of a child or retirement)
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and / or national and world (i.e. the Queen’s coronation or a particularly hot summer) 
events to help improve their recollection of relevant disease-specific events (Parry et al. 
1999). The telephone assessor was blinded to the recorded clinician-derived 
information.
Questionnaire
The questionnaire (appendix 1) initially identified characteristics of the disease 
presentation, such as year of onset, year of diagnosis and whether initial presenting 
symptoms had fully resolved (“In what year did you first have symptoms of Multiple 
Sclerosis?”). Patients were subsequently asked to identify their current disease course 
from a selection comprising RRMS, SPMS and PPMS or unknown. Although these 
terms were not expanded with an explanation of disease type, in order to provide 
additional validity for disease course further questions were provided concerning onset 
of symptom progression (“Looking back, do you think your symptoms of MS are 
gradually worsening despite the effect of relapses?”). Questions were also asked 
regarding initial and recent relapse information and the clinical characteristics of 
relapses from a selection of pre-determined responses. Current EDSS was determined 
by asking patients to select from a series of statements describing walking ability as 
specified by the EDSS with reference distance between well recognized local 
landmarks; for example, 500 meters equated to the length of one of the well known 
shopping streets in Cardiff. Patients who could walk at least 500 meters without rest or 
aid were scored at EDSS equal to or less than 4. Patients were also asked to recall the 
year of reaching specific disability milestones including EDSS >4 (inability to walk at
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least 500 meters without rest or aid), 6 (use of a single walking aid to walk at least 100 
meters) and 8 (use of a wheelchair for all activity). The milestones were selected 
because of their common use as endpoints in previously published epidemiological 
studies and their onset considered as well defined events easily recognized by both 
clinicians and patients.
Statistical analysis
Data analysis was performed using Statistical package for Social Sciences version 16 
(SPSS inc., Chicago, IL, USA). To assess the accuracy of the questionnaire derived 
data for the year of reaching specified disability milestones, the time in years was 
calculated from the clinician derived year of first symptom onset to the specified 
disability endpoints, second relapse, diagnosis and onset of secondary progression. 
Time to disability milestones, second relapse, diagnosis and SPMS was analysed after 
log transformation, as the data were positively skewed, using reliability analysis (two- 
way random ICC with 95% confidence intervals (Cl)). Poor correlation was taken to be 
<0.7, satisfactory correlation 0.7-0.9 and good correlation >0.9. The difference in the 
accuracy of reporting variables via telephone or patient questionnaire was examined 
using Students Mest (data was normally distributed). Bland Altman plots (Bland et al. 
1986) (absolute difference in years plotted against mean difference) were used to 
examine for any systematic bias or unequal variation. Gender, age and disease duration 
were assessed to ascertain any systematic effect on the reliability of self-reported 
measures by dichotomising the data into two groups (perfect agreement -  no difference 
in years taken to reach an EDSS end-point or not perfect agreement) for reaching EDSS 
6 (this being the largest group). The odds ratios with 95% CIs were then calculated for
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females vs. males, old vs. young (cut-off 60 years) and long versus short disease 
duration (cut-off 20 years). For categorical data such as disease course, recovery from 
initial symptoms and occurrence of relapses in the last year, data was cross-tabulated 
and a weighted Kappa coefficient was calculated, taking a Kappa >0.7 as evidence of 
good agreement.
4.3 Results 
Demographics
PQs were returned by 35/49 patients (71.4%), and 44/50 (88%) patients were 
successfully contacted for TI. Mean age of patients in the PQ cohort was 49.4 years 
(SD 10.4) and 62.9% were females; compared with a mean age 48.9 years (SD 10.0) 
and 68.2% females in the TI cohort. According to clinician derived data, 14.3% of 
patients in the PQ cohort had PPMS, 22.9% RRMS and 62.9% SPMS. In the TI cohort 
9.1% had PPMS, 18.2% RRMS and 72.7% SPMS. Mean EDSS was 6.5 (SD 0.7) in the 
PQ cohort and 6.4 (SD 0.8) in the TI cohort with 11.4% in each group of EDSS 8 and 
above.
Disability
Current EDSS derived from the questionnaire (via post or telephone) showed 
satisfactory levels of correlation (ICC 0.69 to 0.86) with the clinician derived data 
(table 4.1) with perfect agreement noted in 75.9% and 88.6% allowing for accepted 
intra-observer variation of +/- 0.5 EDSS points (Goodkin et al. 1992). The proportion 
with perfect agreement was more modest (between 25 to 32%) when assessing time to 
selected disability milestones (EDSS>4, 6 and 8), but widening the time window to
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either +/- 1 (between 59 and 75%) or +/- 2 years (between 75 to 100%) substantially 
improved this (table 4.2). All disability milestones showed good ICC between 
questionnaire and clinician derived data (table 4.1). The Bland Altman plots (fig 4.1) 
did not show evidence of any systematic bias but there were occasional outliers that 
were outside the 95% agreement levels (e.g. EDSS 4). Very occasionally patients 
reported the year of reaching a milestone before clinician reported disease onset; this 
may have been an error in patient or clinician reporting of year and is seen as a negative 
mean difference in the Bland Altman plots. In 26 patients, clinician derived time to 
EDSS>4 was not available due to non-attendance at clinic during this period of disease. 
Of the 18 patients with perfect agreement in time in years to EDSS 6, 13 were female, 4 
were classed as old (>60 years) and 5 classed as having a long disease duration (>20 
years). The odds ratio of reporting exact time in years to EDSS 6 for females versus 
males was 1.37 (95% Cl 0.43-4.39), for old versus young was 1.56 (0.42-5.82) and for 
patients of long versus short disease duration was 1.01 (0.31-3.29).
Disease onset, relapse, diagnosis
Table 4.1 and figure 4.2 show the mean year of symptom onset and time from clinician 
reported onset to second relapse and diagnosis with satisfactory levels of correlation 
between questionnaire and clinician derived data for year of initial symptom onset (ICC 
0.86) and time to diagnosis (ICC 0.86), but poor agreement for time to second relapse 
(ICC 0.55). For all three variables the PQ was more accurate than the TI; however, the 
forms of data collection were only significantly different when concerning time to 
diagnosis (p=0.03) and second relapse (p=0.02). When reporting initial symptoms, 
patients were asked if they obtained complete recovery from their first event. In the PQ
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group there was agreement in only 22 of the 35 responding patients (Kappa coefficient 
0.25), and in the TI group 29 of 44 patients (Kappa coefficient 0.22). When asked to 
select from a series of descriptions regarding their first relapse, only 24.1% of patients 
recorded the exact description as that of the clinical records. However 51.9% reported a 
similar event and of these 34.1% under-reported and 65.9% over-reported their 
symptoms.
Disease course
Patients were asked to record current disease course; analysis showed good agreement 
between the questionnaire and clinician derived data in the PQ group (Kappa 0.89) with 
only 2 of the 33 responding patients reporting RRMS but recorded to have SPMS; both 
of these patients reported that their symptoms were worsening despite the effects of 
relapses, implying progressive disease. In the TI group there was moderate agreement 
(Kappa 0.56) with 7 of the 42 patients reporting RR disease but recorded as having 
SPMS (of these only 4 of 7 reported gradually worsening symptoms), 2 reporting 
PPMS and recorded as having SPMS and 1 person reporting SPMS and recorded as 
having PPMS. To clarify disease progression, patients were asked if they had 
progressive symptoms despite the effect of relapses; analysis showed agreement in 
82.3% (Kappa 0.39). There was satisfactory correlation between questionnaire and 
clinician derived data for time in years from disease onset to SPMS (table 4.1 and 4.2, 
fig 4. 1 and 4.2). The method of data collection appeared to be more accurate in the TI 
group; however, this was due to chance with no significant difference between methods 
of data collection (p=0.64)
Patients were asked to report any relapses they had in the previous year. There was 
poor correlation between patients and clinician reported data (Kappa = 0.39) with 
46.8% of patients reporting at least one relapse compared to 17.7% with clinician 
reported events. Patients were also inclined to report more relapses, with 6 patients 
reporting 2 relapses and 3 reporting 3, compared to only 2 patients recorded as having 2 
relapses.
4.4 Discussion
This novel questionnaire, when compared to clinician collected longitudinal data, was 
accurate in the estimation of current EDSS as well as time from disease onset to well- 
recognised disability milestones EDSS >4, 6 and 8. However, sample size for analysis 
of time to EDSS 8 was limited to 8 patients, making this analysis underpowered. The 
proportion of patients with perfect agreement to milestones was improved with 
increasing the time-window to 2 years, however a 2 year discrepancy in this end-point 
would limit the use of such data in some short-term studies although a variability of 1-2 
years may be more acceptable in studies collecting data over longer periods in a disease 
which commonly spans more than 30 years. Furthermore, missing data points in 
analysis of long term studies is likely to create more bias than using data points with a 
possible 2 years discrepancy. Precise information was also gained from the 
questionnaire regarding date of disease onset and diagnosis, and time to SPMS. There 
was accurate reporting of current disease course; however, the patients interviewed by 
telephone were more likely to incorrectly report their disease as RRMS when the 
clinician considered they had become progressive, and patient reporting of disease 
progression only showed moderate agreement. The reasons for this are not clear but
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patient recollection of disease course may have been biased by what the patient was last 
told in clinic. The questionnaire was less accurate when assessing more detailed 
information related to features at disease onset and relapses where patients tended to 
over-report symptoms compared to physician records.
No major differences were observed between data collected via postal questionnaire 
compared to telephone interview; however, a trend was seen for the postal 
questionnaire to be more accurate, which was significant when assessing year of 
diagnosis and second relapse, despite the telephone group using the extra memory aid 
tool of the life course grid. This is possibly because patients completing the 
questionnaire engage family members and friends for corroboration and spend more 
time considering individual questions. The telephone questionnaire took between 10 
and 30 minutes to complete whereas the postal questionnaire consumed minimal 
administrative resources and therefore may be more effective in collecting larger 
datasets providing return rates can be optimized.
It is important to consider the patient sample with regards to the generalisability of 
results. Because the primary end-point of the study was to assess time to disability 
milestones, only patients with higher EDSS scores were entered into the study. This 
sub-group of MS patients may possibly have a lower recall ability than patients with an 
EDSS <6.0 and a corresponding lower age and disease duration; therefore our study 
may under-represent the accuracy of the questionnaire. Patients selected to take part in 
this study had regular clinic attendance (necessary so that their core data was accurate),
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this was reflected by a lower age, disease duration and EDSS than the non-assessed 
population. They therefore may represent a highly motivated group who has a good 
understanding of their disease and disability levels compared to patients not under 
regular specialist care.
This study assumes that clinician-derived data represents the gold standard; however, 
this may not always hold true especially given that some clinician-derived data is based 
on patient recollection in clinic. Although patients had all been assessed clinically in 
the year prior to the study, recent variation in symptoms may have been missed. This is 
of particular importance when considering current disability and relapses which 
therefore, may have been under-reported in the clinician derived data. However, this 
patient cohort all had an EDSS of > 6 with a high proportion having SPMS and long 
disease duration. The patients could therefore have expected to have a lower than 
average relapse rate and minimal progression over the course of a single year and the 
impact on results was unlikely to have been significant. Due to the size of the cohort 
studied, analysis of the impact of age, gender and disease duration on outcome 
measures was limited and only applied to EDSS milestone 6. Given the small sample 
size and wide confidence intervals from this analysis, systematic differences due to bias 
cannot be excluded. Future work using a larger and more representative data set may 
help further characterise whether there are any particular sub-groups with differential 
recall characteristics.
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Previous work in this area has focused on collection of data to determine a single 
current measure of the EDSS either via postal questionnaire (Solari et al. 1993; 
Verdier-Taillefer et al. 1994; Goodin 1998; Bowen et al. 2001; Cheng et al. 2001) or 
telephone interview (Lechner-Scott et al. 2003). The reliability of self-reported 
disability has been shown to be good in the majority of these studies, with 2 studies 
reporting ICC’s of >0.8 (Solari et al. 1993; Bowen et al. 2001); however, it was noted 
that reliability greatly improves if allowing for variability of +/- 1 EDSS point, which 
equates to varying levels of rise in disability depending on EDSS (Thompson et al. 
1998). In other work Hoogervorst et al analysed the validated self-administered 
questionnaires, Guy's Neurologic Disability Scale (GNDS) (Hoogervorst et al. 2001b) 
and Multiple Sclerosis Impact Scale (MSIS-29) (Hoogervorst et al. 2004b), 
demonstrating good correlation with clinician assessed EDSS. This group then went on 
to assess self-reported changes in disability (showing poor correlation using the GNDS 
at 1 year but improved reliability at 2 years) (Hoogervorst et al. 2003; Hoogervorst et 
al. 2004a) and treatment effects on disability (the GNDS having poor sensitivity to pick 
up acute treatment related changes) (Hoogervorst et al. 2001a). Self-reported mobility 
scales such as the Rivermead Mobility Index (Collen et al. 1991) and the MS Walking 
Scale (Hobart et al. 2003) have also revealed good reliability compared with clinician 
assessment (Pearson et al. 2004); however, inaccuracy of doctors and patients in 
estimating walking distances has been observed, indicating that they may not be 
reliable indicators of health (Sharrack et al. 1997). Self-reporting of current disease 
course has been assessed in only one study, which revealed moderate agreement for 
patient classification and physician assessment (Kappa 0.45 (95% Cl: 0.32-0.59))
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(Bamer et al. 2007). To date all these studies examining self-reported measures are 
restricted to a contemporary analysis of disease state and do not analyse rates of 
disability progression.
Patients with MS frequently present to clinical services many years after the onset of 
symptoms. In these situations it is necessary and common practice to record 
retrospective patient-derived details relating to symptoms at disease onset. This study 
would suggest that although patient-derived data are likely to be valid for disease 
course and disability progression, they may give a less accurate representation of 
symptoms and course at disease onset and relapse rates. If determined retrospectively 
these data should be used with caution, particularly if likely to modify disease 
management options. The data also suggests that patients may over report relapsing 
disease and therefore caution should be observed in a clinical setting to use objective 
measures of progression. Presence of relapses in the previous year is also an important 
element in selecting therapeutic interventions and our study would suggest that patients 
have a tendency to over report clinically significant events and clinicians should be 
cautious in using self-reported relapses as evidence for treatment.
This questionnaire has been shown to be an accurate and cost-effective method of 
determining current and retrospective disability data including time to well-recognized 
disability milestones from MS patients and could be useful for augmenting phenotypic 
information in clinical practice as well as for research purposes. This work could be 
extended by obtaining more data and using covariates to model measurement error so
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that modem methods of imputation can be used, thereby maximising the time to event 
data. Such an approach could be used with other datasets to enhance power and may 
help to reduce bias if patients in longitudinal studies with missing data differ in their 
natural history, thereby producing more realistic outcome data.
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Table 4.1: Correlation of data collection for disease milestones
Differences are shown between data collected from the questionnaire (via post or telephone) and 
clinician derived data for current EDSS, year of disease onset and time in years from clinician recorded
disease onset to disability milestones.
Number P Mean (SD) CD Mean (SD) ICC (95% Cl)
Current EDSS All 79 6.5(0.8) 6.4(0.7) 0.79 (0.69-0.86)
PQ 35 6.6(0.8) 6.5(0.7) 0.89 (0.79-0.94)
TI 44 6.5(0.8) 6.4(0.7) 0.72 (0.54-0.84)
Time to milestones EDSS>4 All 53 10.3(8.3) 10.3(9.1) 0.94 (0.89-0.96)
PQ 23 8.0(7.0) 7.8(7.7) 0.93 (0.84-0.97)
TI 30 11.8(9.3) 12.2(9.8) 0.93 (0.86-0.97)
EDSS 6 All 76 13.1(10.3) 14.0(11.0) 0.94 (0.90-0.96)
PQ 34 12.3(10.7) 12.8(11.3) 0.95 (0.90-0.97)
TI 42 13.7(10.1) 14.9(10.7) 0.93 (0.88-0.96)
EDSS 8 All 8 16.6(11.8) 17.4(12.3) 0.99 (0.96-1.00)
PQ 4 17.0(15.6) 17.8(16.3) 1.00 (0.93-1.00)
TI 4 16.3(9.1) 17.0(9.5) 0.98 (0.78-1.00)
Year of onset All 79 1992.6(9.5) 1991.6(11.1) 0.86(0.79-0.91)
PQ 35 1992.8(10.0) 1992.3(11.6) 0.93(0.86-0.96)
TI 44 1992.3(9.2) 1991.1(10.9) 0.80(0.66-0.89)
Time to milestones Second All 79 2.9(3.7) 4.2(5.9) 0.55(0.37-0.69)
relapse PQ 35 2.2(3.4) 3.4(4.4) 0.64(0.39-0.80)
TI 44 3.5 (4.0) 4.9(6.8) 0.45(0.18-0.66)
Diagnosis All 79 6.2(8.2) 6.2(8.0) 0.86(0.79-0.91)
PQ 35 5.5(7.7) 5.4(7.5) 0.98(0.97-0.99)
TI 44 6.9(8.6) 6.8(8.4) 0.76(0.61-0.86)
SPMS All 57 10.9(10.5) 9.3(8.7) 0.78(0.65-0.86)
PQ 26 9.5(9.5) 7.9(7.4) 0.69(0.42-0.85)
TI 31 12.0(11.2) 10.5(9.7) 0.84(0.69-0.92)
p  = data from questionnaire. CD; clinician derived data. SD; standard deviation. ICC; Intraclass
correlation coefficient. Cl; confidence interval. PQ; postal questionnaire. TI; telephone interview.
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Table 4.2: Reporting of disease milestones
Percent of patients who report the year of disease onset, diagnosis and time from 
symptom onset to disability and clinical milestones to either the exact year or within +/- 
1 or +1-2 years of the clinician-derived data.
Exact year +/- 1 year +/- 2 years
Onset 30.4 57.0 72.2
Diagnosis 53.2 81.0 88.6
EDSS >4 32.1 62.3 81.1
EDSS 6 23.7 59.2 75.0
EDSS 8 25.0 75.0 100.0
SPMS 14.0 47.4 61.4
EDSS; Expanded Disability Scale Status;
SPMS; Secondary Progressive Multiple Sclerosis
96
Figure 4.1: Plots showing no systematic bias in reporting
Bland-Altman plots showing the absolute (clinician - questionnaire data) and mean 
(average of clinician and questionnaire data) difference in years between questionnaire 
and clinician derived data for time to EDSS>4, 6 and 8 and SPSS with 95% absolute 
levels (indicated by dashed line).
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Figure 4.2: Accurate reporting o f disease milestones
Box-plots of clinician-derived (CD) and patient reported (P) age of symptom onset 
(Onset), second relapse (2ndR), diagnosis (Dx) and onset of secondary progressive MS 
(SPMS). Box plots show the median (bold line) and interquartile range (box). Values 
more than 1.5 IQR’s from the end of the box are labeled as outliers (o).
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CHAPTER 5: COMPLEMENT REGULATOR FACTOR H 
AS A SERUM BIOMARKER OF MULTIPLE SCLEROSIS
DISEASE STATE.
5.1 Introduction
C regulator fH is a single chain serum glycoprotein that regulates the formation and 
function of C3 and C5 convertase enzymes. Regulatory activity is attributed to its ability 
to recognize and bind C3b fragments (Zipfel et al. 1999). FH is synthesized in the liver 
and has a normal serum concentration of about 250mg/L; of note, many papers quote 
higher serum levels of fH in normal individuals; optimization of the assays and standards 
for fH on which our normal range is based, has previously been described (Hakobyan et 
al. 2008). Changes in plasma fH levels have been linked to atherosclerosis (Oksjoki et al. 
2003; Goverdhan et al. 2006) and AD (Honda et al. 2000; Hye et al. 2006). In AD, 
plasma fH levels, assessed semiquantitatively, were elevated in disease and shown to 
reflect risk of disease progression in early AD (Thambisetty et al. 2008). The most 
common polymorphism in fH, Tyr402His (allele frequency 62:38 in Caucasians 
(HapMap)), has been associated with increased risk for AMD, homozygosity for the His 
allele conferring a six-fold increased risk (Edwards et al. 2005; Sjoberg et al. 2007). In 
AD, one large study found no association with this polymorphism (Hamilton et al. 2007), 
while another found an association of the His402 allele with disease, but only in those 
also carrying the ApoE4 risk allele (Zetterberg et al. 2008). FH appears to discriminate 
self from non-self by recognizing polyanionic structures on self cells, such as sialic acid
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and the glycosaminoglycan chains of proteoglycans (e.g. heparin sulphate and dermatan 
sulphate), thus inhibiting C activation on host surfaces (Kazatchkine et al. 1979; Carreno 
et al. 1989). The Tyr402His polymorphism located within short consensus repeat 7, a 
putative binding site for glycosaminoglycans (Skerka et al. 2007), may influence surface 
binding. FH and its polymorphic variants have not been measured in MS serum or CSF 
samples to date.
The C system has an established role in the pathogenesis of MS (reviewed in Chapter 2) 
and in light of recent evidence (as described above) outlining a potential role for fH as a 
biomarker in other CNS inflammatory conditions and a recent proteomic study showing 
altered levels of fHL-1 in MS CSF specimens; the hypothesis was tested that serum fH 
levels would reflect chronic inflammation in MS and therefore help define disease state. 
Further, it is speculated that differential expression and/or consumption of the fH 
Tyr402His polymorphic variants would further inform risk of disease progression and 
other disease characteristics in MS. To achieve this, methods to interrogate fH levels and 
polymorphisms were developed and optimized using novel monoclonal antibodies and 
unique enzyme-linked immunosorbant assays (ELISAs) that enable the quantification of 
total fH and the Tyr402His polymorphic variants in plasma, serum or CSF (Hakobyan et 
al. 2008). Here, these unique ELISAs were employed to measure fH and the Tyr402His 
polymorphic variants in subgroups of MS patients with comprehensive clinical 
phenotypic data.
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5.2 Methods
Subjects
Serum samples were prospectively obtained between 2006 and 2008, from 350 patients 
with MS (McDonald et al. 2001), including 212 patients with RRMS (97 with stable- 
RRMS (S-RRMS) who had no clinically evident relapse for at least 12 months and 115 
with acute-RRMS (A-RRMS) sampled during acute relapse), 85 patients with SPMS and 
53 with PPMS. Serial samples were available on 11 patients with clinically stable RRMS 
and 12 patients who were in transition from RRMS to SPMS. Patients with clinically 
stable RRMS were sampled over a limited period of 1 year so as to ensure disease 
stability, whereas transitional patients were sampled over 2 years so that samples were 
available in both RR and SP disease phases. Parallel information was recorded consisting 
of disease course, relapse status, disability (measured by the EDSS (Kurtzke 1983)), co­
morbidity, inter-current infection and medications. The Multiple Sclerosis Severity Score 
(MSSS) was calculated from EDSS and disease duration (Roxburgh et al. 2005). The 
control group comprised 86 non-related age-matched subjects with no personal or family 
history of neurological disease. A replication study was performed on an additional 105 
patients including 70 patients with RRMS (35 of whom were in acute relapse) and 35 
with SPMS, and 40 controls.
Demographic details of cases and controls are outlined in table 5.1 and are broadly 
representative of the population-based characteristics recently reported for this region of 
the UK (Hirst et al. 2009), no patient reported significant co-morbidity. Mean time to 
SPMS from disease onset was 10.14 years (SD 9.40), and mean duration of progressive
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phase disease in SPMS patients was 8.79 years (SD 6.84). Of the 115 patients in acute 
relapse (defined according to (Schumacker et al. 1965), 72.2% were treated with steroids, 
according to the clinical judgment of the assessing neurologist, after blood was sampled. 
No patients were on steroid treatment at the time of sampling and there were no 
coincidental infections at the time of relapse. Of the patients, 27.2% were on some form 
of disease modifying treatment including 45.4% in the S-RRMS group, 23.4% in the A- 
RRMS group and 25.9% of patients with SPMS. Disease modifying treatments included 
Rebif (5.3%), Betaferon (5.3%), Avonex (5.0%), Copaxone (0.8%), alemtuzemab (6.1%) 
and mitoxantrone (4.7%).
CSF was obtained with paired serum samples from 44 patients who had been admitted for 
investigation of suspected or known MS. Of these, 22 patients were subsequently found 
to have symptoms not related to demyelinating disease; these samples were used as 
controls. Subsequent neurological diagnosis within the control group included cervical 
myelopathy in 5 patients, cerebrovascular disease in 2 patients, trigeminal neuralgia in 2 
patients, fibromyalgia, vestibular neuronitis and Sjogrens syndrome. Disease subgroups 
consisted of 15 patients with S-RRMS, 4 patients with A-RRMS in acute relapse and 3 
patients with progressive disease.
Analysis
Assays for quantification of total fH and the fH-His402 polymorphic variant have 
recently been described (Hakobyan et al. 2008). In brief, microtiter plates (96-well Nunc
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MaxiSorp, Life Technologies, Paisley, UK) were coated with affinity-purified rabbit anti- 
fH IgG diluted in bicarbonate coating buffer (pH 9.6) at 5 fig/well and incubated. After 
blocking with 1% bovine serum albumin (BSA) in PBS (phosphate buffer solution) 
(blocking buffer), standards, serum (1:6000 in blocking buffer) or CSF (1:10 in blocking 
buffer) samples were added in triplicate and incubated. Plates were washed 3 times in 
PBS/0.1% Tween 20 (washing buffer) before either HRP-labelled affinity-purified rabbit 
anti-human fH (lOOpl; lmg/1) or HRP-labelled MBI-7 anti-fH-His402 (lOOjul; lmg/1) 
was used to measure total fH or fH-His402 respectively. After incubation and washing (3 
times with washing buffer with 1 min incubation on the last wash), bound antibody was 
detected using orthophenylenediamine (OPD; AbD Serotec, Martinsreid, Germany). 
Development was stopped by the addition of 10% sulphuric acid, and absorbance at 492 
nm was measured. All incubation steps were performed motionless for 1 hour at 37°C. 
Purified fH-His402 and an equimolar mixture of both variants were used as standards for 
estimation of serum and CSF fH-His402 and total fH respectively. Concentrations of total 
fH and fH-His402 in serum and CSF were calculated by reference to the appropriate 
calibration curve prepared from the standards and expressed as mg/L of serum or CSF. 
Concentration of fH-Tyr402 polymorphic variant was calculated by subtraction of fH- 
His402 from total fH concentration. The calculated detection limit of the assay was 0.007 
mg/1 and the working range 0.01 -  0.2 mg/1. The assay performance was assessed by 
taking multiple measures from independently diluted aliquots of the same plasma 
samples, either within the same assay or in separate assays. The within-assay precision, 
measured by the CV%, ranged from 4.1% to 7.0% with an average of 5.5% for total fH 
measurement and from 7.7% to 12.8% with an average of 11.0% for fH-H402
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measurement. Between-assay precision ranged from 4.9% to 10.1% with an average of 
8.0% for total fH measurement and from 10.1% to 15.8% with an average of 12.5% for 
fH-H402 measurement. Serial dilutions of standard, serum and CSF were measured to 
demonstrate parallelism (fig 5.1). Routine CSF analysis has been outlined in Chapter 3.
Statistical analysis
Data analysis was performed using SPSS version 16 (SPSS inc., Chicago, IL, USA). A 
pilot study (table 5.2) demonstrated that a sample size of 35 gave a calculated power of 
0.997 with 5% precision; pilot data were included in the main study. All data were 
normally distributed and mean serum fH levels were compared in disease subgroups 
using one-way ANOVA. Concordance, or C statistic, was calculated based on the area 
under the receiver operating characteristic (ROC) curve, to assess the contribution of fH 
to disease predictability (a perfect score would be 1.0 or 100% predictability). The effect 
of demographic and clinical variables (age, disease duration, EDSS, MSSS) on fH levels 
were determined individually using Pearson’s correlation coefficient and then modelled 
using multivariate regression analysis to assess any dominant effect (data were normally 
distributed). The effect of gender and treatment with disease modifying drugs was 
examined in individual subgroups using a Students Mest. The effect of disease course on 
fH was reanalyzed accounting for variables using a univariate linear model. Where 
sample sizes are limited, medians values and IQRs are presented and data is analysed 
using non-parametric analysis.
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5.3 Results
Serum fH levels reflect disease course in MS
Serum fH levels were significantly elevated in both primary and secondary progressive 
disease compared to controls and S-RRMS patients (p<0.001 for each) (table 5.1, fig 5.2). 
Within the S-RRMS group, fH levels in remission were higher than controls although this 
was not significant (p=0.09). Relapse was associated with a small but significant increase 
in fH concentration compared to controls (p<0.001) and S-RRMS (p=0.009). The C 
statistic based on the area under the ROC curve for SPMS versus S-RRMS was 0.83, 
95% Cl 0.77-0.89; p<0.001 (fig 5.3). Analysis of the data demonstrated that serum fH 
concentration had value as a surrogate marker of disease course in patients with MS, in 
particular in distinguishing SPMS from S-RRMS; sensitivity for this distinction was 
89.41%, with specificity of 69.47% and a positive predictive value of 72.38% (test cut off 
value >237mg/L) (table 5.1). When patients in clinical relapse were included, sensitivity 
and specificity were reduced to 71.18% and 62.40%, respectively, with a positive 
predictive value of 59.48%. Serum fH concentration was less helpful in distinguishing S- 
RRMS from patients in relapse, with a sensitivity of 67.37%; specificity 48.00% and 
positive predictive value 49.61% (cut off value <233 mg/L).
To test whether fH levels fluctuated independent of disease state, concentrations of fH 
were measured in 33 samples from 11 clinically stable patients (from the S-RRMS group) 
venesected sequentially over a 12 month period during which time they were deemed by
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the assessing neurologist to have clinically stable disease based on lack of reported 
relapses and lack of change in EDSS. These sequential samples showed little variation in 
fH concentrations with an average CV% of 6.8% (similar to the documented interassay 
CV% of 8%), suggesting both reproducibility of the assay and stable serum fH 
concentration over a protracted time course in patients with clinically stable disease 
(median AH levels initially were 199.35 mg/L and after 1 year were 193.42 mg/L) (fig 
5.4).
An in-house replication study was performed in an additional 105 patients and 40 
controls which confirmed a significant difference between controls and SPMS, mean 
difference 131.58 mg/L (95% Cl 100.28-162.88; p<0.001); and between S-RRMS and 
SPMS, mean difference 80.90 mg/L (95% Cl 48.57-113.23; p<0.001) (table 5.4).
Serum fH levels increase with disease progression in MS patients
To further investigate the dynamic changes in serum fH levels during the transition from 
relapsing to progressive phase disease, 12 patients were selected in whom 3 serum 
samples were available over a 2 year period from onset of progression. In this small 
cohort, fH levels increased over the two year period in 10 of the 12 patients by a median 
of 59.76 mg/L, with median fH concentrations of 206.64 mg/L (IQR 181.3-220.2) in the 
1st year, 232.89 mg/L (IQR 207.4-262.1) in the 2nd year and 266.70 mg/L (IQR 227.4- 
312.0) in the final year for the whole group (fig 5.4). Non-parametric testing showed that 
these changes in fH levels over the 2-year period were highly significant (p=0.007) and 
fH levels at the endpoint were significantly higher compared to the S-RRMS group from
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the main study (p=0.01). Of note, using the test cut-off for SPMS suggested previously 
(test cut off value >237mg/L), 9 of the 12 patients had a positive test at year 2. Nine of 
the 12 patients were on disease modifying treatments throughout the assessed time; this 
did not affect the outcome.
Serum fH levels do not reflect the nature of the lesion in MS relapse
Relapse clinical characteristics were tested to determine the relation to fH levels. Of the 
115 patients in relapse, 29 had a brainstem event, 56 had a spinal or cortical event, 7 had 
optic neuritis and 23 had a pure sensory event as judged by history, examination and 
clinical criteria; fH levels were similar in these four relapse groups (mean fH 246.51 
mg/L (SD 76.51) brainstem, 247.50 mg/L (SD 65.38) spinal or cortical, 256.61 mg/L (SD 
81.06) optic neuritis, 236.94 mg/L (SD 71.90) sensory, p=0.807). In the whole relapse 
group, mean number of relapses over a four year period was 3.53 (SD 2.16) and the mean 
interval between relapses was 8.75 months (SD 6.09); neither number of relapses nor 
relapse interval correlated with fH levels (data not shown). Mean EDSS in the relapse 
group was 4.55 (SD 1.64) and MSSS was 6.59 (SD 2.31); neither of these parameters 
correlated with fH levels (data not shown).
Serum fH levels reflect disease activity independent of other patient factors
Correlation of fH concentrations with other phenotypic characteristics in the population 
was examined and revealed positive correlation with age (r=0.31, p<0.001), disease 
duration (r=0.16, p=0.003), EDSS (r=0.20, pO.OOl) and MSSS (r=0.14, p=0.010);
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however, in a multivariate regression model, only age remained significant. Disease 
modifying treatment had no effect on fH levels in A-RRMS or SPMS groups; however, in 
the S-RRMS group, patients on treatment had significantly lower fH levels than those off 
treatment (p<0.001) (table 5.4). The effect of disease course on fH was re-analysed when 
adjusted for the covariates above, with no significant changes to the results except 
patients in S-RRMS who, when accounting for treatment, were not different from patients 
in relapse (table 5.5). No independent effect from gender was observed (mean difference 
in fH between males and females was 1.75 mg/L). Serum fH concentrations failed to 
show any additional correlation in the SPMS group with time from disease onset to start 
of progression (r=0.08, p=0.47) or duration of progressive disease (r=0.12, p=0.32). 
These latter findings demonstrate that serum fH levels predominantly reflect the 
prevailing disease course at the time of sampling.
CSF fH levels correlate with serum fH and blood-CSF barrier breakdown
It was possible to measure fH in CSF using the assays described, although concentrations 
were <1% of serum; demographic details of patients and controls are shown in table 5.6. 
CSF fH levels were higher in MS patients compared to controls, however, these 
differences did not reach significance (table 5.7). Of note, the CSF:serum fH ratio was 
significantly higher in MS patients when compared to controls (table 5.7) suggesting that 
CSF fH levels were increased in MS as a result either of blood-CSF barrier (BCB) leak or 
intra-thecal synthesis. CSF:serum albumin ratio has been suggested as the most 
appropriate variable to establish the presence of BCB breakdown (Link et al. 1977; 
Tibbling et al. 1977; Eeg-Olofsson et al. 1981). In disease cases the CSF:serum fH ratio
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was strongly correlated with CSF:serum albumin ratio (Pearson correlation=0.83, 
p<0.001). Patients with BCB leak (demonstrated in 5 cases with a raised CSF:serum 
albumin ratio) had significantly higher CSF fH levels than patients with a normal 
CSFiserum albumin ratio (median fH 1.17 mg/L compared to 0.68 mg/L, p=0.02). An 
abnormally high IgG: albumin index has been shown to reflect intra-thecal IgG synthesis 
(Link et al. 1977; Eeg-Olofsson et al. 1981) and in our patients normal values were 
exceeded in 17 cases including 4 of the 5 relapse cases. However, CSF fH levels were not 
significantly raised in these cases (median fH 0.80 mg/L vs. 0.65 mg/L, p=0.337) and 
there was no related evidence of intra-thecal fH synthesis measured by a fH:albumin 
Index (p=0.151) (table 5.7). These data indicate that raised fH CSF concentrations are 
predominantly due to influx of systemic fH at times of BCB breakdown, rather than local 
synthesis.
Tyr402His allele frequency is identical in MS patients and controls
The Tyr402His polymorphic status was determined for each sample based on the 
quantification of total fH and the fH-His402 variant. Out of 350 MS patients, 43 were 
homozygous for the His allele of the Tyr402His polymorphism, 175 were heterozygous 
and 132 were homozygous for Tyr allele, giving a His allele frequency of 37.28% which 
was not significantly different from frequencies observed in the control population 
(37.21%). Of note, similar analyses in AMD populations readily detect at the protein 
level the over-representation of the His allele anticipated from genetic studies (Hakobyan 
et al. 2008). The Tyr402His allelic status also had no effect on fH levels (mean serum fH 
248.40 mg/L (SD 68.55) in fH-His402 homozygotes, 250.74 mg/L (SD 73.31) in fH-
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Tyr402His heterozygotes and 243.84 mg/L (SD 67.04) in fH-Tyr402 homozygotes), in 
MS patients or controls. An unexpected finding in post-hoc analysis of the fH-Tyr402His 
heterozygote group was that higher concentrations of the fH-His402 variant compared to 
fH-Tyr402 were found in both progressive and relapsing MS but not in controls or MS in 
remission, with significantly higher levels in the SPMS (p<0.01) and PPMS (p<0.05) 
groups (fig 5.5), suggesting either selective synthesis of fH-His402 or consumption of the 
fH-Tyr402 variant in active disease when fH is up-regulated.
5.4 Discussion
In this chapter I have shown, in a large cohort of comprehensively clinically characterised 
patients, that raised serum levels of the C regulator fH strongly correlate with disease 
course independently of other phenotypic parameters such as age, disability or disease 
duration. Serum fH measurement may therefore be a useful non-invasive and simple 
clinical test for patient stratification, particularly to distinguish SPMS from RRMS where 
it has a sensitivity of 89.41% and specificity of 69.47%. FH levels were also raised in 
acute relapse, but not to a level as would provide a useful disease biomarker. Biochemical 
outliers to disease subgroups may have been due in part to clinical misclassification, 
especially in the relapsing and stable RRMS groups where subclinical relapses make 
disease activity difficult to determine without the use of concomitant MR brain and spinal 
cord examinations. Clinical inaccuracies for determination of disease progression are 
more difficult to establish due to the lack of a surrogate marker; it was thought that MR 
measures of brain atrophy could be useful, but this is not yet established with any degree 
of certainty (Furby et al. 2010). The amalgamation of multiple potential disease
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biological markers is more likely to provide a combined biomarker profile with a higher 
predictive probability. Other potential markers could be examined within the complement 
system or from other candidates. In particular when looking at disease progression, it may 
be worth examining other potential markers of axonal damage as discussed in Chapter 1, 
such as NFL and Tau proteins.
It may also be that, with further refinements, measurement of fH levels in patients with 
MS can be used to predict disease course. Clinical details of patients with outlying fH 
levels were reviewed to identify obvious causes or atypical features. Of 29 patients in the 
S-RRMS group with fH levels above the 95% Cl, 1 year follow-up revealed that 8 had a 
relapse shortly after initial evaluation, and 4 developed SPMS within a year of 
evaluation; no other patients in the S-RRMS group underwent relapse or developed 
SPMS within a year of sampling. Further to this it was demonstrated that patients with S- 
RRMS have constant serum fH levels, in contrast to patients developing progressive 
disease in whom serum fH levels increased. These data, though preliminary, suggest that 
elevated fH levels in clinically perceived S-RRMS may predict risk of relapse and 
progression and therefore, may also be useful in recognizing or predicting breakthrough 
disease in patient on disease modifying treatments.
Serum fH is the major fluid-phase regulator of the alternative pathway of C, increasingly 
recognised as a critical player in many diseases (Oksjoki et al. 2003; Edwards et al. 2005; 
Pickering et al. 2008; Thambisetty et al. 2008). Changes in fH levels, as well as being a 
marker for disease course, also imply altered regulation of activation of the alternative
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pathway of C throughout the course of disease and in relation to acute inflammatory 
events. MS relapse is associated with extensive CNS inflammatory infiltration in which 
both the adaptive and innate immune system are up-regulated causing demyelination and 
oligodendrocyte damage. Increased levels of fH at times of relapse therefore may be a 
response to increased C activation. It has been suggested that as patients move through 
their disease course into the progressive phase, the innate immune system (including 
macrophages, dendritic cells, mast cells and C) plays a more significant role (Weiner 
2008). The alternative pathway is largely responsible for the propagation of inflammation 
in a range of inflammatory disorders (Brodeur et al. 1991; Oksjoki et al. 2003; Thurman 
et al. 2006; Scholl et al. 2008); and in animal models of MS (experimental autoimmune 
encephalomyelitis), the alternative pathway contributes to disease process, while the roles 
of the classical and terminal pathways are less clear (Chapter 2). These lines of evidence 
lead us to speculate that increased fH levels in progressive disease reflect chronic 
activation of the alternative pathway contributing to disease.
Although fH is present in CSF at levels quantifiable in our assays, the low concentrations 
and low patient numbers made correlation of concentrations to disease parameters non- 
informative. Due to ethical restrictions in collection of control specimens, collection of 
CSF from non-neurological controls was limited; as a result, the CSF control patients 
may have had some other forms of neurological disease, such as vascular pathology, 
which has also been linked to activation of C. Nevertheless, raised fH CSF concentrations 
were demonstrated in MS corresponding with breakdown of the BCB (measured by
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albumin CSF:serum ratios), thus likely to reflect movement of systemic fH into the CNS 
at times of disease activity.
Analysis of the frequencies of the fH Tyr402His variants, implicated in other 
inflammatory diseases, showed no difference in MS patients and controls, indicating that 
this polymorphism was not linked to disease in the population studied. However, 
measurement of the individual polymorphic variants in serum from Tyr402His 
heterozygotes has revealed differences in levels of the fH-Tyr402 and fH-His402 
variants, with higher levels of the His402 variant in some subgroups of disease. This 
apparent allelic imbalance was seen only in those patient groups where total fH levels 
were also elevated, progressive and relapsing disease, suggesting either that there is 
selective up-regulation of the His402 variant or selective consumption of the Tyr402 
variant in disease. The biological significance of this finding is uncertain.
In summary, work outlined in this chapter has demonstrated that measurement of serum 
FH, with further refinement, may be a simple, robust, cost-effective and transferable test 
for distinguishing disease sub-groups in MS which should have important applications in 
clinical practice. There is now a pressing need for this work to be validated in other 
cohorts. Elevation of fH levels in serum and CSF might imply that systemic C activation 
is in part responsible for driving pathology in progressive and relapsing disease. To 
explore this it will be necessary to measure other C components, activation products and 
regulators in MS serum or plasma and identify associations with changes in fH. C 
deposition in MS plaques was described more than 30 years ago (Woyciechowska et al.
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1977; Compston et al. 1989) and has recently been confirmed by Lassmann and co­
workers who have shown that abundant deposition of antibody and C in a subset of MS 
patients (Lucchinetti et al. 1996; Lucchinetti et al. 2000). Characterisation of alternative 
pathway proteins, particularly fH and its isoforms, in MS tissue will clarify the role of the 
alternative pathway of C in MS and also the relationship of fH to demyelination and 
axonal damage. Work in other inflammatory disorders has implicated dysregulation of 
the alternative pathway, linked to genetic polymorphisms in C components and regulators 
(Scholl et al. 2008; Hecker et al. 2010). A thorough molecular analysis of the C system in 
MS may, in addition to providing new biomarkers, identify contributions of C 
dysregulation to specific aspects of MS pathology.
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Table 5.1: Demographic details and serum fH concentration of MS disease subgroups compared to control
subjects
No. Age Gender Disease EDSS FH cone mg/L FH test
duration
Mean SD % f Mean SD Mean SD Mean SD p* % p*
Control 86 42.26 16.50 62.9 209.54 61.29 N/A <0.001 30.23
S-RRMS 97 39.11 8.95 72.16 9.79 7.16 2.97 1.38 225.29 57.96 0.091 0.009 29.90 1.000
A-RRMS 115 36.27 8.44 80.00 7.97 6.63 4.55 1.64 248.19 68.34 <0.001 N/A 46.96 0.020
SPMS 85 49.99 10.13 62.35 18.74 11.18 6.26 1.27 295.71 51.17 <0.001 <0.001 89.41 <0.001
PPMS 53 53.51 11.34 50.94 10.25 7.38 5.74 1.70 280.58 74.83 <0.001 0.002 60.38 0.001
SD; standard deviation, p*  = comparison with controls, p** = comparison with A-RRMS. FH test is the % ofpatients with fH levels above 
the arbitrary cut-off taken as the upper 95% Cl of the S- RRMS group. S-RRMS; stable-relapsing remitting MS with no relapses reported 
for at least 12 months. A-RRMS; acute-relapsing remitting MS sampled in relapse. SPMS; secondary progressive disease course. PPMS; 
primary progressive disease course. Of note, age, disease duration and EDSS are, as expected, higher in progressive patients; however, 
when accounted for as covariates, did not significantly alter the differences in fH  between disease subgroups.
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Figure 5.1: Parallelism of standards, serum and CSF is demonstrated
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Table 5.2: Pilot data showing demographic details and factor H concentration in MS disease
subgroups compared to controls
Number Age 
Mean SD
Gender
% f
Disease 
duration 
Mean SD
EDSS 
Mean SD
FH mg/L 
Mean SD
p* p**
Control 40 37.20 8.86 77.5 220.46 39.81 N/A 0.023
S-RRMS 19 43.00 9.51 73.68 11.53 7.76 3.13 1.71 246.50 43.38 0.105 0.778
A-RRMS 34 36.38 7.52 82.35 6.97 4.81 4.87 1.73 251.15 71.23 0.023 N/A
SPMS 41 51.02 10.55 63.41 19.20 10.24 6.28 1.21 324.39 70.23 <0.001 <0.001
PPMS 20 50.45 11.48 50.00 8.89 4.54 5.33 1.48 270.65 39.40 0.002 0.229
FH; factor H. p* = comparison with controls, p** = comparison with "RRMS relapse". SD; standard deviation, f; 
female. S-RRMS; stable-relapsing remitting MS with no relapses reported for at least 12 months. A-RRMS; acute- 
relapsing remitting MS sampled in relapse. SPMS; secondary progressive MS. PPMS; primary progressive MS. 
N.B. Pilot data is included in the main analysis.
Figure 5.2: Serum factor H in MS disease subgroups
Serum fH concentrations are significantly raised in patients with progressive disease 
compared with control subjects and patients with RRMS (p<0.001 for each comparison). 
RRMS patients in relapse show higher fH levels compared to those in remission 
(p=0.016). (Data is shown as a dot plot with a horizontal line to denote the mean).
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Figure 5.3: Serum factor H receiver operating curve for distinguishing 
SPMS from RRMS
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Figure 5.4: Serum  factor H  over tim e
FH concentrations increased significantly over a period of 2 years in 10 of the 12 patients 
who showed a clinical change in their MS disease state from RRMS to SPMS over this 
period (transitional patients) (p=0.007). However, there was little change in fH 
concentrations in S-RRMS patients sampled over 1 year with the change in 10 of 12 
samples being less than the calculated inter-assay variation.
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Table 5.3: Replication data showing 
raised serum factor H in MS patients 
compared to controls and in patients 
with SPMS compared to RRMS
Mean SD p* 5fC
Control 40 210.88 63.43 N/A <0.001
S-RRMS 35 261.56 76.78 0.002 0.246
A-RRMS 35 280.62 61.56 <0.001 N/A
SPMS 35 342.46 71.48 <0.001 <0.001
SD; standard deviation, p* — comparison with 
controls, p** = comparison with A-RRMS. S- 
RRMS; stable-relapsing remitting MS with no 
relapses reported for at least 12 months. A- 
RRMS; acute-relapsing remitting MS sampled in 
relapse. SPMS; secondary progressive MS.
Table 5.4: Factor H levels in S-RRMS are 
altered on disease modifying treatment
DMT No.
Mean
FH mg/L 
SD P
S-RRMS No 50 246.13 60.28
Yes 44 198.86 40.49 <0.001
A-RRMS No 87 250.60 67.48
Yes 28 240.72 71.69 0.509
SPMS No 61 299.30 54.22
Yes 22 282.21 40.55 0.182
DMT; disease modifying treatment. No; number. SD; 
standard deviation, p  = comparison of fH levels on 
and offDMTs. S-RRMS; stable-relapsing remitting MS 
with no relapses reported for at least 12 months. A- 
RRMS; acute-relapsing remitting MS sampled in 
relapse. SPMS; secondary progressive MS.
Table 5.5: Serum factor H levels adjusted for covariates
Mean serum fH concentrations in mg/L with 95% Cl are shown after adjustment for age, disease duration, EDSS, MSSS and treatment with disease 
modifying drugs; demonstrating that even when accounting for the affect of covariates, fH is predominantly affected by disease course.
Age Disease duration EDSS MSSS Treatment
Mean difference 
from controls
p*
Mean difference 
from S-RRMS
Mean difference 
from S-RRMS
P * *
Mean difference 
from S-RRMS
Mean 
difference from 
S-RRMS
p«{c s|s
S-RRMS 17.3(-1.2-35.8) 0.066 N/A N/A N/A N/A N/A N/A
A-RRMS 39.6(21.7-57.5) <0.001 20.9(3.6-38.3) 0.018 26.5(7.9-45.2) 0.005 22.5(3.7-41.2) 0.019 14.5(-2.7-31.8) 0.098
SPMS 82.6(63.3-102.0) <0.001 71.3(51.2-91.5) <0.001 81.7(58.0-105.4) <0.001 71.9(51.7-92.2) <0.001 64.3(45.6-89.3) <0.001
PPMS 65.8(43.5-88.3) <0.001 55.4(33.9-76.8) <0.001 64.8(40.1-89.5) <0.001 57.2(33.6-80.8) <0.001 41.4(18.8-63.1) 0.002
p* = p  value for mean difference between disease groups and controls after adjustment for covariate. p** = p  value for mean difference from S-RRMS 
group after adjustment for covariate. S-RRMS; stable-relapsing remitting MS with no relapses reported for at least 12 months. A-RRMS; acute- 
relapsing remitting MS sampled in relapse. SPMS; secondary progressive MS. PPMS; primary progressive MS.
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Table 5.6: Demographic details and routine CSF results in MS patients and controls
Number Age Gender Disease
duration
EDSS OCB Albumin
ratio
Ig Index
Mean(SD) % f Mean(SD) Mean(SD) % +ve Mean(SD) Mean(SD)
Control 22 50.09(14.11) 77.27 0 5.12(2.83) 0.49(0.05)
MS 22 41.68(12.68) 68.18 7.55(9.34) 2.6(2.3) 100 5.53(1.92 1.08(0.47)
EDSS; expanded disability status scale. OCB; oligoclonal bands. Albumin ratio; CSF albumin mg/L /  
serum albumin g/L ratio. Ig Index; derived from CSF/serum ratios o f IgG and albumin concentrations. SD; 
standard deviation.
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Table 5.7: Factor H CSF and serum concentrations in MS patients and controls
CSF fH mg/L Serum fH mg/L FH CSF/Serum ratio FH index
Mean(SD) p Mean(SD) p Mean(SD) P Mean(SD) P
Control 0.65(0.32) 288.84(39.97) 2.38(1.24) 0.50(0.23)
MS 0.78(0.32) 0.209 245.87(39.77) 0.001 3.24(1.43) 0.046 0.60(0.20) 0.151
FH Index; an analogous ratio, calculated by substituting FH for IgG in the Ig Index. SD; standard 
deviation, p  = comparison ofMS patients with controls.
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Figure 5.5: Factor H Tyr-402His polymorphism in MS
In fH-Tyr402His heterozygotes, significantly higher concentrations of the fH-His402 
variant compared to fH-Tyr402 were found in both SPMS (mean fH-His402 166.45 
mg/L (SD 51.47) vs. mean fH-Tyr402 144.68 mg/L (SD 53.73); p<0.01) and PPMS 
(156.55 mg/L (SD 57.58) vs. 132.21 mg/L (SD 45.14); p=0.05) with higher 
concentrations also seen in relapsing patients, although this did not reach significance 
(135.36 mg/L (SD 59.48) vs. 109.13 mg/L (SD 58.54); p=0.06). There was no 
difference in variant concentrations observed in the control (120.35 mg/L (SD 41.53) 
vs. 117.19 mg/L (SD 61.75)) or RRMS (107.65 mg/L (SD 43.00) vs. 111.44 mg/L 
(SD 34.15)) groups. (Data is shown as a dot plot with a horizontal line to denote the 
mean).
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CHAPTER 6: ELEVATED PLASMA C4A LEVELS IN 
MULTIPLE SCLEROSIS CORRELATE WITH DISEASE
ACTIVITY
6.1 Introduction
C4 is one of the most abundant of the C proteins and is present in both classical and 
lectin pathways contributing to the formation of C4b2a, C3 convertase. Routinely 
measured in laboratories, it has been targeted in many studies examining C in both 
serum and CSF of MS patients. Although one such study has shown increased levels 
of serum C4 (Jans et al. 1984), this work has not been replicated and results of CSF 
studies have been conflicting (Kuwert et al. 1965; Link 1972; Jongen et al. 2000). 
More recent work has utilised proteomic analysis to evaluate biological samples from 
MS patients. In one such study (Sawai et al. 2010) a global protein/peptide analysis of 
plasma samples from 31 patients with RRMS obtained during acute relapse, revealed 
raised levels compared to controls of a peptide derived from the classical pathway 
component C4, and specifically, present in the C4 activation fragment, C4a ( 
NGFKSHALQLNNRQI). Furthermore in a sub-group of patients on whom 3-6 month 
convalescent samples were available, levels of this peptide had fallen back to normal. 
This small study suggested that C4a levels might correlate with certain clinical 
components of MS disease activity and represent an informative biomarker of disease 
state. In this chapter I have analysed plasma C4 and C4a levels as well as CSF C4a 
levels in a large group of comprehensively phenotyped MS patients in order to 
determine the nature and clinical relevance of these parameters in disease.
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6.2 Methods
Subjects
Plasma was collected from 107 patients with MS (McDonald et al. 2001), including 
20 with S-RRMS who had experienced no relapse for at least 12 months, 55 with A- 
RRMS sampled during an acute relapse, 20 patients with SPMS and 12 patients with 
PPMS. Detailed clinical information was available on all patients including age, age 
at onset, disease duration and disability assessed by the EDSS (Kurtzke 1983). 9.62% 
of patients were on disease modifying treatments, including Interferon la  and lb, 
Copaxone, Mitoxantrone and Alemtuzemab. Of 55 A-RRMS patients, 43 
subsequently remained relapse free over a 5-7 month period and underwent serial 
plasma sampling at intervals of between 2-3 months and 5-7 months post-relapse. 
None of the patients seen in relapse had inter-current infections; 69.64% were treated 
with oral or intravenous steroids after plasma samples had been collected, the 
reminder were untreated. Relapses were classified according to detailed anatomical 
and clinical characteristics; 7 patients had experienced brainstem or cerebellar 
relapses, 37 pyramidal or long tract motor relapses, 4 optic neuritis and 7 pure long 
tract sensory relapses. In patients who were serially sampled, mean EDSS at relapse 
was 4.71 (SD 1.66), this improved by a mean of 1.08 points (SD 1.07) at 2-3 months 
and by 1.09 points (SD 1.15) at 5-7 months following relapse. The control group 
comprised 40 non-related subjects with no personal or family history of neurological 
disease. Demographic details of patients and controls are provided in table 6.1.
CSF was obtained with paired plasma samples from 34 patients who had been 
admitted for investigation of suspected or known MS. Of these, 11 patients were
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subsequently found to have symptoms unrelated to a CNS demyelinating disorder and 
these samples were used as controls. Subsequent neurological diagnosis within the 
control group included cervical myelopathy (5), cerebrovascular disease (3), 
trigeminal neuralgia (1), vestibular neuronitis (1) and lumbar radiculopathy (1). Of 
patients with MS, 18 had S-RRMS, 2 had A-RRMS and 3 had PPMS.
Analysis
C4a levels were determined using a commercial assay from BD Biosciences (assay kit 
no. 550947, BD Biosciences, 2350 Qume Drive, San Jose, CA 95131-1807; 
bdbiosciences.com); all samples were tested in duplicate. C4 concentrations were 
measured by nephelometry on a Beckman BN11 nephlometer in the University 
Hospital of Wales Clinical Immunology laboratory using commercial standards. 
Routine CSF analysis has been outlined in Chapter 3.
Statistical analysis
Data was analysed using SPSS version 16 (SPSS inc., Chicago, IL, USA). All data 
were normally distributed and are therefore presented as means with SDs and 
analysed using parametric tests. Disease subgroups were compared using either 
Students /-test (for 2-way analysis) or one-way ANOVA (for multiple comparisons). 
Concordance, or C statistic, was calculated based on the area under the ROC curve, to 
assess the contribution of fH to disease predictability (a perfect score would be 1.0 or 
100% predictability). Correlations were performed using Pearson’s correlation 
coefficient and then modelled using multivariate regression analysis to assess any 
dominant effect. Subgroup analysis of CSF was limited by number of samples and is 
therefore presented as median values and analysed using the non-parametric Mann- 
Whitney test to compare groups.
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6.3 Results
Plasma C4 levels weakly correlated with plasma C4a (r=0.27, p=0.001). C4 levels 
were raised in the MS population overall compared to controls, although this did not 
reach significance (table 6.2), and levels did not distinguish between clinical 
subgroups. Plasma C4a levels were significantly elevated in patients compared to 
controls (p=0.001), but sub-group analysis revealed that C4a levels were significantly 
elevated only in patients with A-RRMS compared to both controls (p<0.001) and 
patients with S-RRMS (p=0.004) (table 6.2, fig 6.1). The C statistic for A-RRMS 
versus S-RRMS was 0.69, 95% Cl 0.56-0.82; p=0.012 (fig 6.2). Analysis of MS sub­
phenotypes revealed weak correlation of C4a with EDSS (r=0.22; p=0.02); however, 
when accounting for other clinical characteristics including age, age-at-onset and 
disease duration, using a multivariate regression model, significance was not 
maintained (Beta coefficient 0.379, p=0.143).
Serial samples were available from 43 patients with A-RRMS who were subsequently 
relapse-free for 5-7 months. C4a levels were higher in acute relapse compared to 
convalescent samples in 28 of the 43 patients (fig 6.3). Mean C4a levels in acute 
relapse were significantly higher than in convalescent samples taken at 2-3 months 
(p=0.04); however, although relapse C4a levels were higher than those measured at 5- 
7 months, this did not reach significance (p=0.12) (table 6.3). Univariate analysis 
accounting for EDSS as a covariate did not alter these findings (data not shown). 
There was no difference in C4 levels between A-RRMS and convalescent samples 
(table 6.3).
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CSF concentrations of C4a were <1% that of plasma but were quantifiable in the 
assay. Demographic details for the patient cohort from whom CSF samples were 
obtained are displayed in table 6.4. CSF C4a levels, C4a CSF:plasma ratio and C4a 
Index (derived from a ratio of C4a and albumin concentrations in CSF and plasma; 
C4a CSF ng/mL:plasma mg/L / Albumin CSF mg/L:plasma g/L) were all 
significantly higher in MS patients than the control population (table 6.5). CSF C4a 
levels showed moderate correlation with CSF:serum IgG (r=0.53, p=0.01) but not 
CSF:serum albumin (r=0.21, p=0.34). In addition, patients with a raised CSF:serum 
IgG ratio (indicating intrathecal IgG synthesis (Link et al. 1977; Eeg-Olofsson et al. 
1981)) had significantly higher levels of CSF C4a (n=8; median 66.32 ng/mL, IQR 
48.72-69.82); p<0.001) compared to patients with a normal IgG ratio (n=26; median 
27.89 ng/mL, IQR 21.70-32.24). Patients with a raised CSF:serum albumin ratio 
(indicating leak of the BCB (Link et al. 1977; Eeg-Olofsson et al. 1981)) did not have 
significantly raised CSF C4a levels (n=4; median 45.63 ng/mL, IQR 42.52-56.86; 
p=0.082) compared to patients with a normal albumin ratio (n=30; median 28.46 
ng/mL, IQR 21.90-44.93). This indicates that raised C4a levels in MS patients are 
most likely a result of intrathecal production of C4a as opposed to leakage from 
plasma through the BCB. Plasma C4a levels were non-significantly higher in patients 
with both a raised CSF:serum IgG ratio (median plasma C4a 0.78 mg/L (IQR 0.35- 
1.19) vs. 0.64 mg/L (IQR 0.37-1.24); p=0.262) and a raised CSF:serum albumin ratio 
(median plasma C4a 1.05 mg/L (IQR 0.62-1.95) vs. 0.64 mg/L (IQR 0.35-1.00);
p=0.082).
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6.4 Discussion
Although C has an established role in the pathogenesis of MS, the extent and nature of 
activation remains unknown. Previous studies have suggested that the classical and 
terminal pathways of C may have central roles with the identification of C4 fragments 
and terminal C complex deposition within MS plaques, one distinguishing a 
pathological subset of MS patients (Lucchinetti et al. 1996; Storch et al. 1998; Brink 
et al. 2005). There is also evidence from small studies that C4 may be elevated in MS 
serum and reduced in CSF compared to controls (Jans et al. 1984), although, to date, 
this work has not been convincingly replicated (Link 1972; Yam et al. 1980; Jongen 
et al. 2000). Conversely, evidence from animal models demonstrate that C4-deficient 
(classical pathway absent) animals, show onset and progression of EAE which is 
virtually identical to wild-type animals (Morariu et al. 1978; Boos et al. 2005). C4a is 
a short-lived fragment of C4, generated during activation of the classical or lectin 
pathways. Although found to be elevated in plasma in several other diseases where 
activation of the classical pathway occurs (Kasuya et al. 1989; Wild et al. 1990; 
Abou-Ragheb et al. 1992), it has hitherto escaped detailed examination in MS. A 
recent peptide biomarker study in MS plasma identified a peptide derived from the 
C4a sequence (Sawai et al.), motivating us to look more closely at C4a levels in MS 
patients.
Work in this chapter has demonstrated that MS patients with clinically active disease 
have raised plasma C4a levels compared to either patients in remission or healthy 
controls. Furthermore, dynamic changes in C4a post-relapse show C4a levels decrease 
after the acute inflammatory event. However, these changes were inconsistent within 
the patient cohort examined and therefore it is unlikely that the observed changes in
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C4a levels would be reliable enough to be employed alone as a surrogate marker of 
inflammation in clinical practice. In particular, convalescent samples at 5-7 months 
post-relapse did not demonstrate the same degree of reduction in C4a levels as at 2-3 
months, for reasons that are unclear. It may be that there is a quiescent period post­
relapse during which time further inflammatory events are less likely, before the 
return of clinical or sub-clinical events in some patients by around 6 months. MR 
studies would enable further clarification of these issues.
The demonstration of elevation of CSF C4a levels adds to the growing evidence for C 
activation in the CNS contributing to the pathogenic process in MS. Our results point 
towards intrathecal activation of the classical pathway of C in CSF; however, since 
C4a is relatively small (76 amino acids) in comparison with most proteins, it will 
likely cross the intact BCB to some degree, and changes in barrier permeability may 
have little effect on C4a transit (Felgenhauer et al. 1976). Indeed, our results show no 
significant impact of BCB breakdown on CSF C4a levels. Plasma levels of C4a were 
high during acute relapse, suggesting that there is a significant systemic inflammatory 
component to the disease. The concept of systemic inflammation in primary central 
nervous system inflammatory disorders is not novel and is perhaps best illustrated by 
the presence of serum oligoclonal IgG, indicating systemic immune activation, which 
is also associated with intrathecal IgG synthesis (Zeman et al. 1996) in MS as well as 
a number of other disorders. Analyse of CSF C4a in disease subgroups was limited 
due to the low number of patients.
In summary, plasma and CSF levels of C4a are shown to be elevated in MS, the 
former restricted to patients in relapse. I speculate that the classical pathway is
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activated both in the CNS and systemically in MS patients, particularly at times of 
relapse highlighting a possible role for anti-C agents in MS, although inter-individual 
variability implies that different patterns of C activation may represent distinct 
pathological subgroups. Further work is needed to establish the details of C activation 
in MS subgroups and disease stages, and the relative contributions of classical and 
alternative pathways.
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Table 6.1: Demographic details of MS disease subgroups and control patients
No. Age Sex AAO Disease duration EDSS
Mean SD %f Mean SD Mean SD Mean SD
Control 40 36.28 9.84 72.50 N/A N/A N/A N/A N/A N/A
Total MS 107 43.80 11.72 67.29 31.39 10.68 11.81 11.51 4.79 2.00
S-RRMS 20 41.85 9.48 55.00 32.25 8.34 8.60 7.41 3.30 1.66
A-RRMS 55 38.44 9.85 76.36 28.45 7.75 9.76 9.07 4.48 1.72
SPMS 20 55.55 8.38 65.00 29.85 13.31 24.70 14.53 6.85 1.40
PPMS 12 52.08 9.75 50.00 46.00 9.82 5.08 4.70 5.29 1.80
AAO; age at onset. EDSS; expanded disability status scale. SD; standard deviation./; female. S- 
RRMS; stable relapsing remitting MS with no reported relapse for at least 12 months. A-RRMS; 
active relapsing remitting MS in acute relapse. SPMS; secondary progressive MS. PPMS; 
primary progressive MS.
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Table 6.2: Plasma C4 and C4a levels in MS disease subgroups and 
control patients
No.
Mean
C4 mg/L 
SD p* Mean
C4a mg/L 
SD p* p**
Control 40 247.50 78.57 N/A 1.37 0.75 N/A <0.001
Total MS 107 282.82 99.16 0.056 1.80 0.96 0.01 N/A
S-RRMS 20 299.33 116.11 0.060 1.39 0.79 0.91 <0.01
A-RRMS 55 278.70 92.41 0.130 2.07 1.07 <0.001 N/A
SPMS 20 292.42 74.96 0.10 1.69 0.70 0.18 0.10
PPMS 12 259.09 139.64 0.72 1.40 0.67 0.89 0.02
SD; standard deviation. p*= comparison o f C4/C4a levels compared to control 
patients. p**= comparison of C4a levels compared to acute relapse. S-RRMS; stable 
relapsing remitting MS with no reported relapse for at least 12 months. A-RRMS; 
active relapsing remitting MS in acute relapse. SPMS; secondary progressive MS. 
PPMS; primary progressive MS.
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Figure 6.1: C4a levels in MS disease subgroups
C4a levels in MS are raised in patients with relapsing remitting MS in acute relapse (A- 
RRMS) compared to both controls (p<0.001) and stable relapsing remitting (S-RRMS) 
(p=0.004) patients. No elevation of C4a was seen in secondary progressive (SPMS), 
primary progressive (PPMS) or stable relapsing remitting (S-RRMS) patients when 
compared to controls. Box plots demonstrate median levels, with box margins indicating 
the interquartile range.
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Figure 6.2: Plasma C4a receiver operating curve for distinguishing 
acute RRMS in relapse from stable RRMS
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Figure 6.3: Plasma C4a levels post-relapse
Plasma C4a levels are shown in 43 patients with MS in acute relapse (0), from 
convalescent samples taken 2-3 months or 5-7 months post relapse, showing reduction in 
plasma C4a in 28 of the 43 patients post relapse. Student’s t test demonstrated a 
significant reduction in mean C4a levels at 2-3 months (p=0.04) but not 5-7 months
( p = 0 .1 2 ) .
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Table 6.3: EDSS, plasma C4 and C4a levels are shown from 
patients in acute relapse with convalescent samples 2-3 and 5-7 
months post relapse
No. EDSS C4 mg/L C4a mg/L
Mean SD Mean SD P Mean SD P
A-RRMS 43 4.71 1.66 270.53 81.29 N/A 2.27 1.07 N/A
2-3 months 43 3.64 2.08 251.35 77.02 0.27 1.85 0.91 0.04
5-7 months 43 3.61 2.04 260.56 84.07 0.57 1.95 0.81 0.12
EDSS; expanded disability status scale. SD; standard deviation. p=  comparison 
of C4/C4a levels with acute relapse. A-RRMS; active relapsing remitting MS in 
acute relapse. 2-3 and 5-7 months refer to convalescent samples after acute 
relapse.
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Table 6.4: Demographic details and routine CSF biochemistry is shown from MS
patients and controls sampled for CSF
No. Age Sex DD EDSS Alb ratio Ig Index OCB
Mean SD %f Mean SD Mean SD Mean SD Mean SD % +ve
Control 11 50.18 18.10 72.73 N/A N/A N/A N/A 5.09 2.64 0.49 0.05 0.00
MS 23 41.30 10.84 78.26 7.09 8.85 2.98 1.89 5.42 2.30 1.05 0.53 95.65
DD; disease duration. EDSS; expanded disability status scale. Alb ratio; Albumin CSF mg/L: Serum g/L 
ratio. Ig Index; derived from ratios ofIgG and albumin concentrations in CSF and serum. OCB; 
oligoclonal bands. SD; standard deviation, f; female.
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Table 6.5: C4a in MS patients and controls sampled for CSF
No. CSF C4a ng/ml Plasma C4a mg/L C4a ratio C4a Index
Mean SD P Mean SD P Mean SD P Mean SD P
Control 11 26.66 10.48 N/A 0.90 0.58 N/A 44.33 36.34 N/A 8.79 6.64 N/A
MS 23 42.41 20.61 <0.01 0.79 0.60 0.63 92.18 84.06 0.04 19.14 18.21 0.03
C4a ratio; C4a CSF ng/ml: plasma mg/L ratio. C4a Index; an analogous ratio calculated by substituting C4a 
for IgG in the Ig Index (C4a CSF ng/mL:plasma mg/L /  Albumin CSF mg/L:plasma g/L). SD; standard 
deviation.
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CHAPTER 7: SYSTEMIC COMPLEMENT PROFILES IN 
MULTIPLE SCLEROSIS ARE USEFUL AS BIOMARKERS
OF DISEASE STATE
7.1 Introduction
So far, work in this thesis has outlined evidence suggesting a contribution from C to 
pathogenic processes in MS (Chapter 2); however, the extent and precise nature of C 
activation, and its contribution to disease phenotype and long term outcome, remains 
unclear. Studies of C levels and activation in MS plasma and CSF to date have been 
limited and disparities in results may relate either to differences in measurement 
techniques, low patient numbers leading to underpowered studies, or poor stratification of 
patients with a complex disease.
Work in Chapters 5 and 6 demonstrate dynamic changes in systemic C levels shown in C 
protein C4, activation product C4a and regulator fH. This was evident especially in 
relation to acute relapse, associated with raised C4a and fH; and disease progression, 
associated with raised fH. Furthermore, serum fH was identified as a potentially useful 
clinical marker of disease progression with a predictive value based on the C statistic of 
83%. Local changes in C in CSF were more difficult to analyse given the low levels and 
limited number of patients. However, it was clear from this work that there are local 
changes in C production and/or consumption.
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Based on evidence from these initial studies, this chapter extends the analysis of the role 
and extent of activation and regulation of C in a comprehensively phenotyped population 
of MS patients. Representative elements of various aspects of C activity were 
strategically chosen to compile a comprehensive set of C proteins, activation products 
and regulators of classical, alternative and terminal pathways. C profiles were established 
for different disease courses and evaluated as predictive models of disease state.
7.2 Methods 
Subjects
Plasma samples were selected from 194 patients with MS (McDonald et al., 2001), 
including 40 patients with S-RRMS, with no clinically evident relapse for at least 12 
months; 78 with A-RRMS sampled in relapse, 39 with SPMS and 37 with PPMS. Assays 
were initially performed in a pilot study with 20 patients in each group. Additional 
analysis of 150 patients was performed for components showing some variation between 
groups; with further analysis, in relevant components, of 44 patients serially sampled in 
acute relapse. Detailed clinical information was available on all patients including age, 
age at onset, disease duration and disability assessed by the EDSS (Kurtzke 1983). Of the 
194 patients, 8.76% were on disease modifying treatments, including Interferon la  (2 
patients) and lb (5 patients), Copaxone (3 patients), Mitoxantrone (4 patients) and 
Alemtuzemab (4 patients). Of the 78 patients with A-RRMS, 44 remained relapse free 
over a 5-7 month period and underwent serial plasma sampling at intervals of between 2- 
3 months and 5-7 months post-relapse. No patients seen in relapse had inter-current 
infections; 71.79% were treated with oral or intravenous steroids after plasma samples
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had been collected, the reminder were untreated. Relapses were classified according to 
detailed anatomical and clinical characteristics; 13 patients had experienced brainstem or 
cerebellar relapses, 50 pyrimidal or long tract motor relapses, 5 optic neuritis and 10 pure 
long tract sensory relapses. In patients who were serially sampled, mean EDSS at relapse 
was 4.72 (SD 1.64), this improved by a mean of 1.08 points (SD 1.07) at 2-3 months and 
by 1.09 points (SD 1.15) at 5-7 months following relapse. The control group comprised 
35 non-related subjects with no personal or family history of neurological disease. 
Demographic details of patients and controls are displayed in table 7.1. Patients selected 
for this study included the RRMS and SPMS patients and controls used in the replication 
phase of Chapter 5 and the patients from Chapter 6 who were serially sampled post 
relapse.
CSF was obtained with paired plasma samples from 66 patients who had been admitted 
for investigation of suspected or known MS. Of these, 5 had a CIS and 24 patients were 
subsequently found to have symptoms not related to demyelinating disease; these samples 
were used as controls. Subsequent neurological diagnosis within the control group 
included cervical myelopathy, cerebrovascular disease, trigeminal neuralgia, 
fibromyalgia, vestibular neuronitis and Sjogren’s syndrome. Of the 37 patients with MS, 
disease subgroups consisted of 28 patients with S-RRMS, 5 patients with A-RRMS in 
acute relapse and 4 patients with progressive disease.
Measurement of factor B
A sandwich ELISA for quantification of fB in plasma, serum or CSF samples was 
developed in-house. Maxisorp (Nunc, Life Technologies, Paisley, UK) plates were coated
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with in-house monoclonal mouse anti-human fB (JC1, lOOpl, 5mg/l) overnight at 4°C, 
washed in 0.1% Tween 20 in PBS (washing buffer) and blocked with 200jal 1% BSA/10 
mM EDTA (blocking buffer) in PBS. After a single wash in washing buffer, lOOjul of 
standards, plasma (diluted 1:3000 in blocking buffer) or CSF (diluted 1:10 in blocking 
buffer) samples were added in duplicate and incubated. Wells were washed 3 times in 
washing buffer and incubated with lOOpl of HRP-labelled affinity-purified rabbit anti­
human fB (100 fiL; 1 mg/L). All incubations were stationary, 1 hour, 37°C, unless stated 
otherwise. Wells were washed 3 times in washing buffer and bound antibody was 
visualised with orthophenylenediamine (SIGMAFAST™ OPD; Sigma-Aldrich, Dorset, 
UK). Development was stopped by the addition of 10% sulphuric acid, and absorbance at 
492nm was measured. Purified human fB was used as a standard for estimation of plasma 
fB. Control standards were included on each plate. Concentration of fB in plasma or CSF 
was calculated by reference to the appropriate calibration curve prepared from the 
standards and expressed as mg/L of plasma or CSF. A nonlinear regression model was 
used to fit standard curves generated by ELISA. The calculated detection limit of the 
assay was 0.006 mg/L and the working range 0.01-0.2 mg/L. The assay performance was 
assessed by taking multiple measures from independently diluted aliquots of the same 
plasma samples, either within the same assay or in separate assays. The within-assay 
precision, measured by the CV%, ranged from 6% to 8% with an average of 7%. 
Between-assay precision ranged from 5% to 11% with an average of 9%.
Measurement of C9
Sandwich ELISAs for quantification of C9 in plasma, serum or CSF samples were 
developed in-house with methods as described above. Coating antibody for C9 detection
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was used at 0.1 ug/well (B7, in-house). Plasma samples were diluted 1:2000 in blocking 
buffer and CSF was diluted 1:10 in blocking buffer. HRP-labelled monoclonal mouse 
anti-human C9 (MAC68, in-house) was added to wells for detection of C9 (100 /dL; 1 
mg/L). A pool of control plasma samples was used as a standard and results are expressed 
as a percentage of the control. The calculated detection limit of the C9 assay was 0.005% 
with a working range of 0.015-0.25%. The within-assay precision ranged from 0% to 4% 
with an average of 3% and between-assay precision ranged from 0% to 11% with an 
average of 6%.
Measurement of C ls
Sandwich ELIS As for quantification of C ls in plasma, serum or CSF samples were 
developed in-house with methods as described above. Coating antibody for Cls (F33, in- 
house) was used at 0.5 ug/well. Plasma samples were diluted 1:2000 in blocking buffer 
and CSF was diluted 1:10 in blocking buffer for both assays. For detection of Cls, goat 
polyclonal antiserum to human C ls (Quidel; assay no. A302; Quidel Corporation 
Headquarters, 10165 McKellar Court, San Diego, CA 92121; www.quidel.com) was 
added to each well, and after 1 hour stationary incubation at 37°C, HRP-labelled 
polyclonal rabbit anti-goat immunoglobulins (Dako; assay no. P0449; Dako UK Ltd, 
Cambridge House, St Thomas Place, Ely, Cambridgeshire, CB7 4EX; www.dako.com) 
was added. A pool of control plasma samples was used as a standard in both assays and 
results are expressed as a percentage of the control. The calculated detection limit of the 
Cls assay was 0.003% with a working range of 0.015-0.25%. The within-assay precision 
ranged from 0% to 5% with an average of 4% and between-assay precision ranged from 
0% to 12% with an average of 6%.
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Measurement of fH
The assay for the detection of fH has previously been described in Chapter 5. 
Measurement of clusterin, TCC, Bb and C4a
Clusterin was quantified using a commercial assay from ALPCO diagnostics (assay no. 
44-CLUHU-E05; ALPCO Diagnostics, 26G Keewaydin Drive, Saem, NH 03079; 
www.alpco.com). TCC was quantified using a commercial assay from Hycult Biotech, 
working range 8.2 - 2000 mAU/ml (assay no. HK328; Frontstraat 2a, 5405 PB UDEN, 
The Netherlands; www.hby.nl). Bb was quantified using a commercial assay from Quidel 
(assay no. A027; Quidel Corporation, 10165 McKellar Court, San Diego, CA 92121; 
www.quidel.com). C4a was quantified using a commercial assay from BD Biosciences 
(assay kit no. 550947, BD Biosciences, 2350 Qume Drive, San Jose, CA 95131-1807; 
bdbiosciences.com) as described in Chapter 6.
Measurement of C3, C4, C l inhibitor and C-reactive protein
C3, C4 and Cl-inh concentrations were measured by nephelometry on a Beckman BN11 
nephelometer in the using commercial standards. The assay working range for C3 was 
0.02-4.1 g/L, for C4 was 0.01-1.9 g/L and for Cl-inh was 0.02-0.6 g/L. High sensitivity 
C-reactive protein (CRP) was measured by laser nephelometry in the University Hospital 
of Wales Clinical Immunology laboratory, with a lower detection limit of 0.04 mg/L.
Routine CSF analysis
CSF analysis has been outlined in Chapter 3.
148
Statistical analysis
Data analysis was performed using SPSS version 16 (SPSS inc., Chicago, IL) statistical 
package. All data was normally distributed. Quantitative concentrations were compared 
between disease subgroups using either Students’ Mest for 2-way analysis, or Anova with 
Bonferonni correction for multiple comparisons. Odds ratios (ORs) with 95% CIs were 
calculated individually for each variable and positive variables were then used in a 
logistic regression model. Objective clinical characteristics such as age, gender and 
disease duration were added to the model and concordance, or the C statistic was 
calculated based on the area under ROC curve, to assess whether individual components 
or combined models contributed to predicting binary outcomes (a perfect score would be 
1.0 or 100% predictability). Correlations were performed using Pearson’s correlation 
coefficient and then modelled using multivariate regression analysis to assess any 
dominant effect. Subgroup analysis of CSF was limited by number of samples and is 
therefore presented as median values and analyzed using the non-parametric Mann- 
Whitney test to compare groups.
7.3 Results
Plasma complement levels predict MS compared to a control population
Compared with healthy controls, the total MS population analysed showed increased 
mean levels of plasma C3 (OR 1.00, 95% Cl 1.00-1.00, p=0.004) and C4 (OR 1.01, 
95%CI 1.01-1.02, p=0.001); reduced levels of plasma C9 (OR 0.98, 95% Cl 0.97-0.99, 
p<0.001); and no difference in mean levels of plasma proteins CIs (OR 1.00, 95% Cl
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0.99-1.01) and fB (OR 1.00, 95% Cl 0.99-1.00, p=0.400) (table 7.2, fig 7.1). There was a 
significant increase in plasma levels of activation product C4a (OR 1.00, 95%CI 1.00-
1.00, p<0.001); however, as shown previously this elevation was seen only in the A- 
RRMS group. No changes were seen in activation product Bb (OR 1.48, 95% Cl 0.22- 
10.12) and levels of TCC were undetectable in the plasma with a lower assay detection 
limit of 8.2mAU/ml (table 7.3). C regulators Cl-inh (OR 1.02, 95% Cl 1.01-1.03, 
p<0.001) and fH (OR 1.01, 95% Cl 1.00-1.02, p<0.001) were significantly raised in MS 
patients compared to controls with no difference seen in plasma levels of clusterin (OR
1.01, 95% Cl 0.99-1.02) (table 7.4, fig 7.1). A logistic regression model examining MS 
patients and normal healthy controls was constructed and limited to analysis of C9, C3, 
C4, Cl-inh and fH. The C statistic based on this model was 0.97 (95% Cl 0.94-1.00, 
p<0.001) and superior to any individual component (fig 7.2).
Dynamic changes in plasma complement levels in acute relapse
Analysis of disease course subgroups demonstrated elevation of mean levels of plasma 
proteins C9 (p=0.027) and fB (p=0.065) (table 7.2), activation product C4a (p=0.011) 
(table 7.3) and regulator fH (p=0.557) (table 7.4) in A-RRMS compared to S-RRMS. A 
logistic regression model was developed to assess A-RRMS compared to S-RRMS; an 
initial model using fB, C9, C4a and fH along with objective clinical features age, gender 
and disease duration; revealed there was no contribution to the model from fB (the 
significance of change if fB was removed from the model = 0.979), gender (the 
significance of change if gender was removed from the model = 0.214), C4a (the 
significance of change if C4a was removed from the model = 0.146) or fH (the 
significance of change if fH was removed from the model = 0.144). The optimal model
150
used C9 (OR 1.03, 95% Cl 1.01-1.04, p=0.003), age (OR 0.90, 95% Cl 0.85-0.96, 
p=0.001) and disease duration (OR 1.07, 95% Cl 1.01-1.14, p=0.025). The C statistic 
based on the area under the ROC curve for this model to predict A-RRMS from S-RRMS 
was 0.75, 95% Cl 0.66-0.84 (fig 7.3).
Where higher mean plasma levels were seen in A-RRMS, an extended analysis was 
conducted with measurement of convalescent samples post-relapse at 2-3 and 5-7 
months. There were no differences in mean plasma levels seen between acute relapse and 
convalescent samples for either C9 or fB (table 7.5). Mean plasma fH levels were 
significantly higher in A-RRMS compared to both 2-3 (p=0.013) and 5-7 (p=0.007) 
month samples (table 7.5, fig 7.4); however, levels were only reduced in 26 of 44 subjects 
at 2 months and 30 of 44 subjects at 6 months suggesting inconsistencies across 
individuals. Changes in C4a post-relapse have been reported in Chapter 6.
Analysis of phenotypic parameters showed no correlation of any measured components 
with gender, disease duration, EDSS, MSSS, treatment with disease modifying drugs or 
time to secondary progressive disease from onset. There was weak correlation of both 
plasma C9 (r=0.16) and CIs (r=0.12) with age, however, using age as a covariate in our 
previous analysis did not alter results (data not shown). There was no difference in levels 
of CRP between the total MS population (mean CRP 4.09, SD 5.23) and the control 
group (mean 3.16, SD 6.94), or between MS disease subgroups (S-RRMS mean 4.2, SD 
5.76; A-RRMS mean 3.04, SD 4.12; SPMS mean 4.86, SD 6.12; PPMS mean 3.94, SD
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4.10), demonstrating the absence of another indicator of systemic inflammation at times 
of C upregulation.
Changes in complement levels in the CSF
It was possible to measure C components fB, C9, CIs, clusterin and TCC in CSF using 
the assays described (levels of fH and C4a in CSF have been described previously in 
Chapters 5 and 6); demographic details of patients and controls are shown in table 7.6. 
Levels of both CSF and plasma fB and C9 were reduced in patients with MS and CIS 
compared with the control population; however, this only reached significance in plasma 
C9 levels (table 7.7). C9 CSF/plasma ratio and C9 index were also non-significantly 
reduced in MS patients compared to controls (table 7.7). Levels of CSF and plasma 
clusterin, CIs and TCC were increased in patients with MS and CIS compared to 
controls; this only reached significance in the plasma clusterin CIS cases and given 
sample size, this finding may be the result of a type 1 error.
In order to examine the degree to which levels of C were due to BCB breakdown or 
intrathecal synthesis, correlation was assessed with either raised CSF:serum albumin or 
raised IgG:albumin index respectively (Link et al. 1977; Eeg-Olofsson et al. 1981) (table 
7.8). CSF:plasma fB and C9 showed good correlation with both the IgG index and the 
CSF:serum albumin ratio; in addition, levels of CSF fB and C9 were elevated in patients 
with a raised IgG index (fB p=0.056, C9 p=0.01) and a raised CSF:serum albumin ratio 
(fB p=0.173, C9 p=0.010) indicating both systemic and local synthesis of fB and C9. 
CSF:plasma ratios of CIs and clusterin showed moderate correlation with CSF:serum 
albumin, and raised CSF levels were seen only in patients with a raised CSF: serum
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albumin ratio (CIs, p=0.024, clusterin, p=0.011) indicating that local CIs and clusterin 
appeared predominantly due to influx at times of BCB breakdown. Levels of CSF TCC 
showed no correlation with either CSF IgG or albumin.
Examination of disease characteristics showed weak to moderate correlation of CSF fB, 
C9, CIs and clusterin with age (fB r= 0.23, p=0.068; C9 r=0.39, p=0.002; CIs i=0.23, 
p=0.079; clusterin r=0.38, p=0.002); however, no correlation was seen with disease 
duration. CSF C9 showed a weak correlation with disability measured by EDSS (r=0.33, 
p=0.03).
7.4 Discussion
Although MS is a predominantly T cell mediated disease, it is well established that C 
plays an important role. I have previously demonstrated both systemic and local up- 
regulation of C regulator fH (Chapter 5) and fragment C4a (Chapter 6). Here, analysis of 
local and systemic C in MS patients is extended with the aim of clarifying the 
contribution of C to disease processes and combined complotype and phenotype models 
are examined to determine possible combined biomarkers of disease and disease course.
Given the complex and variable immunopathogenesis of MS, the use of combinations of 
plasma markers to develop informative biomarkers of disease and disease course is likely 
to be more informative than using isolated measurement. The model developed here for 
distinguishing MS from controls uses a combination of plasma C components C3, C4,
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C9, fH and Cl-inh to give a predictive probability of 97%. The use of this model 
clinically is limited in its current form given that distinguishing MS from differential 
diagnosis or from CIS was beyond the scope of this study. Additional complotypes to 
distinguish disease subgroups were not established. No measured component other than 
fH was specific for disease progression; and although C9, C4a and fH showed differential 
changes in relapse, when combined, did not produce a predictive model. This may have 
been because of difficulties in the clinical classification of relapse and progression as 
discussed in Chapter 5, or it may be that other complement components or inflammatory 
markers would be more useful in establishing biomarker profiles. The addition of C 
measurements to objective clinical characteristics, disease duration and age, to 
distinguish disease state did seem to be of value with a combined model predictive 
probability for relapse of 75%. This chapter establishes the potential use of complotypes 
as plasma biomarkers for diagnosis and it is now necessary to evaluate this further with 
neurological control groups. The use of complotypes for distinguishing disease course 
needs further evaluation in a prospective cohort of patients with parallel MR data. There 
is clearly a need for this work to be replicated by independent groups to confirm the use 
of these models in clinical practice, which would be best achieved in an independent 
prospective cohort.
Systemic up-regulation of C regulators and systemic and local consumption of C 
components was demonstrated throughout various stages of the MS disease course, 
implying continuous activation of C and dynamic effects that are both local and systemic. 
The previously noted increase in alternative pathway regulator fH predominantly in
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progressive disease, contrasts with up-regulation of Cl-inh which shows no differential 
expression between disease subgroups; possibly indicating the need for regulation of the 
classical pathway of C throughout disease course with the alternative pathway playing a 
more prominent role as disease progresses. Levels of plasma fH, raised at times of acute 
relapse, also correlate with clinical disease activity with a significant reduction in plasma 
fH in convalescent samples post relapse, possibly implying the transient need for 
systemic regulation of the alternative pathway at times of acute inflammatory events. 
Although in this study CSF Cl-inh was not measured, local expression of fH and 
increased CSF fH levels corresponding with breakdown of the blood-CSF barrier has 
previously been demonstrated. I speculate that C regulation is important both locally and 
systemically in MS.
Reduced levels of both plasma fB and plasma and CSF C9 in the total MS population 
imply consumption of these components throughout disease with increased systemic 
production in acute relapse. This corresponds with raised plasma C3 and C4 levels in MS. 
Chapter 6 demonstrated raised levels of C4a, a fragment of C4, isolated to acute relapse; 
and raised CSF C4a in the total MS population examined. Together, these results may 
indicate both local and systemic activation of classical and alternative pathways of C in 
MS.
Although 2 previous studies have examined plasma C9 in MS patients showing no 
difference from controls (Morgan et al. 1984; Compston et al. 1986), these studies were 
limited in terms of patient numbers and may have been underpowered to detect change.
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Local reduction of C9 levels shown here is consistent with previous studies (Morgan et 
al. 1984; Compston et al. 1986); however, given the nature of our CSF control group, 
there may have been more C activation in the controls than would be seen in normal 
healthy controls, limiting the difference in C9 observed. Interestingly, CSF C9 in our 
study did show some degree of correlation with disability, previously only shown in CSF 
TCC measurements in a single study (Sellebjerg et al. 1998). Further work with extended 
analysis of CSF C9 and/or TCC in MS disease subgroups and CIS patients may be useful 
in determining whether they could be clinically informative.
In vitro studies have established that not only can CNS cells produce all C components 
necessary for C lysis (Gasque et al. 1992; Gasque et al. 1993; Gasque et al. 1995), but 
also C is a tissue-damaging factor in demyelination and neurodegeneration (Scolding et 
al. 1989; Wren et al. 1989; Piddlesden et al. 1993b). It is still unclear how this relates to 
in vivo pathology and whether C components seen in MS white matter plaques are locally 
produced or are a result of BCB breakdown. This study demonstrates the majority of C 
components including C9, CIs, fB, fH and clusterin leak into the CSF at times of BCB 
breakdown; in addition there is suggestion of local biosynthesis of some components 
including fB, C9 and C4a. Although not conclusive, this evidence suggests both locally 
and systemically synthesised C contribute to the disease process in MS.
In summary I have developed potential complotype models to distinguish MS from 
controls and differentiate disease course subgroups. I have shown both local and systemic 
activation and regulation of C in MS patients, in the absence of changes in CRP, an acute
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phase reactant raised in systemic inflammatory responses, indicating C activation is likely 
due to MS rather than a second disease process. Differential C component concentrations 
showed correlation with clinical disease activity, disease course or disability and I 
suggest that both classical and alternative pathways of C play an important role at times 
of acute inflammatory attack, but also act throughout the whole disease. Systemically 
produced C is shown to cross the BCB at times of inflammation and given that the vast 
majority of C synthesis is hepatic, it is possible that systemically targeted anti-C therapies 
may significantly reduce the extent of local C attack and may be of use in MS patients in 
addition to more traditional adaptive immune targeted therapies.
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Table 7.1: Demographic details of total MS population and controls
No. Gender
% f
Age
Mean SD
DD
Mean SD
EDSS
Mean SD
MSSS
Mean SD
Control 35 60.00 50.57 19.54 N/A N/A N/A N/A N/A N/A
Total MS 194 67.53 44.07 12.38 11.74 10.45 4.94 2.07 6.54 2.55
S-RRMS 40 80.00 41.58 9.30 8.00 9.39 2.58 1.38 4.40 2.60
A-RRMS 78 76.92 36.54 9.54 8.68 7.84 4.69 1.51 6.72 2.44
SPMS 39 51.28 53.15 9.56 22.95 10.67 6.95 1.16 7.26 2.00
PPMS 37 51.35 53.05 11.62 10.43 8.02 5.92 1.66 7.71 1.86
DD; disease duration. EDSS; expanded disability status scale. MSSS; MS severity score, f; female. SD;
standard deviation. S-RRMS; stable-relapsing remitting MS with no relapses reported for at least 12 
months. A-RRMS; acute-relapsing remitting MS sampled in relapse. SPMS; secondary progressive MS. 
PPMS; primary progressive MS.
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Table 7.2: Comparison of concentrations of complement components between MS disease subgroups and controls
FB mg/L C3 mg/L CIs % of C4 mg/L C9 % of arbitrary standard
arbitrary
standard
No. Mean SD p* Mean SD P Mean SD Mean SD P Mean SD P p*
Control 35 194.02 68.28 1 1263.14 268.38 N/A 97.91 44.75 187.43 57.09 N/A 151.11 35.78 N/A 0.001
Total MS 194 184.74 57.55 N/A 1449.13 357.38 0.004 103.42 46.53 237.08 83.39 0.001 113.02 34.09 <0.001 N/A
S-RRMS 40 171.26 34.04 0.065 1450.38 370.23 0.206 100.47 48.34 222.79 66.60 0.581 103.93 20.97 <0.001 0.027
A-RRMS 78 202.29 75.43 N/A 1398.59 348.49 0.549 101.79 47.69 232.23 70.43 0.060 123.74 43.18 0.001 N/A
SPMS 39 169.86 33.59 0.048 1506.26 306.80 0.028 113.16 51.24 258.30 97.83 0.002 104.78 24.09 <0.001 0.044
PPMS 37 177.99 44.54 0.371 1499.58 413.23 0.052 99.79 36.15 249.00 145.97 0.256 108.94 26.84 <0.001 0.282
SD; standard deviation. P values are measured using one-way Anova with Bonferroni correction and are only shown in groups displaying a positive
result. P  = comparison with control group. P* = comparison with A-RRMS group. S-RRMS; stable-relapsing remitting MS with no relapses reported for 
at least 12 months. A-RRMS; acute-relapsing remitting MS sampled in relapse. SPMS; secondary progressive MS. PPMS; primary progressive MS.
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Table 7.3: Comparison of concentrations of complement 
activation products between MS disease subgroups and 
controls
No.
Bb mg/L 
Mean SD No. Mean
C4a mg/L 
SD P p *
Control 35 1.04 0.21 35 819.65 570.94 N/A <0.001
Total MS 82 1.07 0.3 194 1487.20 971.28 <0.001 N/A
S-RRMS 20 1.03 0.32 40 1134.22 774.91 1.000 0.011
A-RRMS 20 0.98 0.19 78 1726.57 1100.41 <0.001 N/A
SPMS 22 1.14 0.31 39 1292.25 788.04 0.316 0.190
PPMS 20 1.31 0.42 37 1579.80 646.69 0.154 1.000
SD; standard deviation. P  values are measured using one-way Anova with
Bonferroni correction and are only shown in groups displaying a positive 
result. P — comparison with control group. P* = comparison with A-RRMS 
group. S-RRMS; stable-relapsing remitting MS with no relapses reported for 
at least 12 months. A-RRMS; acute-relapsing remitting MS sampled in 
relapse. SPMS; secondary progressive MS. PPMS; primary progressive MS.
Table 7.4: Comparison of concentrations of complement regulators between MS disease
isubgroups and controls
Cl inhibitor g/L Clusterin mg/L Factor H mg/L
No. Mean SD P p* No. Mean SD No. Mean SD P p*
Control 35 0.29 0.05 N/A <0.001 35 52.74 23.09 35 212.94 63.08 N/A 0.010
Total MS 150 0.36 0.07 <0.001 N/A 121 55.05 19.55 194 265.55 80.22 <0.001 N/A
S-RRMS 40 0.35 0.06 0.001 1.000 20 55.48 14.90 40 235.82 78.18 1.000 0.557
A-RRMS 34 0.36 0.09 <0.001 N/A 59 55.51 19.76 78 263.89 58.93 0.010 N/A
SPMS 39 0.37 0.06 <0.001 1.000 22 56.99 23.72 39 343.01 70.02 <0.001 <0.001
PPMS 37 0.34 0.05 0.013 1.000 20 51.13 18.91 37 274.11 77.26 0.003 1.000
SD; standard deviation. P values are measured using one-way Anova with Bonferroni correction and are only 
shown in groups displaying a positive result. P  = comparison with control group. P* = comparison with A-RRMS 
group. S-RRMS; stable-relapsing remitting MS with no relapses reported for at least 12 months. A-RRMS; acute- 
relapsing remitting MS sampled in relapse. SPMS; secondary progressive MS. PPMS; primary progressive MS.
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Figure 7.1: Plasma levels of C3, C4, fH and C l inhibitor were increased 
and plasma levels of C9 were decreased in MS patients compared to 
normal controls
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Figure 7.2: Receiver operating characteristic curve to predict the 
probability of MS compared to control subjects
Combined model C statistic 0.97. For the individual components of the model; C3 C 
statistic 0.66, C4 C statistic 0.71, C9 C statistic 0.15, Cl-inh C statistic 0.84 and fH C 
statistic 0.79.
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Figure 7.3: Receiver operating characteristic curve to predict the 
probability of A-RRMS from S-RRMS
Combined model C statistic 0.75. For the individual components of the model; C9 C 
statistic 0.63, disease duration C statistic 0.56 and age C statistic 0.35.
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Table 7.5: Mean concentrations of serum factor H, factor B and C9 are shown in 44 
patients with serial samples post relapse
Months Factor H mg/L Factor B mg/L
C9 % of arbitrary 
standard
post
relapse No. Mean SD P Mean SD P Mean SD P
0 44 205.72 63.80 N/A 247.50 86.18 N/A 149.15 48.42 N/A
2-3 44 178.81 42.93 0.013 270.69 70.05 0.158 153.53 45.44 0.678
5-7 44 176.39 39.28 0.007 243.62 71.52 0.813 150.59 49.44 0.891
FH; Factor H. FB; Factor B. SD; standard deviation, p  = p  value for comparison with acute relapse 
(month 0).
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Figure 7.4: Plasma factor H levels post relapse
A reduction in plasma factor H is seen post relapse in 26 of 44 patients at 2-3 months and 
30 of 44 patients at 5-7 months. Mean levels are significantly reduced at both time points 
(p=0.013 at 2-3 months and p=0.007 at 5-7 months).
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Table 7.6: Demographic details and routine CSF results in controls, patients with MS and 
CIS
No. Age Gender Disease EDSS Albumin ratio Ig index OCB
duration
Mean SD %f Mean SD Mean SD Mean SD Mean SD % +ve
Control 24 49.79 13.52 79.17 0.50 0.71 5.24 2.79 0.50 0.05 0 . 0 0
MS 37 38.81 10.76 75.68 7.11 8.57 2.55 2 . 1 0 5.33 1.93 1 . 0 0 0.48 91.89
CIS 5 40.00 9.35 1 0 0 . 0 0 0.80 0.45 2 . 0 0 1.58 6.14 2.31 0.79 0.44 40.00
EDSS; expanded disability status scale. Albumin ratio; CSF albumin mg/L / serum albumin g/L. Ig Index; derived 
from CSF/plasma ratios o f IgG and albumin concentrations. OCB; oligoclonal bands. SD; standard deviation. 
CIS; clinically isolated syndrome.
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Table 7.7: CSF factor B, C9, CIs and clusterin are compared between patients
with MS, CIS and controls
Mean
CSF
SD
Plasma 
Mean SD
CSF:plasma ratio 
Mean SD
Calculated index 
Mean SD
FB Control 0.90 0.46 202.81 76.19 4.11 2.08 0 . 8 6 0.32
MS 0.79 0.34 182.40 44.14 4.50 1.96 0.95 0.56
CIS 0.80 0.30 174.08 62.44 4.80 2.45 0.74 0.15
C9 Control 0.49 0.30 175.30 42.43 3.14 2.17 0.56 0.14
MS 0.36 0.19 143.98* 38.29 2.59 1.42 0.46 0.17
CIS 0.34 0.17 121.74* 34.16 4.66 4.41 0.45 0.16
CIs Control 1.65 0.44 142.19 53.30 13.52 7.16 3.11 1.61
MS 1.73 0.72 126.49 26.17 13.93 6.85 2.90 1.47
CIS 2 . 1 2 0.95 125.50 35.83 15.56 13.45 2.82 0.99
Clusterin Control 1.59 0.90 34.67 1 0 . 8 8 54.52 43.97 11.78 9.82
MS 1.77 0.81 40.68 14.17 54.31 35.72 10.52 7.19
CIS 1 . 8 6 1.04 5 4 .4 4 ** 44.69 92.07 63.83 14.39 7.33
TCC Control 9.96 13.19 N/A N/A N/A N/A N/A N/A
MS 13.23 14.48 N/A N/A N/A N/A N/A N/A
CIS 25.77 42.07 N/A N/A N/A N/A N/A N/A
CSF and plasma values shown in mg/L for factor B (FB) and clusterin, % of arbitrary standard for
C9 and mAU/ml for TCC. CSF:plasma Ratio; CSF mg/L / Serum g/L. Calculated index, calculated 
by substituting the specified Cprotein for IgG in the Ig Index. SD; standard deviation. CIS; 
clinically isolated syndrome. * P=0.01, ** P=0.03
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Table 7.8: Correlation of complement components and regulators with raised IgG
index and CSF:serum albumin ratios
CSFiplasma Correlation Normal Raised
C ratio r P Mean 
C ratio
SD Mean 
C ratio
SD P
FB IgG Index
0.41 0 . 0 0 1 0.74 0.41 0.92 0.33 0.056
Albumin ratio 0.38 0.004 0.79 0.39 0.96 0.31 0.173
C9 IgG Index 0.46 <0 . 0 0 1 0.33 0.17 0.48 0.28 0 . 0 1 0Albumin ratio 0.65 <0 . 0 0 1 0.35 0.17 0.65 0.34 0.013
CIs IgG Index 
Albumin ratio
0 . 1 1
0.35
0.423
0 . 0 1 1
1.69
1.67
0.59
0 . 6 6
1.82
2.16
0.75
0.57
0.468
0.024
Clusterin IgG Index
0 . 2 2 0 . 1 1 0 1.57 0.95 1 . 8 6 0.75 0.175
Albumin ratio 0.36 0.007 1.58 0.83 2.28 0.82 0 . 0 1 1
CSF TCC IgG Index 0.19 0 . 2 1 0 10.61
13.22 14.95 19.85 0.385
Albumin ratio -0 . 1 1 0.482 12.96 14.13 10.60 25.81 0.717
Correlations are shown between CSF'.plasma C ratio and either the IgG index or CSF:serum
albumin ratio (expect for TCC where plasma levels were not detectable and correlation is shown with 
CSF TCC). Normal and raised refer IgG index or CSF:serum albumin ratio in reference to their 
normal laboratory values; a raised value indicates either intrathecal IgG synthesis (raised IgG 
index) or breakdown of the blood-CSF barrier (raised CSF'.serum albumin ratio). The p  value refers 
to the difference between mean levels o f the CSF .-plasma C ratio when the IgG index or CSF'.serum 
albumin ratio is normal or raised. FB; factor B. TCC; terminal complement complex.
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CHAPTER 8: AN IMMUNOHISTOCHEMICAL ANALYSIS 
OF COMPLEMENT IN MULTIPLE SCLEROSIS POST­
MORTEM TISSUE.
8.1 INTRODUCTION
Deposition of C components within MS plaques was first demonstrated in 1971 
(Lumsden 1971) and several immunohistochemical studies subsequently localised C 
within white matter lesions suggesting a pathological role for C in demyelination 
(Woyciechowska et al. 1977; Compston et al. 1989; Gay et al. 1991; Lucchinetti et al. 
1996; Bitsch et al. 2000; Prineas et al. 2001; Barnett et al. 2004; Breij et al. 2008). 
However, labelling in these studies was generally limited to one or several of C proteins 
Clq, C3 and C4, or activation products C3d, C4d and C9 neoantigen (C9neo). In 
addition, staining was often reported as either specific to fragmented myelin or diffusely 
present throughout the plaque with little information provided regarding cellular 
localisation. A more complete immunohistopathological analysis of the role of C in MS 
has been described, although limited to one patient, showing diffuse staining throughout 
selected plaques, with periplaque accentuation, of C proteins CIs, C3, C4, C6 , C7, C8  
and C9, C activation products C5b and C9neo and C regulators CD59, CD46, S Protein 
and Cl-inh (Storch et al. 1998). Controversially the specificity to MS of C staining of 
disrupted myelin has been questioned in one study which concluded that demonstrating
170
deposition of C3d and C9neo provided no direct evidence to support C or antibody 
mediated injury in MS (Barnett et al. 2009).
It is also unclear whether consistent C immunoreactivity occurs in all cases of MS; one 
study demonstrated only 53% of cases with staining of C9 neo at sites of active myelin 
destruction (Lucchinetti et al. 1996). One explanation may be that lesion heterogeneity is 
present in the initial disease phase and only tissues from more established disease 
demonstrate consistent C staining, although pathological heterogeneity cannot be 
excluded (Breij et al. 2008). Furthermore, some observers have reported that C 
immunoreactivity in MS is exclusive to white matter lesions suggesting that axonal 
damage within the grey matter may be independent of C (Brink et al. 2005).
In summary, the extent of C activation in MS and its contribution to the various disease 
components of demyelination and axonal degeneration remains unclear. I speculate that 
both classical and alternative pathways of C may be important in acute inflammatory 
demyelinating events and also in chronic progressive phases resulting in chronic 
inflammation and causing progressive axonal degeneration. In this study I investigated an 
extensive array of C proteins, activation products and regulators in MS brain and spinal 
cord, choosing key members of classical, alternative and terminal pathways; to assess the 
extent of activation and regulation of C in MS and its deposition in relation to MS 
plaques and axonal damage.
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8.2 METHODS
Cases
Human tissue used in this study was provided by the UK Multiple Sclerosis Tissue Bank. 
Archival, 10% formalin-fixed, paraffin-embedded CNS tissue was obtained at autopsy 
from 9 MS cases (median age at death 66.0 years, median disease duration at death 26.5 
years, median death to tissue preservation time 17.0 hours), 2 non-neurological control 
cases and 1 Alzheimer’s control case (median age at death 91.0 years, median death to 
tissue preservation time 51.0 hours). One block of tissue was obtained from both brain 
cerebral cortex and spinal cord for 7 of 9 MS cases and all controls. The remaining two 
MS cases had blocks available from brain cerebral cortex only. In total, 13 plaques from 
8  individuals were examined from MS cases. Clinical background data is summarised in 
table 8 .1 .
Histological staining and lesion characterisation
Paraffin wax tissue sections 4 microns in thickness were stained with Luxol fast blue 
(LFB) to assess presence of myelin and identify areas of demyelinated plaque, peirplaque 
and normal appearing white matter (NAWM). Areas of NAWM were defined as a region 
of white matter at least 1cm away from the edge of the demyelinating plaque. Anti-HLA- 
DR antibody staining was carried out to assess the number of positive microglia within 
the plaque or surrounding white matter. MS white matter lesions were classified as either 
active (plaque centre heavily infiltrated with HLA-DR positive microglia and LFB 
positive macrophages), chronic active (inactive centre surrounded by area of activity with
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HLA-DR positive microglia and LFB positive macrophages) or inactive (few or no HLA- 
DR positive microglia or LFB positive macrophages) (Ferguson et al. 1997; Komek et al. 
2000). Accuracy of lesion classification was confirmed by two independent observers.
Immunohistochemistry
Parraffin wax sections were de-paraffinated using xylol and rehydrated in reducing 
concentrations of ethanol (100%, 96%, 70% and water). Endogenous peroxidase was 
blocked by 30-minute incubation in methanol with 0.02% H2 O2. For antigen retrieval 
sections were either heated in citraconic anhydride (pH 7.4) or immersed in protein 
kinase 20 /-ig/ml (for primary antibody B7 only). Prior to staining, sections were blocked 
in 10% normal goat serum. Staining was achieved using DAKO autostainer with DAKO 
EnVision™+ System, Peroxidase (DAKO EnVision™+ System, HRP). Primary 
antibodies, including antigen target, clone, concentration, dilution and source, are listed 
in table 8 .2 .
For double labelling experiments, after an initial 30 min blocking step with 10% normal 
goat serum, sections were incubated for 1 hour with the first primary antibody followed 
by 30 mins with the secondary antibody (Dako REAL™ EnVision™/HRP reagent). 
Sections were stained for visualising using Vector SG peroxidase substrate kit (grey) 
(Vector Laboratories LTD, www.vectorlabs.com) before undergoing a shorter 10 min 
blocking step with 1 0 % normal goat serum followed by a 1 hour incubation with the 
second primary antibody and 30 min incubation with the secondary antibody (as above). 
The second primary was visualised with Dako REAL™ diaminobenzidine (DAB) +
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Chromogen (brown) so that the 2 primary antibodies were visualised on the same slide in 
a different colour. The sections were dehydrated for reading.
Positive controls used were from renal biopsies of patients with glomerulonephritis 
sectioned in microarrays (Soverchia et al. 2005). Negative controls were performed using 
non-immune immunoglobulins of the same isotype as, and diluted to the same 
concentration as, the primary antibody. Negative controls were also performed with 
omission of the primary antibody.
Quantitative analysis
All sections were digitally scanned and 5 different areas of plaque, peri-plaque, NAWM 
and grey matter (GM) were selected manually from each specimen at x40 magnification 
of the objective lens (0.037mm2/field) for further analysis. For quantification, the 
immunostained fields were overlaid by a grid and positively stained cells for each of the 
individual antibodies were manually counted. Values were expressed as the number of 
positively stained cells per mm2. In order to verify data, an inter-rater agreement was 
assessed between two independent investigators over 30 scanned fields from different 
sections, patients and primary antibodies, with an ICC of 0.99.
Statistical analysis
Data was not normally distributed and therefore was analysed using non-parametric tests 
and results are displayed with a median and range. Differences between disease
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subgroups were analysed using the Kruskal-Wallis test with post-hoc procedures using 
Mann-Whitney tests. Given the inflation of type I errors due to multiple testing, a p value 
of <0.016 was taken as significant (0.05 divided by the number of tests).
8.3 RESULTS
For 7 of 9 MS patients, a single plaque from each of brain cerebral cortex white matter 
and spinal cord was analysed. For the remaining 2 patients, one case had a section from a 
brain cerebral cortex white matter lesion and a section from cortex NAWM available, and 
the other case had only a cortex NAWM section available. Lesions were classified as 
described and in total 2 active, 8  chronic active and 3 inactive lesions were analysed 
(table 8.1, fig 8.1). Paraffin wax sections from kidney tissue with glomerulonephritis 
were used as positive controls and showed staining for all antibodies used (fig 8 .2 ). 
Sections stained for isotype control antibodies were consistently negative in both MS 
cases and controls (fig 8 .2 ).
Activation and regulation of complement in late stages of MS
All C proteins (C3b, fB and Clq), activation products (C3b, iC3b, C4d and C9neo) and 
regulators (fH, Cl-inh, clusterin, CD59 and CD46) examined were present in MS lesions 
(table 8.3 and 8.4, fig 8.3). Staining was not consistent in all sections with some patients 
showing more C immunoreactivity than others; however, staining was seen to some 
degree in every specimen analysed independent of plaque activity. Within brain sections, 
significantly more staining was seen in the plaque compared to periplaque areas and areas 
of NAWM (table 8.5, fig 8.3, fig 8.4). In a few cases marked staining was seen for some
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antibodies (predominantly C lq and fH) in the periplaque area. NAWM from MS patients 
was generally devoid of staining except for C3b staining seen in 1 brain specimen, C lq in 
2, clusterin in 4 and Cl-inh in 3, with marked staining of Cl-inh seen in 1 case with no 
additional C staining seen (fig 8.5). In addition, myelin staining of fH was seen in 
NAWM of 1 brain specimen with no plaques present (fig 8.5).
C3b showed the strongest immunoreactivity with similar iC3b staining in 3 verified 
sections (intraclass correlation coefficient between C3b (stained with C330) and iC3b for 
quantitative cellular staining = 0.85, 95%CI 0.76-0.91, p<0.001) indicating activated C3b 
present in MS plaques. Marked cellular staining was also seen for C lq and clusterin with 
weaker cellular staining seen for fB, C4d, C9neo and fH, (fig 8.3). Control specimens 
were consistently negative for cellular staining with the only positive staining seen in the 
Alzheimer’s tissue which showed positive C staining within amyloid plaques and 
adjacent vessels.
Complement co-localizes with astrocyes in MS brain plaque
C staining within the plaque and periplaque area was consistently specific to cells 
morphologically resembling astrocytes (fig 8.3). Double labelling experiments showed no 
co-localization of C3b staining with HLA +ve microglia; however, positive co­
localization with GFAP +ve astrocytes was seen within the plaque and periplaque (fig 
8.5). Astrocytes within the grey matter did not stain for C3b (fig 8.5). In some sections, 
periplaque areas stained more strongly for Clq; however, even in these sections there was 
little or no co-localization with HLA, and positive co-localization with GFAP.
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Complement staining of myelin localises in areas of axonal damage
Myelin staining for C was limited and variable (table 8.3 and 8.4). Within the plaque, 
staining of fragmented myelin with C3b and clusterin antibodies was only seen in 1 brain 
section. Myelin staining in areas of NAWM with antibodies to C lq and fH was seen in 
several MS brain sections from different patients (also seen strongly in the periplaque 
areas); while myelin staining for clusterin in NAWM was seen in 2 different patient 
sections. Staining of white matter myelin was more commonly seen in spinal cord 
sections with 2 of 6  cord sections showing fH staining (fig 8.5), 1 showing Cl-inh 
staining (fig 8.5) and 1 showing C lq staining. Staining of C antibodies was often specific 
to areas in which axons were positive for APP indicating damage (fig 8.5), with little C 
staining of myelin seen in sections that were APP negative.
Complement localizes to neurones in brain periplaque grey matter
Within the brain, GM showed relatively little C staining; however, in areas of GM 
adjacent to the plaque there was frequently increased immunoreactivity of C components 
C3b and C lq (fig 8.2) and regulators fH, Cl-inh and clusterin (fig 8.4) in normal 
appearing neurones, suggestive of C protein synthesis from neurones. These areas had the 
appearance of a white matter plaque extending into the cortex with increased HLA +ve 
microglia and astrocytes within the area.
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Complement staining switches from white to grey matter in spinal cord
Less cellular staining of C was seen within plaque and periplaque areas of spinal cord 
sections; however, there was marked staining of C3b in the anterior horn cells of affected 
spinal cord sections (table 8.4). In the 5 cord sections with plaques present, a median of 
75.8% of neurones were positively stained with C3b (range 40.5%-100%). Neuronal 
staining for other C antibodies was absent except for clusterin in 1 section (6 8 .8 % of 
neurones) and fH in another different section (47.4% of neurones). The observed 
neuronal staining may be due to the close proximity of the inflammatory lesion and 
neurones in spinal cord sections and therefore similar to the periplaque GM staining seen 
in cortical lesions. However, this does not explain the lack of white matter cellular 
staining seen in the spinal cord.
8.4 DISCUSSION
There is ongoing debate as to the specific contribution of C to pathology in MS. It is well 
known that in vitro, neuronal cell lines can express a full lytic C cascade along with an 
array of C inhibitors, and that neurones and oligodendrocytes are susceptible to C 
mediated attack (Gasque et al. 2000). In addition, there is strong evidence from the 
animal model of MS, EAE, for C driven pathology (van Beek et al. 2005). Several studies 
in human MS brain have shown C deposition in areas of myelin degradation (Storch et al. 
1998; Prineas et al. 2001) and serum and CSF show changes in C levels (detailed in 
Chapter 2). However, it is still not clear from literature to date whether C activation in 
MS, is a primary event contributing to myelin and axonal damage, or a non-specific 
feature similar to that seen in other diseases (Barnett et al. 2009).
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This study shows extensive cellular staining of C proteins (C3b, fB and Clq), activation 
products (C3b, iC3b, C4d and C9neo) and regulators (fH, Cl-inh, clusterin, CD46 and 
CD59), indicating activation and deposition of C in areas of disease activity. This 
demonstrates that activation of C via both classical and alternative pathway persists into 
the chronic phases of MS, even when there is little other evidence of immune mediated 
inflammation. Staining seen was specific to astrocytes and neurones in MS patients but 
not in the normal controls or the Alzheimer’s control; in addition the observed pattern of 
cellular staining has not been described previously in other neurological inflammatory 
diseases (Barnett et al. 2009) indicating this is an MS specific phenomenon.
A characteristic feature of MS is production of oligoclonal IgG seen in >95% of patients 
(Andersson et al. 1994). There is some evidence to suggest that oligoclonal IgG in MS is 
the results of clonal expansion of B cells resident within the CNS (Qin et al. 1998). This, 
along with deposition of C immunohistochemically, has been cited as evidence for MS 
being an antibody driven process (Storch et al. 1998). However, in vitro studies have 
shown C activation due to disrupted myelin and independent of antibody (Vanguri et al. 
1982) and even the classical pathway, traditionally considered to be activated primarily 
by immune complexes, can be activated in other ways such as by apoptotic cells and C- 
reactive protein bound to ligand. C activation via the classical pathway in MS, therefore, 
cannot be taken as proof of an antibody driven process. It was not possible from data in 
this chapter to distinguish whether the classical or alternative pathway predominantly
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contributed to C activation and the results provide no evidence to support a pathogenic 
role for antibodies in MS.
Staining of disrupted myelin in MS lesions, previously cited as evidence of C-mediated 
pathology (Compston et al. 1989; Storch et al. 1998; Prineas et al. 2001), was limited and 
variable in this study. Myelin staining of proteins C3b (1 case), fB (1 case) and C lq (1 
case both brain and spinal cord sections) and regulators fH (3 cases and 1 control), 
clusterin (1 case) and Cl-inh (3 cases) was seen to some degree in a total of 10/23 
sections from 7 of 9 MS patients and 1 of 3 controls. This positive myelin staining was 
seen in cases with active, chronic active and inactive plaques; in some cases in the centre 
of the plaque and in other cases in periplaque tissue or in adjacent areas of NAWM; also 
myelin staining was observed independently of age at death, disease duration and tissue 
preservation time. Although myelin staining can be a non-specific feature when C is 
present in brain tissue, in this study most C staining of myelin localized to the same areas 
of the plaque or periplaque that showed APP positive axons indicating axonal damage, 
suggesting C-mediated myelin damage.
The median age of patients seen in this study was 6 6  years (range 42-78) with median 
disease duration 25 years (range 8-50). The majority of plaques had an inactive centre 
with or without a periplaque rim of inflammatory activity. However, even in these 
plaques with little inflammation, evidenced by lack of HLA-DR positive microglia or 
LFB positive macrophages, in progressive patients with relatively long disease durations; 
there was evidence of ongoing C activation with synthesis mid cellular deposition of C
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proteins, activation products and regulators providing evidence of an inflammatory 
component to pathology in progressive disease phases. This is supported by our previous 
studies showing increased levels of C proteins and regulators in MS throughout disease 
course (Chapter 7); in particular, increased levels of fH were specific to progressive 
disease (Chapter 5) suggesting up-regulation of C in late disease stages.
Traditionally it was considered that axonal degeneration in MS was caused by 
inflammation, evidenced predominantly by the frequency of transected axons in MS 
lesions showing correlation with the degree of inflammation (Trapp et al. 1998). 
However, this relationship has been questioned, most importantly, because of the lack of 
effect of anti-inflammatory treatments on preventing accruement of disability in 
progressive disease secondary to axonal loss (Molyneux et al. 2000), and lack of MRI 
correlation between inflammation and brain atrophy (Filippi et al. 2005). A more recent 
immunopathological study of 67 MS patients and 28 controls has demonstrated highly 
significant association between inflammation and axonal injury in all lesions and disease 
stages (Frischer et al. 2009) and a recent MRI study of 963 patients has shown relentless 
brain atrophy throughout MS disease course (De Stefano et al. 2010). The findings of this 
chapter demonstrate ongoing C activity in late disease and would support the concept of 
ongoing inflammation causing axonal loss and atrophy throughout disease.
The pathological heterogeneity of MS lesions was first described by Lucchinetti et al 
(Lucchinetti et al. 1996) who suggested 4 distinct patterns of MS lesion with only 50% of 
patients showing C staining; this has been contested by another study which
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demonstrated more consistent C staining throughout their patient sample (Breij et al. 
2008). It was postulated that this variation could have been a result of differing disease 
durations in the 2 populations studied (discussed in Chapter 2); however, measurement of 
C in the study by Lucchinetti et al was limited to antibody against C9neo, sourced and 
analysed using the same technique described in this chapter. The staining observed for 
C9neo in this chapter was not consistent across patients with 2 MS patients showing no 
C9neo staining, despite staining of other C components; and weak staining in most 
sections examined. This could explain some, but not all, of the heterogeneity seen in the 
study by Lucchinetti et al. Despite this, there were clear differences in staining intensity 
across the MS patients in this study supporting the idea of heterogeneous 
immunopathological processes in MS patients, possibly arising from the diverse genetics 
and resulting in the variable phenotypic disease courses. It could be suggested that anti-C 
or anti-B cell therapies may have a role in combination with more traditional T cell 
mediated therapies in limiting disease progression in some, but perhaps not all, patients.
In summary, this chapter demonstrates upregulation and activation of C to a varying 
degree, in all MS patients. Specific staining of astrocytes and neurones in areas of 
inflammation indicate a pathogenic role for C in disease processes throughout MS disease 
course. It is now essential to clarify these findings in a larger set of MS patients with 
more disease subgroups. In particular, this study was limited to patients with long­
standing disease and comparison with a group of early relapsing or aggressive MS 
patients with active plaques would provide insight into changes in complement 
expression throughout disease. Additional tissue would also allow examination of an
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expanded set of inflammatory markers such as Ig and T cell and B cell markers. 
Colocalization of inflammatory markers along with axonal marker NFL, and neural cell 
markers such as for oligodendrocytes, to complement staining, would offer a more 
comprehensive assessment of the pathological implications of complement expression in 
disease.
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Table 8.1: Demographic details, number of lesions and cause of death for MS
patients and controls
Case Diseasestatus
Age
at
death
Sex
Death 
to TPT 
(hrs)
MS
Disease
duration
MS
Disease
course A
Lesions
CA I
Cause of death
MS055 MS 47 f 15 32 SPMS 0 1 1 Pneumonia
MS058 MS 51 f 15 2 1 SPMS 0 2 0 MS
MS061 MS 56 f 6 >15 PRMS 0 1 1 Adenocarcinoma
MS064 MS 6 6 m 56 28 SPMS 0 2 0 Pneumonia
MS 128 MS 78 f 2 2 50 SPMS 0 1 1 Pneumonia
MS179 MS 70 f 2 0 25 SPMS 1 1 0 Pneumonia
Infective
MS306 MS 78 m 17 42 SPMS 0 0 0 diarrhoea
MS383 MS 42 m 17 8 PPMS 1 0 0 Pneumonia
MS24 MS 71 f 96 2 2 PPMS 0 0 0 Pneumonia
C21 Control 91 f 127 N/A N/A N/A N/A N/A Pneumonia
N/A N/A N/A N/A Abdominal
C29 Control 71 m 33 N/A haemorrhage
N/A N/A N/A N/A Alzheimer’s
C23 Control 93 f 51 N/A disease
TPT; tissue preservation time. A; active. CA; Chronic active. I; inactive, f; female, m; male. SPMS;
secondary progressive MS, PRMS; progressive relapsing MS, PPMS; primary progressive MS.
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Table 8.2: Primary antibodies used for immunohistochemistry
Antibody Antigen / 
Target
C
pathway
Type Source AR
Method
Cone
(mg/ml)
Dilution
Complement 
proteins /
activation products
C3-30 C3b CP &AP MAb, m In-house CA/Heat 4.82 1:1500
Catalogue no. A209 iC3b CP & AP MAb, m Quidel CA/Heat 1 .2 1:500
JC1 Factor B AP MAb, m In-house CA/Heat 1 . 0 1:300
SE9G11 Clq CP MAb, m In-house CA/Heat 1.16 1:60
Catalogue no. A215 C4d neo CP MAb, m Quidel CA/Heat 1 . 0 1:50
B7 Neo C9 TP MAb, m In-house PK 0 . 6 1 : 2 0
Complement
regulators
Ox-24 Factor H AP MAb, m In-house CA/Heat 2 . 8 1 : 2 0
Mbi 6 Factor H- AP MAb, m In-house CA/Heat 5.7 1:300
Mbi 7
Tyr402 
Factor H- AP MAb, m In-house CA/Heat 6.9 1:600
Clinh
His402
Cl-inh CP PAb, r In-house CA/Heat 16.93 1:400
Material no. 552886 Clusterin TP MAb, m BD CA/Heat 5.47 1:300
MEM 43 CD59 TP MAb, m
Pharmingen
In-house CA/Heat 0.4 1:400
FI 1 CD46 TP MAb, m In-house CA/Heat 0.9 1:300
Markers
APP Axons N/A MAb, m Millipore CA/Heat 38.7 1 : 2 0 0
GFAP Astrocytes/ N/A PAb, m DAKO, CA/Heat 3.94 1:500
HLA-DR
Ependymal
cells
Microglia N/A MAb, m
Denmark
DAKO, CA/Heat 5.93 1:150
Denmark
CP; classical pathway. AP; alternative pathway. TP; terminal pathway. MAb; monoclonal antibody. PAb;
polyclonal antibody. M; mouse. R; rabbit. AR method; antigen retrieval method. CA/Heat; heated in 
citraconic anhydride. PK; protein kinase.
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Figure 8.1: MS lesions
Case A = MS382; active brain lesion shown with LFB positive macrophages and multiple 
HLA positive microglia within the plaque. Case B = MS58; brain lesion shown is chronic 
active with a rim of HLA positive microglia around the plaque and few LFB containing 
macrophages within the plaque. Case C = MS61, brain lesion shown is inactive with few 
LFB or HLA positive cells. 1 = LFB stain, plaque x4. 2 = LFB stain, plaque x40. 3 = 
HLA stain, plaque x40. 4 = HLA stain periplaque x40.
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Figure 8.2: Control samples
Tissue microarrays of kidney for positive controls (A-L). A=C330, B=iC3b, C=JC1, 
D=Clq, E=B7, F=MBI6, G=MBI7, H=Clinh, I=Clusterin, J= CD59, K=CD55, L=CD46. 
Negative controls in MS tissue (M-P). M= IgGl in MS55 brain lesion plaque. N = IgGl 
in MS 55 brain lesion grey matter. O = IgG2 in MS58 spinal cord plaque. P= IgG2 in 
MS58 spinal cord grey matter.
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Table 8.3: Cellular and myelin staining of complement in individual brain sections
examined
ID Plaque
type
C3b Factor
B
C lq neo
C4d
neo
C9
Factor
H-
Tyr402
Factor
H-
His402
Clusterin Cl inh
MS 55 CA P +++ P + P+-H-
G++
P + P++ P + - P +++ -
MS 58 CA P++ - P +++ 
N +
- P++ P + P + PP++
P+
P++
MS 61 Inactive P +++ 
G++
- P++
G++
- - - - P + 
G++
-
MS 64 CA P -H—t- 
PM + 
N + 
G ++
PP+++
P++
G++
P + P++
G+++
P++ 
G +++
P++ 
PM + 
G +
MS 128 Inactive P++ P + P++
NM+
- P + P++
PPM++
P + 
PPM++
P++ 
G +
P++
MS 179 Active P +++ 
G++
P + P++ 
N +
P + P + P++
G+++
P + P +++ P++
MS 383 Active P+++ 
G ++
PP++
P+
P + PP + P + PP++
P+
P++ 
PM + 
PPM +
MS 383 None V NM + G++ N++
NM
++
G++
MS 306 None N++
NM
++
G++
MS 24 None - - - - - NM+++ NM++ - -
C 21 None - - - - - - - - -
C 23 None V - V - - AP AP V -
C 29 None - - - - - - - - -
MS; MS case. C; control case. CA; chronic active, P; plaque, PP; periplaque, N; NA W, G; grey matter. P;
myelin staining in the plaque, PPM; myelin staining in the periplaque, NM; myelin staining in the NA W. V; 
staining of vessels. AP; staining of amyloid plaques.+++; strong staining, ++; moderate staining, +; weak 
staining, -; no staining seen. Apart from myelin staining, this refers to specific cellular staining.
Table 8.4: Cellular and myelin staining of complement in individual spinal cord
sections examined
ID Plaque
type
C3b Factor
B
C lq neo
C4d
neo
C9
Factor
H-
Tyr402
Factor
H-
His402
Clusterin Cl inh
MS 55 Inactive P +++ 
G+-H-
- PP+++
P++
- PP + PP++ - P++ NM
++
MS 58 CA P +++ 
G+++
- PP++ - P + - - P+++ P +
MS 61 CA P++
G+++
“ “ " _ “ “
MS 64 CA P++ 
G ++
- P++ - - - PP +
G++
- P +
MS 128 CA G++ - NM
++
- - - - PP +
G++
-
MS 179 CA G++ - - - - NM+++ N ++ - -
MS 24 None - - - - - NM ++ NM + - -
C 21 None - - - - - - - - -
C 23 None - - - - - - - - -
C 29 None - - - - - NM + - - -
MS; MS case. C; control case. SC; spinal cord, CA; chronic active, P; plaque, PP; periplaque, N; NA W,
G; grey matter. P; myelin staining in the plaque, PPM; myelin staining in the periplaque, NM; myelin 
staining in the NA W. V; staining of vessels. AP; staining o f amyloid plaques. +++; strong staining, ++; 
moderate staining, +; weak staining, -; no staining seen. Apart from myelin staining, this refers to specific 
cellular staining.
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Figure 8.3: Complement staining in MS sections (I)
MS64, sections shown are from a chronic active brain lesion. Series A shows marked 
iC3b staining of cells and myelin predominantly within the plaque (insert in Al is a iC3b 
+ve astrocyte xlOO magnification). Clq staining shown in series B was more prominent 
in the periplaque area but also seen in the plaque. C 1 q staining of neurones was seen in 
areas of grey matter adjacent to the plaque. Series C shows C9neo staining predominantly 
in the plaque. A = iC3b, B = Clq, C = C9neo. 1 = Plaque, 2 = Periplaque, 3 = NAW, 4 = 
GM. Images magnification x40.
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Table 8.5: Cellular immunoreactivity of complement proteins, activation products and regulators
No.
C3b
Med
(min-max) P
Factor B 
Med 
(min-max) p
Clq
Med
(min-max) P
C4dneo 
Med 
(min-max) p
C9neo
Med
(min-max) P
Brain Plaque 7 269 (54-591) 0 (0-296) 134 (27-350) 0(0-323) 108 (0-376)
Periplaque 7 81 (0.0-215) <0.001 0(0-81) 0.018 81 (0-296) 0.003 0(0-81) 0.044 0 (0-242) <.0001
NAW 10 0 (0-188) <0.001 0 (0-0) <0.001 0(0-81) <0.001 0 (0-0) <0.001 0 (0-0) <.0001
GM 10 0 (0-108) <0.001 0 (0-0) <0.001 0 (0-269) <0.001 0 (0-0) <0.001 0 (0-0) <0.001
Spinal Plaque 6 81 (0-511) 0 (0-0) 0 (0-430) 0 (0-0) 0(0-81)
cord
Periplaque 6 0 (0-54) <0.001 0 (0-0) 1 0(0-403) 0.993 0 (0-0) 1.000 0 (0-27) 0.238
Factor H-Tyr402 Factor H-His402 Cl inhibitor Clusterin
Med Med Med Med
No. (min-max) P (min-max) P (min-max) P (min-max) P
Brain Plaque 7 81 (0-350) 108 (0-350) 215 (0-645) 81 (0-269)
Periplaque 7 27 (0-108) <0.001 27(0-81) <0.001 81 (0-296) <0.001 0 (0-215) 0.073
NAW 10 0 (0-0) <0.001 0 (0-0) <0.001 0(0-81) <0.001 0 (0-296) <0.001
GM 10 0 (0-457) <0.001 0 (0-108) <0.001 0 (0-424) <0.001 0(0-161) <0.001
Spinal
cord
Plaque 6 0 (0-350) 0(0-215) 54 (0-538) 0(0-108)
Periplaque 6 0 (0-484) 0.973 0 (0-54) 0.185 0(0-188) 0.047 0 (0-54) 0.445
Cell counts are expressed as immunoreactive positive cells /  mmA2, with the median (med), minimum (min) and maximum (max) values. P value is for
comparison to the plaque.
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Figure 8.4: C ellu lar sta in ing in  M S brain  sections
More positively stained cells are seen in plaque the compared to periplaque, NAW 
and GM areas (data shown for MS brain sections).
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Figure 8.5: C om plem ent staining in M S sections (II)
Case A = MS55, sections shown are from a chronic active brain plaque. Al (xlO) and 
A2 (xlOO) show a double stain of HLA-DR with Vector SG (grey) followed by C330 
with DAB (brown), taken at the lesion edge, with no co-localization shown between 
C3b and HLA +ve microglia. A3 (x40) and A4 (x40) show double staining of GFAP
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with Vector SG (grey) followed by C330 with DAB (brown). A3 shows co­
localization of C3b (brown) with GFAP (grey) +ve astrocytes in the plaque (insert 
shows an astrocyte xlOO magnification with double staining). A4 shows no co­
localization of C3b with the GFAP +ve astrocytes in cortex where there are C3b +ve 
neurones (insert shows an astrocyte stained only grey with GFAP). Case B = MS24, 
sections shown are from spinal cord with no lesion present. There is positive fH 
staining of axons shown in both the Tyr402 (Bl, x40) and His402 (B2, x40) fH 
antibodies. B3 (x40) shows positive APP staining of axons and B4 (x40) shows a 
double stain of Tyr402 fH with Vector SG (grey) co-localizing with APP stained 
axons with DAB (brown). Cl shows MS55 spinal cord (x40); co-localization is seen 
of APP (Vector SG, grey), with Cl-inh (DAB, brown). C2 shows MS179 brain (xlOO) 
with +ve staining of MBI6  in neurones adjacent to the active plaque. C3 and C4 
(MS306, x40) show Cl-inh cellular staining in the NAWM (C3) and neurones in the 
GM (C4) of a section with no plaque present and no staining of other C proteins, 
activation products or regulators.
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CHAPTER 9: INFLAMMATORY DISEASE ASSOCIATED 
COMPLEMENT POLYMORPHISMS DO NOT 
CONTRIBUTE TO DISEASE PHENOTYPE IN 
MULTIPLE SCLEROSIS
9.1 Introduction
There is growing evidence in CNS disorders with a significant inflammatory 
component, such as AD, AMD and vascular disease, for a significant contribution 
from C. Some of this is thought to be attributed to dysregulation of the C system 
caused by polymorphisms in C components and regulators. AMD is a 
neurodegenerative disease with several susceptibility genes within the C pathway 
including fH, fB, C2 and C3. SNPs in the locus encoding C regulator fH (rs1061170, 
Tyr402His and rs800292, V62I) have been shown by a number of groups to be 
significantly associated with increased risk of disease (Hageman et al. 2005; Haines et 
al. 2005; Klein et al. 2005). Furthermore, it has been suggested that rs 1061170 is 
associated with classical AMD with no occult choroidal neovascularization rather 
than other disease phenotypes (Wegscheider et al. 2007). Variants within C3 
(rs2230199, R102G and rsl047286, P314L) (Despriet et al. 2009), fB (L9H and 
R32Q) and C2 (E318D and a variant in intron 10) (Gold et al. 2006) have also been 
shown to confer a significantly reduced risk of disease, and combined haplotype 
analysis of fB and C2 has shown variation in these two loci predicts clinical outcome 
in 74% of the affected individuals and 56% of the controls.
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In AD, deposition of fH in brain tissue (Honda et al. 2000) and elevated serum fH 
levels correlated with cognitive decline (Hye et al. 2006; Thambisetty et al. 2008), 
suggesting to investigators that molecular analysis of the C fH gene may be a 
productive line of investigation. Association with the Tyr402His polymorphism of fH 
was shown in AD patients, but was restricted to those also carrying the ApoE4 risk 
allele (Hamilton et al. 2007; Zetterberg et al. 2008). More recently a GWAS in AD 
has revealed further SNPs in C regulator clusterin (rsl 1136000) and C receptor 1 
(CR1) (rs6656401) with odds ratios for disease of 0.81 and 1.21 respectively 
(Lambert et al. 2009).
There is considerable evidence to suggest a role for C in Schizophrenia with 
activation of classical, alternative and lectin pathway demonstrated in serum 
(Hakobyan et al. 2005; Boyajyan et al. 2008; Mayilyan et al. 2008). Genetic analysis 
in Schizophrenia shows variants of the C3 and fB gene associated with disease risk 
(Rudduck et al. 1985; Fananas et al. 1992).
Cerebral ischemia and reperfusion initiate the inflammatory system resulting in 
secondary neuronal damage. C cascade activation has been demonstrated following 
cerebral ischemia (Komotar et al. 2008) and strong activation has been associated 
with worse outcome (Szeplaki et al. 2009). Also, therapies directed at the C system 
have been suggested to reduce cerebral damage in the mouse modal (Komotar et al. 
2008; Gesuete et al. 2009), and SNPs in C5 (rsl7611, I802V) (Greisenegger et al. 
2009) and fH (rsl061170, Tyr402His) (Volcik et al. 2008) have been shown to be 
significantly associated with an increased risk for stroke.
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C is known to play an important role in MS and in this thesis altered levels of local 
and systemic C proteins, activation products and regulators have been demonstrated 
associated with disease state. Also, work in Chapter 5 suggested that allelic imbalance 
of the fH Tyr402His polymorphism was seen only in those patient groups where total 
fH levels were also elevated, suggesting either selective up-regulation of the His402 
variant or selective consumption of the Tyr402 variant in disease. Previous work 
looking for susceptibility genes within complement components and regulators have 
so far been unsuccessful (reviewed in Chapter 2); however, evidence, outlined above, 
from other diseases suggests that the impact of genetic variation in C genes may not 
be solely restricted to disease risk and may have an independent effect on phenotype. 
No studies to date have examined MS phenotype-genotype correlations in C 
polymorphisms. The work in this chapter assesses 8  SNPs (described above) in C 
genes, known to be associated with other neuro-inflammatory diseases, and examines 
genotype-phenotype correlations in a comprehensively characterised population of 
MS patients.
9.2 Methods 
Subjects
Samples were collected from 887 patients with clinically definite or probable MS on 
whom multiple clinical assessments (7725 current status datasets) were available for 
multiple time points throughout their disease course. Additional information was 
collected from the validated locally relevant historical patient questionnaire (Chapter 
4 , appendix 1 ), designed to harvest information on disease onset and diagnosis, time 
to SPMS, current EDSS and time to EDSS milestones >4, 6  and 8 .
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Venous blood was collected for serum and DNA, and sputum samples were collected 
for DNA. Processing of serum samples and extraction of DNA has been described in 
Chapter 3.
SNP analysis using Taqman
384 well plates with 15ng DNA in 3 /d per well were dried overnight. A mix of 1 x 
TaqMan Universal PCR Mastermix, and 0.5 x SNP primer (from Applied 
Biosystems) made to a volume of 4 fi\, was added to each well. The plates then 
underwent PCR using the Perkin Elmer 9700 in cycles as follows: initial denaturing 
step of 95°c for lOmins, 50 cycles of 95 °c for 10 mins and 50 °c for 1 min. Plates 
were read using the TaqMan SNP Genotyping assays and samples determined as 
either homozygous for either allele or heterozygote.
Molecular analysis of Factor H Tyr402His polymorphism
A wet nitrocellulose membrane was marked with 1 jul serum and, when dry, was 
incubated in 5% milk with PBS for 1 hour at room temperature under rotation. The 
membrane was subsequently probed for a further 1 hour incubation step (at room 
temperature under rotation) with either HRP-labelled affinity-purified rabbit MBI- 6  
anti-human fH-Tyr402 (lOOpl; lmg/1) or HRP-labelled MB 1-7 anti-fH-His402 (lOOpl; 
lmg/1) to detect fH-Tyr402 or fH-His402 respectively (development of antibody 
MBI- 6  (Hakobyan et al. 2008) and MBI-7 (Hakobyan et al. 2010) has been previously 
described). Membranes were washed 3 times in PBS/0.1% Tween 20 with incubation 
of 15 minutes for each wash and bound antibody was detected using TMB substrate
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and chemiluminesence detection. Films were scored for presence of either MBI- 6  
and/or MB 1-7 and classified as homozygote or heterozygote for variants (fig 9.1).
Statistical Analysis
Association between different subgroups was performed using chi-square test and 
one-way ANOVA with Bonferonni correction. Association between genotype and 
disease progression was tested using standard survival analysis methods and hazard 
ratios were calculated (95% Cl and p-values) for median time to EDSS 4, 6  and 8  
using an additive model of genetic risk. Because of the low numbers in the minor 
allele homozygote group for 5 o f the 8  SNPs, this group was combined with the 
heterozygote group for analysis. The analysis was not corrected with Bonferroni 
method as the tests were not independent; therefore each EDSS milestone was 
corrected for the number of SNPs analysed and associations were deemed posistive if 
p<0.006 (0.05 divided by the number of tests).
9.3 Results
Genotyping success rate ranged between 91% and 93% for all SNPs analysed on 
taqman (table 9.1). Minor allele frequency for each SNP was not significantly 
different from European control group data on the 1958 birth cohort 
(http://www.b58cgene.sgul.ac.uk/) or HapMap (http://hapmap.ncbi.nlm.nih.gov/) 
(table 9.1). Demographic characteristics including gender, age, disease duration, 
disease course and % of patients with EDSS>6.0, were similar in all genotypic 
subgroups except for a trend towards lower age in rs1065489 minor allele group 
(p=0.039), a trend to lower disease duration in the minor allele groups of both
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rsl 1136000 (p=0.046) and rsl061170 (p=0.071) and a slight overrepresentation of 
SPMS in the major allele subgroup of rsl 061770 (p=0.002) (table 9.2).
The hazard ratios for time to reaching disability milestones EDSS>4, 6  and 8  were 
reduced in C5 SNP rsl7611. An addition, the 2 SNPs in C3 showed a similar trend 
only observed in time to EDSS>4 and 6  (rsl047286 and rs2230199); this effect may 
not have been seen for milestone EDSS 8  given the lower number of patients reaching 
this point (table 9.3). Two other SNPs showed a reduced hazard ratio for time to 
either EDSS 6  (rsl 1136000) or 8  (rsl061770); however, this was not bom out across 
the other milestones and therefore is more likely to be due to a type I error (table 9.3). 
After correction for multiple analysis only one of the associations seen remained 
significant (EDSS>4 in C3 SNP r s l047286) and it is likely that the other associations 
seen were due to type I errors. Other disease characteristics (age at onset, age at 
diagnosis, time from disease onset to SPMS, age at SPMS, disease course at onset and 
% of patients with PPMS) were not different between disease subgroups except for a 
slightly higher age at onset in the rs6656401 (CR1) heterozygote group (p=0.041) 
(table 9.4).
Information on characteristics at disease onset was also analysed in relation to C 
genotypes. There was no difference seen for disease course at onset (full or partial 
recovery from relapse or progressive disease from onset) in any genotypic subgroup 
(table 9.4). There was also no difference seen in the clinical features of first relapse 
between genotypic subgroups (data not shown). Correlation of the results of initial 
investigations MRI, OCBs and VEPs were examined in relation to genotypic 
subgroups (table 9.5). There were a higher proportion of patients with positive MRI
200
scans in the minor allele group, with a similar trend in the heterozygote group, for the 
fH SNP, rs l065489. The same trend was also observed in the other two fH SNPs, 
rsl061770 and rs800292; however, these did not reach significance probably due to 
the low numbers in the minor allele subgroup. There were no genotype correlations 
seen with any other parameter.
9.4 Discussion
Detailed analysis was performed of phenotype-genotype correlations in MS selecting 
8  SNPs, on a candidate gene approach, in various C genes based on prior evidence for 
those SNPs conferring increased risk and altered phenotype in other 
neuroinflammatory diseases. SNPs located in chromosome 6  (genes for fB and C2) 
were excluded due to their effect being masked by the dominant association of MS 
with the HLA genes located in this region.
No convincing associations were shown between these candidate SNPs and MS 
phenotype. Although 3 SNPs showed some degree of association with time to 
disability milestones, after correcting for multiple comparisons to limit type I errors, 
only one of these remained significant. Higher age at onset was seen in the CR1 
polymorphism heterozygote group (rs6656401); and positive MRI at diagnosis was 
associated with a SNP in regulator fH (rsl065489) with a similar trend seen in the 
other 2 fH SNPs (rsl061770 and rs800292). Replication in larger cohorts is needed to 
test relevance of these findings.
Previous studies looking at genotype-phenotype correlations in MS have been limited. 
One Scandinavian study has reported correlation of HLA-DRB1*15 with a younger
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age at disease onset (corrected p=0.009) (Hensiek et al. 2002); whilst another group 
examined 808 patients with cross-sectional data and reported HLA-DR2 homozygotes 
to be associated with a more aggressive disease course (p<0.05), although patient 
numbers were small with only 35 patients in the aggressive disease group (Barcellos 
et al. 2003). Another group employed cross-sectional data from patient subsets with 
benign and aggressive MS, reporting HLA-DRB1*01 was under-represented in the 
patients with aggressive disease (DeLuca et al. 2007). More recently a group have 
also analyzed the affect of DRB1*15 on disease severity stratified according to MSSS 
and time to EDSS 6  concluding that DRB1*15 is able to modulate the course of 
RRMS and hypothesizing that this occurred as a result of early initiation of the 
progressive phase (Coumu-Rebeix et al. 2008). A further study has examined the 
effects of functional polymorphisms in the immune mediators CCL5 and CCR5 which 
although not associated with an absolute risk for MS did seem to be correlated with 
observed variations in MRI markers and MSSS (van Veen et al. 2007).
Numbers of patients employed in all of these studies varied and since none has been 
convincingly replicated it is difficult to determine numbers needed to appropriately 
power such a study especially given that the effect size from epidemiological studies 
is unclear. Also, the power to detect effect will vary depending on the minor allele 
frequency of the analysed SNP; however, the positive effects seen in this study were 
not in those with the highest minor allele frequency. It may be this study was 
appropriately powered and there is little genetic dysregulation of C from the analysed 
SNPs contributing to disease phenotype in MS; but the limited positive results seen in 
this study may suggest that the study was under-powered. If similar numbers are 
needed as for susceptibility studies, it will be some time before this kind of in-depth
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study with longitudinal disability data and comprehensive phenotypic data, can be 
achieved. An optimal approach would be to use data gained from GWAS with 
similarly detailed phenotypic data as has been employed in this study; but such an 
analysis was beyond the scope of this thesis. In addition, there is an increasing 
precedence in GWAS for additional SNP associations to become evident only on 
pathway analysis. The use of these approaches may reveal phenotype-genotype 
associations in C genes.
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Figure 9.1: M olecular analysis o f  Factor H T yr402H is polym orphism
The upper photographed membrane shows staining of 96 patient samples with the 
MBI- 6  antibody (fH Tyr402), and the lower shows the same 96 patients stained with 
the MBI-7 antibody (fH His402). Arrow 1 denotes a His402 homozygote, arrow 2 a 
Tyr402 homozygote and arrow 3 a heterozygote patient.
MBI-6
#  #
MBI-7
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Table 9.1: Genotyping details
rs l047286 rs2230199 rsl7611 rs l065489 rs800292 rsl061170 r s l1136000 rs66564
No. 887 887 887 887 887 819 887 887
Gene C3 C3 C5 Factor H Factor H Factor H Clusterin CR1
Chromosome 19 19 9 1 1 1 8 1
Genotyping success rate 91.2 91.5 91.4 92.8 91.4 1 0 0 . 0 91.5 92.3
Minor allele f 18.3 18.9 40.1 16.6 20.5 38.5 37.9 14.7
Control minor allele f 23.9 17.5 42.0 17.0 24.0 38.0 40.0 18.0
Table 9.2: Demographic characteristics of the cohort are not different in genotypic subgroups
No. Sex
% f Mean
Age
SD P
Disease duration 
Mean SD p
RRMS
%
SPMS
%
PPMS
%
EDSS>6.0
%
rsl 047286 CC 514 69.46 45.82 1 1 . 8 8 N/A 14.07 10.62 N/A 50 40.47 9.53 29.77
C T 266 69.92 46.24 12.59 1.000 15.22 11.48 0.513 50.75 39.85 9.4 29.7
T T 29 68.97 45.59 14.31 1.000 15.34 14.54 1.000 62.07 31.03 6.9 27.59
rs2230199 CC 507 68.84 46.18 12.03 N/A 14.27 1 0 . 8 6 N/A 49.7 41.22 9.07 30.18
CG 275 70.91 45.77 12.7 1.000 15.28 11.56 0 . 6 8 6 51.27 39.64 9.09 28.36
G G 30 66.67 45.67 11.43 1.000 14.8 12.57 1.000 60 33.33 6.67 26.67
rsl7611 G G 250 70.00 46.57 12.3 N/A 14.72 11.61 N/A 50 41.6 8.4 31.2
A G 411 70.32 46.33 12.54 1.000 14.98 11.28 1.000 49.39 39.17 11.44 28.71
A A 150 64.67 44.64 10.92 0.377 13.32 1 0 0.684 53.33 41.33 5.33 29.33
rs l065489 G G 559 68.16 45.31 12.26 N/A 14.09 10.93 N/A 51.7 38.46 9.84 29.34
G T 233 71.67 47.67 12.08 0,039 15.36 11.4 0.433 46.78 44.64 8.58 30.04
T T 31 74.19 44.13 10.97 1.000 15.9 12.19 1.000 58.06 32.26 9.68 25.81
rs800292 CC 494 70.24 46.24 1 2 . 6 6 N/A 14.53 11.57 N/A 49.8 40.08 1 0 . 1 2 30.77
C T 271 70.11 45.46 11.47 1.000 14.12 10.14 1.000 52.03 38.75 9.23 25.83
T T 46 58.7 45.22 11.45 1.000 15.87 12.07 1.000 47.83 47.83 4.35 39.13
rsl061170 Y Y 307 68.73 46.33 11.77 N/A 15.9 11.93 N/A *46.25 *46.5§ MS 34.53
H Y 394 67.77 45.44 11.96 0.991 13.42 10.49 IB 56.09 34.01 9.9 26.65
H H 118 72.88 44.22 12.95 0.319 13.17 10.94 0.071 51.69 36.44 1 1 . 8 6 27.12
rsl 1136000 CC 272 66.18 47.24 12.4 N/A 15.2 11.29 N/A 47.06 41.91 11.03 28.31
C T 408 70.83 45.73 12.29 0.338 14.71 11.38 1.000 53.68 37.99 8.33 30.88
T T 132 72.73 44.42 10.94 0.087 12.35 9.49 0 -Cf6 49.24 41.67 9.09 25.76
rs6656401 G G 588 6 8 . 8 8 45.89 1 2 . 1 1 N/A 14.81 11.19 N/A 49.32 41.33 9.35 29.93
A G 2 0 2 70.30 46.84 12.4 1.000 13.92 11.11 0.973 52.97 38.12 8.91 27.23
A A 29 72.41 44.14 12.82 1.000 13.48 9.02 1.000 55.17 31.03 13.79 31.03
f; female. SD; standard deviation, p  = comparison with major allele group with Bonferroni correction. *rsl061170, analysis of disease
subgroups, chi = 20.92, p=0.002. Positive results highlighted in grey.
Table 9.3: Hazard ratios for reaching time to disability milestones are 
shown for each SNP
SNPs Time to EDSS>4 Time to EDSS 6 Time to EDSS 8
HR 95% Cl P HR 95% Cl P HR 95% Cl P
rsl047286 0.73 0.59-0.90 0.003 0.70 0.54-0.91 0.007 0.84 0.52-1.39 0.511
rs2230199 0.77 0.63-0.94 0 . 0 1 2 0.72 0.56-0.93 0 . 0 1 2 0.84 0.51-1.36 0.476
rsl7611 0.73 0.57-0.95 0.019 0 . 6 6 0.48-0.91 0 . 0 1 1 0.51 0.28-0.92 0.025
rsl065489 0.92 0.74-1.13 0.404 0.97 0.75-1.26 0.843 0.58 0.33-1.03 0.065
rs800292 0.97 0.80-1.19 0.791 0.87 0 .6 8 -1 .1 2 0.275 0.71 0.43-1.16 0.178
rsl061770 0.94 0.70-1.27 0.704 0.89 0.62-1.28 0.540 0.50 0.27-0.94 0.031
rsl 1136000 0.94 0.70-1.27 0.530 0.76 0.58-0.99 0.045 1.03 0.63-1.70 0.902
rs6656401 1 .0 1 0.81-1.27 0.898 0 . 8 6 0.64-1.15 0.304 0.96 0.55-1.69 0.890
HR; hazard ratio. Cl; confidence interval. In each case the minor homozygote group was
combined with the heterozygote group for comparison. Positive p values (<0.006) are 
highlighted in grey.
Table 9.4: Phenotypic disease characteristics are shown in genotypic subgroups
PPMS Age at onset Age at diagnosis Time to SPMS Age at SPMS Disease course at onset
% Mean SD P Mean SD P Mean SD P Mean SD P RO SO POR
rsl047286 C C 9.53 31.12 10.08 N/A 35.40 10.32 N/A 10.16 8.71 N/A 41.52 10.14 N/A 62.06 28.02 9.53
C T 9.40 30.49 9.74 1.000 35.63 10.50 1.000 12.13 12.93 0.424 43.53 9.59 0.359 62.41 27.44 9.40
T T 6.90 29.76 1 0 . 1 2 1.000 34.76 1 2 . 0 0 1.000 11.43 14.95 1.000 37.14 14.71 0.781 68.97 24.14 6.90
rs2230199 CC 9.07 31.30 10.06 N/A 35.51 10.29 N/A 10.26 8 . 6 8 N/A 41.84 1 0 . 1 1 N/A 62.33 28.21 9.07
C G 9.09 29.96 9.69 0.213 35.42 1 0 . 8 6 1.000 12.15 13.18 0.468 42.75 9.73 1.000 62.91 27.27 9.09
G G 6.67 30.23 9.25 1.000 33.77 7.84 1.000 12.33 12.52 1.000 40.44 13.33 1.000 66.67 26.67 6.67
rsl7611 G G 8.40 31.15 9.76 N/A 35.89 10.42 N/A 11.69 12.69 N/A 42.72 10.15 N/A 6 6 . 0 0 24.80 8.40
A G 11.44 30.84 10.07 1.000 35.50 10.73 1.000 11.33 9.96 1.000 42.66 10.42 1.000 59.61 28.71 11.44
A A 5.33 30.72 9.84 1.000 34.95 9.45 1.000 8 . 6 6 7.96 0.280 40.21 9.93 0.454 64.67 29.33 5.33
rs l065489 G G 9.84 30.63 9.93 N/A 35.07 10.33 N/A 10.33 10.32 N/A 40.77 9.50 N/A 60.82 28.80 9.84
G T 8.58 31.72 1 0 . 0 1 0.481 36.07 10.57 0.658 11.74 10.44 0.872 44.38 10.98 1.000 64.81 26.18 8.58
T T 9.68 27.61 9.59 0.302 36.23 10.73 1.000 14.00 13.90 0.915 43.11 1 1 . 6 8 1.000 74.19 16.13 9.68
rs800292 C C 1 0 . 1 2 31.11 10.42 N/A 35.59 1 0 . 8 6 N/A 10.89 11.16 N/A 42.27 10.14 N/A 63.97 25.30 1 0 . 1 2
C T 9.23 30.76 9.36 1.000 35.47 9.71 1.000 10.55 9.43 1.000 41.82 9.83 1.000 61.62 28.78 9.23
T T 4.35 28.85 8.69 0.429 34.04 9.56 1.000 11.50 1 0 . 1 2 1.000 40.76 11.62 1.000 56.52 39.13 4.35
rsl061170 Y Y 7.17 29.82 9.55 N/A 35.07 9.75 N/A 12.31 1 2 . 2 2 N/A 41.17 1 0 . 2 2 N/A 68.08 24.43 7.17
H Y 9.90 31.44 9.55 0.088 35.59 10.37 1.000 1 0 . 2 2 9.24 0.382 42.78 8.79 0.596 62.44 26.90 9.90
H H 1 1 . 8 6 30.50 10.79 1.000 34.26 10.89 1.000 8.85 8.24 0.225 39.95 10.05 1.000 58.47 29.66 1 1 . 8 6
r s l1136000 CC 11.03 31.44 10.28 N/A 36.15 10.45 N/A 11.58 11.32 N/A 42.76 10.06 N/A 63.97 24.63 11.03
C T 8.33 30.43 9.32 0.579 35.01 10.15 0.476 10.98 10.35 1.000 42.68 9.71 1.000 62.01 28.92 8.33
T T 9.09 31.51 10.59 1.000 35.81 10.63 1.000 9.26 9.14 0.631 39.60 11.35 0.228 62.12 28.79 9.09
rs6656401 G G 9.35 30.45 9.81 N/A 35.46 10.52 N/A 11.23 1 1 . 1 0 N/A 42.00 1 0 . 1 2 N/A 62.59 27.38 9.35
A G 8.91 32.45 9.96 0.041 35.69 10.16 1.000 9.97 8.84 1.000 42.64 10.16 1.000 64.36 26.73 8.91
A A 13.79 30.17 10.92 1.000 34.79 10.19 1.000 11.00 3.21 1.000 39.88 14.94 1.000 58.62 27.59 13.79
RO; full recovery. SO; partial recovery. POR; progressive disease from onset, p  = comparison with major allele group with Bonferroni correction. Positive
results highlighted in grey.
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Table 9.5: Genotypic correlations with initial investigations
No.
MRI findings 
Neg Pos
% %
P No.
OCB 
Neg Pos
% %
P No.
VEP findings 
Neg Pos
% %
P
rsl047286 C C 441 6 . 6 93.4 333 9.3 90.7 226 40.8 59.2
C T 244 4.3 95.7 2 2 0 5.3 94.7 187 9.1 90.9
T T 29 0 . 2 99.8 0.405 28 0 . 8 99.2 0.321 28 1.4 98.6 0.131
rs2230199 C C 433 6 . 0 94.0 334 8.9 91.1 236 38.1 61.9
C G 255 4.5 95.5 225 6 . 0 94.0 189 10.7 89.3
G G 30 0.4 99.6 0.580 29 0 . 6 99.4 0.585 29 1 . 0 99.0 0.867
rsl7611 G G 231 3.7 96.3 204 3.9 96.1 183 1 0 . 8 89.2
A G 364 5.3 94.7 301 7.7 92.3 229 24.4 75.6
A A 145 2 . 2 97.8 0.537 136 2.5 97.5 0.975 124 5.0 95.0 0.942
rsl 065489 G G 469 7.0 93.0 342 1 0 . 8 89.2 2 1 2 47.8 52.2
G T 218 3.4 96.6 198 4.7 95.3 177 8.5 91.5
T T 31 1 .1 98.9 WM 31 0 . 6 99.4 0.557 30 1 . 6 98.4 0.274
rs800292 C C 419 7.1 92.9 340 9.0 91.0 234 37.5 62.5
C T 254 3.4 96.6 215 5.5 94.5 188 9.8 90.2
T T 45 0 . 8 99.2 0.648 45 0 . 6 99.4 0.271 43 1.4 98.6 0.155
rsl 061770 Y Y 243 6 . 1 93.9 204 6 . 8 93.2 173 14.2 85.8
Y H 365 5.1 94.9 301 6 . 6 93.4 2 2 2 24.9 75.1
H H 126 1 . 0 99.0 0.079 1 2 1 1 . 6 98.4 0.240 114 5.7 94.3 0.394
rsl 1136000 C C 282 2.9 97.1 253 4.8 95.2 2 2 0 1 1 . 8 8 8 . 2
C T 350 6.4 93.6 285 8 . 1 91.9 216 23.4 76.6
T T 114 2 . 0 98.0 0.397 107 1.7 98.3 0.769 1 0 1 5.3 94.7 0.822
rs6656401 G G 496 8.5 91.5 355 12.5 87.5 2 0 2 53.3 46.7
A G 189 2 . 8 97.2 177 4.1 95.9 160 7.9 92.1
A A 29 0.4 99.6 0.997 28 0 . 2 99.8 0.599 28 1.4 98.6 0.171
MRI; magnetic resonance imaging. OCB; oligoclonal bands. VEP; visual evoked potential. Neg; negative (in
the MRI group this refers to any scan not fulfilling Barkof diagnostic criteria). Pos; positive (in the MRI group 
this refers to any scan fulfilling diagnostic criteria. p =  comparison o f disease subgroups by Chi square. 
Positive results highlighted in grey.
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CHAPTER 10: CONCLUDING REMARKS AND 
DIRECTIONS FOR FURTHER RESEARCH
10.1 Development of a biological bank
Central to this thesis was the establishment of a well-maintained and functional 
biobank with rigorously processed serum, plasma, CSF and DNA samples linked to 
comprehensive clinical information. This biobank was established with the aim of 
being readily available for a wide range of projects extending over many years. The 
samples were therefore processed in a manner designed to make them fit for analysis 
of even unstable products. Given the large amount of samples being taken from 
clinics, it was not possible to foresee and account for all problems. There would be 
benefit when analysing some potential markers for samples to be immediately placed 
on ice, separated and frozen within 30mins. In addition the extraction of cells, not 
planned for by this biobank, may be beneficial for some work. However, for the 
purposes of many projects our protocol is sufficient and multiple aliquots from each 
sample makes measurement of different factors in the same individual easier. One of 
the main problems encountered was gaining samples from sufficient patients in 
various disease subgroups so as to make biomarker studies feasible. At the end of the 
project, serum and plasma samples had been collected from over 900 patients and 
DNA from over 1100 patients. The collection o f CSF was limited to about 30 patients 
and 30 controls which meant CSF studies in the project were limited. Collection of 
longitudinal samples from individuals is valuable for biomarker studies especially 
when looking at prognostic markers. The biobank has been set up to collect samples 
yearly from patients attending clinic and more frequently if  there is a change in their
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disease state, so that in-depth studies looking at prognosis, although beyond the scope 
of this thesis, can be achieved in future projects.
The extent of clinical information linked to the sample biobank was a strength of this 
project; however, given the nature of MS and the disease duration there were gaps in 
the data which I attempted to fill in with a historical postal questionnaire. This was 
successfully used but further validation of some components such as the reporting of 
relapses, is needed in patients with relapsing remitting disease.
10.2 Systemic complement biomarkers for multiple sclerosis
This work firmly establishes C regulator fH as a biomarker of MS disease course with 
a test sensitivity and specificity to distinguish secondary progressive from relapsing 
remitting disease sufficient to make this a practical and useful clinical marker. 
Although replicated in-house, there is a need for this work to be validated and 
replicated by other groups so as to firmly establish the reproducibility of this work. 
Despite its usefulness as a biomarker of disease course, the data available on its use in 
predicting disease outcome is limited. To establish the ability of a biomarker to 
predict disease outcome, it would be necessary to have samples, together with 
corresponding clinical data, collected over many years. In Chapter 5 I present 
preliminary data with serial samples collected from 1 2  patients over a 2  year period in 
which the patients change disease course from relapsing to progressive; however, the 
collection of more samples over a protracted period was beyond the scope of this 
thesis. Another important element in establishing its usefulness as a biomarker, was to 
look at the stability of fH levels in clinically stable disease. This was performed in 11
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patients over 1 year; extending this work would make findings more robust and 
should be possible in future projects when the biobank is more established.
It seems more likely that a combination of different markers will produce a sensitive 
and specific model for particular elements of disease. Chapter 7 shows combined 
phenotype-C component models which increase the predictive value of a particular 
test compared to using the individual component alone. The models described in this 
thesis allow the distinction of MS from healthy controls and relapse from remission. 
These models now need testing in prospective cohorts of patients. Firstly, to be useful 
as a clinical marker of MS, the model would have to be tested in patients with other 
neurological disease within the MS differential such, as vasculitis; as well as in 
patients with a CIS. The optimal method of examining this in more detail would be to 
use a prospective cohort of patients with CIS allowing correlation of the objective 
model with time to conversion to MS; although again this would require collection of 
samples over a longer period than this thesis allowed. The optimal way to validate a 
model to distinguish relapse would be in a prospective group of patients attending an 
acute rapid access MS service who believe they have a clinical relapse. The objective 
model could then be correlated with clinical features and disease activity on MR 
scans.
Further ways to improve the models generated would be the use of objective 
phenotypic variables such as age, gender and disease duration. This was discussed in 
Chapter 7 and left out of the initial analysis so as to not cause confusion in the initial 
steps of generating an objective biomarker. Correlation with other inflammatory 
markers or axonal injury markers would also provide additional information which
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may add to the models generated. In addition, the use of accepted markers such as 
MRI would enable correlation of a potential biomarker with more accepted and 
objective disease measures.
10.3 The contribution of complement to the pathophysiology of 
multiple sclerosis
The extent and nature of C activation and its involvement in the acute and chronic 
phases of disease is currently controversial. Although animal model studies have 
given us some indication of the role of C in acute MS, they have hitherto provided 
little information on any contribution to axonal degeneration seen throughout disease 
but more predominantly in progressive phase. The development of a novel mouse 
model for chronic EAE may lead to more informative research regarding axonal 
damage and remyelination in demyelinating diseases. Pathological studies in human 
brain have mostly been limited to the examination of relatively few components of the 
C system and provide only a limited snap-shot view of the pathological process 
depending on the patients’ disease course at death. This thesis examines an array of C 
components, fragments and regulators both systemically in serum/plasma and locally 
in CSF and immunohistochemically in brain and spinal cord sections, in an attempt to 
clarify some of these issues.
Work in this thesis demonstrates extensive systemic and local activation and 
regulation of the C system even in late stages of MS indicating a contribution from C 
to pathogenesis throughout the disease course, and supporting the hypothesis of 
inflammatory driven axonal degeneration causing progressive MS. Furthermore, in
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Chapter 8 , immunohistochemical analysis shows C deposition in long-standing MS in 
and around plaques which would otherwise be classified as inactive; also C deposition 
on damaged axons co-localized with APP. Further work examining brain tissue from 
patients with early, active disease; comparing C deposition to patients with long­
standing, chronic disease, would provide additional information on changes in the 
immune system over disease course. In addition the establishment of a brain bank 
from local patients with prior collected serum, plasma, CSF and DNA during their 
disease would be of great benefit when examining the contribution of systemic and 
local C to pathology.
CSF studies were limited in this thesis due to a relative lack of specimens; further, the 
control group available included neurological controls with a degree of inflammation 
possibly contributing to the condition; for example, cerebrovascular disease. Further 
CSF studies with a larger non-inflammatory neurological control group in addition to 
larger MS and CIS groups would be of benefit not only to confirm the source of C in 
MS brain whether it be largely local or systemic in origin, and therefore how 
amenable it will be to systemically administered therapies. This work suggests both 
the classical and alternative pathways contribute to disease, although further 
investigation of other alternative pathway components in progressive disease may 
help further elucidate the differential expression of fH seen in these patients.
Most treatments for MS have so far focused predominantly on controlling the T cell 
mediated immune response which initiates and drives relapsing disease. The majority 
of anti-inflammatory therapies have failed to have any significant effect in delaying 
disease progression when used in either the relapsing remitting or progressive disease
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phase, leading to speculation amongst investigators as to the contribution of 
inflammation to axonal degeneration. New evidence outlined in this thesis supports 
the role for inflammation in chronic disease and suggests therapies targeting innate 
immune responses in combination with more traditional therapies, may have greater 
success in preventing or halting axonal degeneration.
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Appendix 1: EDSS questionnaire
ID Name
Question 1. When were you diagnosed with Multiple sclerosis?
Month...................Year.......................
If you can’t remember the month please can you ring the season? 
Spring Summer Autumn Winter
Question 2. When did you first have symptoms of MS?
Month...................Year.......................
If you can’t remember the month please can you ring the season? 
Spring Summer Autumn Winter
Question 3. What were your very first symptoms? please tick yes or no
Arm or hand weakness Yes □
No □
Dizziness / vertigo Yes □
No □
Leg weakness or heaviness Yes q
No □
Unsteadiness / loss of balance Yes q
No □
Facial weakness / drooping Yes □
No n
Double vision Yes □
No °
Pins and needles Yes D
No □
Blurring of loss of vision Yes □
No □
Loss of sensation in body Yes □
No □
Bladder or bowel problems Yes □
No □
Loss of sensation in face Yes □
No □
Speech or swallowing problems Yes □
No □
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Question 4. Did these initial sym ptom s com pletely go aw ay a t any tim e in the following 
year?
Question 5. Did these initial sym ptom s g radually  d e te rio ra te  in the Yes □  
following year? No □
Question 6. How long was it before y o u r next relapse? ....months
(episode o f  symptoms lasting at least a day but not at a time
when you had an infection e.g. urine infection / fever) .../....years
please specify to the half year
Question 7. W hat type of M ultip le Sclerosis do you u n d ers tan d  you have?
(please tick the box that best describes your MS)
Relapsing remitting □ Secondary Progressive □
Primary Progressive □ Don’t know □
Question 8. M any patients w ith  M S feel th a t th e ir  condition is stable 
in-between relapses; how ever, som e patien ts  feel th a t th e ir  condition Yes □
is gradually worsening. Looking b ack  do you th in k  y o u r sym ptom s No D
of MS are gradually  w orsening despite  the effect o f relapses?
If  yes, when do you th ink  this s ta r te d  to hap p en ? Month...................
Year......................
If you can’t remember the month please can you ring the season?
Spring Summer Autumn Winter
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Question 9. Have you had any relapses in the past year?
(episodes o f  symptoms lasting at least a day but not at a time when you had 
an infection e.g. urine infection / fever)
□ Yes - Please fill in chart below □  No - Please go to Question 10
How many relapses have you had in the last year? .................
Relapse 1
M onth............................ Y ear.................
If  you can 't remember the month please can you ring the season? 
Spring Summer Autumn Winter
Did these new symptoms go away at any time during the following year? Yes □
No □
Arm or hand weakness Yes □
No □
Dizziness / vertigo Yes □
No □
Leg weakness or heaviness Yes q
No □
Unsteadiness / loss o f balance Yes □
No □
Facial weakness / drooping Yes □
No D
Double vision Yes □
No D
Pins and needles Yes D
No □
Blurring o f  loss o f vision Yes □
No □
Loss o f sensation in body Yes □
No □
Bladder or bowel problems Yes □
No □
Loss o f  sensation in face Yes □
No □
Speech or swallowing problems Yes □
No □
I f  you have had more than 1 relapse this year, there is an additional chart attached at
the back of the questionnaire. Please contact us if  you need extra sheets.
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Q uestion 10. A re  you able to w alk  independently  - w ithout the use o f a w alking 
stick o r fram e o r  person to hold o r  FES m achine o r o ther support?  (please tick)
O Yes - Please go to Q uestion 11 □  No -  Please go to Q uestion 12
Question 11. A t your BEST, how fa r  can you w alk  w ithout a rest o r  help 
from  a stick o r  fram e o r  person o r  FES o r  o th e r w alking aid? (please tick)
□ Unrestricted (I can walk fo r  2-3 hours with no problem)
□ Clearly more than 500 metres / 550 yards
□  About 500 metres / 550 yards
(about the length o f  Queens Street in Cardiff)
^  About 300 metres / 330 yards 
(the length o f  3 football pitches)
□  About 200 metres / 220 yards
(half o f  Queens street in Cardiff or 2 football pitches)
O About 100 metres / 110 yards
(the length o f  one football pitch or the outpatients 
corridor in the UHW hospital)
□ Less than 100 metres / 110 yards
> Go to Q uestion 
IS a t the end
Go to
Q uestion 12
Question 12. Do you rem em ber w hen, to the nearest m onth 
and year, you becam e unable to w alk fo r 500 m etres / 550 yards 
w ithout a rest o r help from  a stick  o r  fram e o r  person?
If you can’t remember the month please can you ring the season? 
Spring Summer Autumn Winter
Month.
Year...
I f  you can w alk w ithout the use o f a w alking aid such as a stick , you have finished the 
questionnaire, please proceed to Question 18 a t the  end.
If  you need help to w alk o r use a w heelchair, please con tinue to Q uestion  13.
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Question 13. Please tick the box below that best describes your walking ability.
^  I can walk more than, or about, 100 metres /110 yards {the length o f  a football pitch) 
with 1 stick or person for support
□  I use an FES machine to walk (on one leg / on both legs - please ring)
□  1 need support on both sides to walk, such as 2 sticks or a walker / frame
□  I can only walk about 10 metres (just about across a room)
□  I can only walk a few steps even with help and normally use a wheelchair
□  I use a wheelchair all of the time and can’t take even a few steps
Question 14. Do you remember when you first started to need Month.................
constant help from either a stick or person and could only walk Year....................
about 100 metres / 110 yards (the length of a football pitch)?
If you can’t remember the month please can you ring the season?
Spring Summer Autumn Winter
If you are still mobile please go to Question 18 at the end 
If you use a wheelchair all of the time, please go to Question 15
Question 15. Do you remember when you first started to need Month................
to use your wheelchair to get around and you were no longer Year..................
able to take any steps more than to transfer?
If you can’t remember the month please can you ring the season?
Spring Summer Autumn Winter
Question 16. If you are bed or chair bound, do you have trouble Yes □
using your hands for writing and eating, etc. No □
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Question 17. Are you totally confined to bed and need help with Yes □
all daily tasks? No □
Many thanks for filling in this questionnaire which will be very helpful. 
Please now return it using the prepaid envelope.
If you have any questions, or struggle to fill in any parts of the questionnaire, 
please phone Dr Gillian Ingram on 02920 743454. If you leave a message 
with your name and number I will get back to you as soon as possible.
Question 18.
Could you tell us who filled in this questionnaire? □  You alone
^  You and a carer 
O Carer alone
Who is your carer (please ring) husband / wife / partner / sibling / parent / child
Name..................................................... Signature............................................Date..................
Other comments
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Relapse2
Month........................  Year...............
If you can’t remember the month please can you ring the season? 
Spring Summer Autumn Winter
Did these new symptoms go away at any time during the following year? Yes □
No □
Arm or hand weakness Yes □
No □
Dizziness / vertigo Yes □
No □
Leg weakness or heaviness Yes q
No □
Unsteadiness / loss of balance Yes q
No □
Facial weakness / drooping Yes □
No
Double vision Yes □
No
Pins and needles Yes Q
No □
Blurring of loss of vision Yes D
No □
Loss of sensation in body Yes □
No □
Bladder or bowel problems Yes □
No □
Loss of sensation in face Yes □
No □
Speech or swallowing problems Yes □
No □
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